The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy – clinical effectiveness and safety until 2 years after delivery, with economic evaluation by Cooper, Sue et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 18 ISSUE 54 AUGUST 2014
ISSN 1366-5278
DOI 10.3310/hta18540
The SNAP trial: a randomised placebo-controlled trial 
of nicotine replacement therapy in pregnancy – 
clinical effectiveness and safety until 2 years  
after delivery, with economic evaluation
Sue Cooper, Sarah Lewis, James G Thornton, Neil Marlow, Kim Watts,  
John Britton, Matthew J Grainge, Jaspal Taggar, Holly Essex, Steve Parrott, 
Anne Dickinson, Rachel Whitemore and Tim Coleman for the Smoking, 
Nicotine And Pregnancy (SNAP) Trial Team

The SNAP trial: a randomised
placebo-controlled trial of nicotine
replacement therapy in pregnancy –
clinical effectiveness and safety
until 2 years after delivery,
with economic evaluation
Sue Cooper,1* Sarah Lewis,2 James G Thornton,3,4
Neil Marlow,5 Kim Watts,6 John Britton,2
Matthew J Grainge,2 Jaspal Taggar,1 Holly Essex,7
Steve Parrott,7 Anne Dickinson,1 Rachel Whitemore1
and Tim Coleman1 for the Smoking, Nicotine
And Pregnancy (SNAP) Trial Team†
1Division of Primary Care, University of Nottingham, Nottingham, UK
2Division of Epidemiology and Public Health, University of Nottingham,
Nottingham, UK
3Division of Child Health, Obstetrics and Gynaecology, University of Nottingham,
Nottingham, UK
4Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
5Institute for Women’s Health, University College London, London, UK
6Academic Division of Midwifery, University of Nottingham, Nottingham, UK
7Department of Health Sciences, University of York, York, UK
*Corresponding author
†Additional members of the team are listed in the Acknowledgements.
Declared competing interests of authors: Neil Marlow reports personal fees from Novartis, personal
fees from Elsevier, outside the submitted work. Tim Coleman reports personal fees from Pierre Fabre
Laboratories, France, outside the submitted work.
Published August 2014
DOI: 10.3310/hta18540

This report should be referenced as follows:
Cooper S, Lewis S, Thornton JG, Marlow N, Watts K, Britton J, et al. The SNAP trial: a randomised
placebo-controlled trial of nicotine replacement therapy in pregnancy – clinical effectiveness and
safety until 2 years after delivery, with economic evaluation. Health Technol Assess 2014;18(54).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.116
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is
assessed for inclusion in the Database of Abstracts of Reviews of Effects.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and
(2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods
(to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 06/07/01. The contractual start date
was in February 2006. The draft report began editorial review in June 2013 and was accepted for publication in October 2013. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Cooper et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR  
Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK
Professor Jane Norman Professor of Maternal and Fetal Health, University of Edinburgh, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, University College London, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
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Background: Smoking during pregnancy causes many adverse pregnancy and birth outcomes. Nicotine
replacement therapy (NRT) is effective for cessation outside pregnancy but efficacy and safety in pregnancy
are unknown. We hypothesised that NRT would increase smoking cessation in pregnancy without
adversely affecting infants.
Objectives: To compare (1) at delivery, the clinical effectiveness and cost-effectiveness for achieving
biochemically validated smoking cessation of NRT patches with placebo patches in pregnancy and (2) in
infants at 2 years of age, the effects of maternal NRT patch use with placebo patch use in pregnancy on
behaviour, development and disability.
Design: Randomised, placebo-controlled, parallel-group trial and economic evaluation with follow-up at
4 weeks after randomisation, delivery and until infants were 2 years old. Randomisation was stratified by
centre and a computer-generated sequence was used to allocate participants using a 1 : 1 ratio.
Participants, site pharmacies and all study staff were blind to treatment allocation.
Setting: Seven antenatal hospitals in the Midlands and north-west England.
Participants: Women between 12 and 24 weeks’ gestation who smoked ≥ 10 cigarettes a day before and
≥ 5 during pregnancy, with an exhaled carbon monoxide (CO) reading of ≥ 8 parts per million (p.p.m.).
Interventions: NRT patches (15mg per 16 hours) or matched placebo as an 8-week course issued in two
equal batches. A second batch was dispensed at 4 weeks to those abstinent from smoking.
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Main outcome measures: Participants: self-reported, prolonged abstinence from smoking between a quit
date and childbirth, validated at delivery by CO measurement and/or salivary cotinine (COT) (primary
outcome). Infants, at 2 years: absence of impairment, defined as no disability or problems with behaviour
and development. Economic: cost per ‘quitter’.
Results: One thousand and fifty women enrolled (521 NRT, 529 placebo). There were 1010 live singleton
births and 12 participants had live twins, while there were 14 fetal deaths and no birth data for
14 participants. Numbers of adverse pregnancy and birth outcomes were similar in trial groups, except for
a greater number of caesarean deliveries in the NRT group. Smoking: all participants were included in the
intention-to-treat (ITT) analyses; those lost to follow-up (7% for primary outcome) were assumed to be
smoking. At 1 month after randomisation, the validated cessation rate was higher in the NRT group
{21.3% vs. 11.7%, odds ratio [OR], [95% confidence interval (CI)] for cessation with NRT, 2.05 [1.46 to
2.88]}. At delivery, there was no difference between groups’ smoking cessation rates: 9.4% in the NRT
and 7.6% in the placebo group [OR (95% CI), 1.26 (0.82 to 1.96)]. Infants: at 2 years, analyses were
based on data from 888 out of 1010 (87.9%) singleton infants (including four postnatal infant deaths)
[445/503 (88.5%) NRT, 443/507 (87.4%) placebo] and used multiple imputation. In the NRT group,
72.6% (323/445) had no impairment compared with 65.5% (290/443) in placebo (OR 1.40, 95% CI 1.05
to 1.86). The incremental cost-effectiveness ratio for NRT use was £4156 per quitter (£4926 including
twins), but there was substantial uncertainty around these estimates.
Conclusions: Nicotine replacement therapy patches had no enduring, significant effect on smoking in
pregnancy; however, 2-year-olds born to women who used NRT were more likely to have survived without
any developmental impairment. Further studies should investigate the clinical effectiveness and safety of
higher doses of NRT.
Trial registration: Current Controlled Trials ISRCTN07249128.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 54. See the NIHR Journals Library
programme website for further project information.
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Plain English summary
Smoking in pregnancy harms developing babies, but stopping smoking before childbirth improvesinfants’ health. Nicotine replacement therapy (NRT) helps non-pregnant smokers quit but, in pregnancy,
women’s bodies process nicotine faster. Therefore, we cannot assume that NRT will help pregnant smokers
and previous research studies have not shown that it does. We tested whether or not NRT patches help
pregnant women stop smoking and looked at effects on their newborn babies and when they reached
2 years of age.
A total of 1050 smokers joined the study and were randomly allocated to a 2-month supply of either
NRT or identical dummy patches. Women’s smoking was monitored 1 month after joining the study,
at childbirth and at 6, 12 and 24 months afterwards. Babies’ health was monitored at birth and their
development and breathing problems were assessed when they were 2 years old.
Effects on smoking were modest. Those using NRT were twice as likely to stop smoking for 4 weeks
immediately after joining the study; however, at childbirth and until 24 months, although there were
slightly fewer smokers in the NRT group, this small difference would not usually be considered important.
Babies’ health at birth was very similar no matter which patches mothers had been allocated. However,
2-year-old children born to women in the NRT group were more likely to have no development problems
and there was no difference in the frequency of breathing problems between groups.
We need further research to find out if higher doses of NRT could help pregnant women to stop smoking.
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Scientific summary
Background
Maternal smoking in pregnancy causes substantial morbidity and mortality and remains a public health
problem internationally. Although in many developed countries the rates of smoking in pregnancy are
falling, increases in populous middle- and low-income jurisdictions are expected to transfer a rising health
burden to these nations in future years. In addition to improving women’s health, stopping smoking in
pregnancy improves fetal and infant health outcomes; cessation has, for example, been shown to reduce
the incidence of low-birthweight (LBW) infants. Unfortunately, there is a limited evidence base to guide the
delivery of cessation support in pregnancy. Only behavioural support from a health professional and
‘self-help’ support, are of proven efficacy.
Pregnant women generally avoid medications and the only drug treatment for cessation that is widely used
during gestation is nicotine replacement therapy (NRT). The consensus view is that NRT should be safer
than smoking because it contains medicinal nicotine alone, whereas inhaled tobacco smoke contains
nicotine and many additional toxins. However, there are strong, biological reasons to suspect that standard
doses of NRT, which have only been demonstrated to work in non-pregnant smokers, may be less effective
for smoking cessation in pregnancy. Nicotine metabolism is much quicker in pregnancy, therefore,
nicotine substitution will be less complete when pregnant women use this and successful amelioration of
nicotine withdrawal symptoms is less likely. Prior to this trial, only 695 women had been enrolled in
studies investigating the efficacy and safety of NRT in pregnancy and, together, these provided insufficient
evidence to say whether or not NRT could be effective or safe when used for smoking cessation in
pregnancy. The Smoking, Nicotine And Pregnancy (SNAP) trial was designed to provide much needed
evidence for both issues.
Objectives
The overall aim of the study was to investigate whether NRT is more effective than placebo in achieving
smoking cessation for women between 12 and 24 weeks pregnant, who currently smoke five or more
cigarettes per day and who smoked at least 10 cigarettes per day before pregnancy.
The specific study objectives were to compare:
i. the clinical effectiveness and cost-effectiveness for achieving biochemically validated smoking cessation
of 15mg per 16 hours transdermal nicotine patches with placebo patches in women at delivery
ii. the effects of maternal NRT patch use with placebo patch use during pregnancy on (1) disability,
behaviour and development and (2) respiratory symptoms in infants at 2 years of age.
Methods
The SNAP trial was a double-blind, randomised, placebo-controlled trial with an accompanying health
economic evaluation. Potentially interested pregnant smokers with the above characteristics (see
Objectives) were identified as they attended ultrasonography appointments at seven hospital antenatal
clinics in the Midlands and north-west England. Research midwives (RMs), who worked in each centre,
discussed the study with potential participants and enrolled them and gained consent, as appropriate.
Participants set quit dates and RMs provided behavioural support lasting up to 1 hour before randomising
women to receiving either a 4-week supply of 15mg per 16 hours transdermal nicotine patches or visually
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identical placebos. One month later, women who remained abstinent were issued another 4-week patch
supply. RMs provided three more telephone behavioural support sessions on participants’ quit dates,
3 days afterwards and at 1 month. Those women who collected a second month’s supply of NRT also
received face-to-face support at 1 month. Women were offered further support from the RM and
from local NHS Stop Smoking Services (SSS), and delivery of behavioural support was guided by a
shared manual.
Research midwives followed up participants at 1 month after their quit dates and when women were
admitted to hospital in established labour, or as soon as possible afterwards. Following delivery, RMs
retrieved birth outcome data from medical records. After childbirth, follow-up was conducted from a
central trial office and postal questionnaires were sent to women at 6, 12 and 24 months after childbirth
with a variety of methods used to maintain contact with participants and maximise response rates. If
responses were not received at 24 months, follow-up questionnaires enquiring about infants’ health was
sent to participants’ general practitioners (GPs).
The primary outcome was self-reported prolonged abstinence from smoking between the quit date and
childbirth, validated at delivery by exhaled carbon monoxide (CO) and/or salivary cotinine (COT) estimation.
Temporary, brief smoking lapses of up to five cigarettes in total (on up to five occasions) were permitted.
Further outcomes were collected 2 years after birth and the primary outcome at this time point was infant
survival ‘without impairment’, defined as no disability or problems with behaviour and development having
been detected using standard parental or health professional questionnaires (HPQs).
Smoking status and smoking behaviour were ascertained at all follow-up points. The following outcomes
were also ascertained: at delivery, maternal and fetal birth outcomes and pregnancy morbidity; at
6 months, health status [using the European Quality of Life-5 Dimensions (EQ-5D) scale] and health service
use; at 1 year, respiratory symptoms and, at 2 years, child development outcomes, including ‘survival
without impairment’ and respiratory symptoms.
We aimed to recruit 1050 participants providing 93% power at a 5% significance level to detect a 9%
absolute difference between groups. We anticipated a 16% cessation rate in the placebo group, based on
the observations that 10% of smokers stop with usual care after their first antenatal visit and behavioural
support results in cessation by another 6–7%. We sought to detect the same treatment effect that NRT
patches have outside of pregnancy [odds ratio (OR) 1.74, 95% confidence interval (CI) 1.57 to 1.93],
giving a projected 25% NRT group cessation rate.
At delivery, participants who, for any reason, had missing smoking outcome data were assumed to be
smoking. For fetal outcomes, the primary analysis was of singleton births and for all outcomes, analysis
was on an intention-to-treat (ITT) basis and logistic regression, adjusted for centre, was used to compare
treatment groups. At 2 years, impairment of infants (i.e. disability or behaviour and development problems)
was assessed using parent-completed items from the Ages and Stages Questionnaire®, third edition
(ASQ-3™) (Squires J and Bricker D. Ages and Stages Questionnaire: A Parent-Completed Child-Monitoring
System. 3rd edn. Baltimore, MD: Paul H Brookes Publishing Co.; 2009) and questionnaires returned by
health professionals. The proportions of singleton infants without impairments were compared and
multiple imputation methods investigated the impact of missing data. Singleton ‘complete case’ analyses
using data from both questionnaires and an analysis including twin births with allowance for clustering
were also conducted.
Economic analyses aimed to determine costs of delivering the intervention, to conduct a cost-effectiveness
analysis using ‘cost-per quitter’ as an outcome and, also, to undertake a cost–utility analysis using EQ-5D
data collected at 6 months after delivery, combined with modelling of the impacts of any variation in
birth outcomes.
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Results
A total of 1050 women were enrolled in the trial (521 NRT, 529 placebo). From 1050 pregnancies, there
were 1034 live births (1010 singletons, 24 twins), five miscarriages, seven stillbirths, one elective termination,
one missed abortion (documented as having occurred before randomisation) and 14 for which birth
outcomes were unknown. Completeness of follow-up rates were similar in both groups at all time-points and
ascertainment rates based on participants’ responses were at 1 month, 82%; at delivery, 93%; at 6 months,
66%; at 1 year, 58% and at 2 years, 90%. Ascertainment rates for birth outcomes were even higher. Rates
of biochemical validation of smoking status at delivery were 89% in NRT and 92% in placebo groups,
respectively, and, at one month, corresponding rates were 89% and 85%. Adverse event (AE) rates were
similar in both groups. All 1034 (1010 singleton) infants were included in the follow-up and, of singletons,
among whom principal analyses were conducted, information on 88.2% (891; 445 NRT and 446 placebo
group) was returned at 2 years.
Smoking outcomes: at delivery, the validated, prolonged smoking cessation rate was 9.4% in the NRT
and 7.6% in the placebo group (OR for cessation with NRT 1.26, 95% CI 0.82 to 1.96). At 1 month, the
validated cessation rate was significantly higher in the NRT group (21.3% vs. 11.7%, OR for cessation with
NRT 2.05, 95% CI 1.46 to 2.88). After delivery, there were no statistically significant differences in
cessation. Self-reported prolonged abstinence since the quit date was: at 6 months, 5.4% in the NRT
group and 3.2% in the placebo group; at 1 year, 3.7% and 2.1%; and, at 2 years, 2.9% and
1.7%, respectively.
Adherence: relatively few participants reported using a full 8-week course of NRT. Of the 981 participants
followed up at delivery, only 7.2% (35/485) of women randomised to NRT and 2.8% (14/496) randomised
to placebo reported using trial medications for over 1 month. Additionally, of the 205 women who
reported abstinence at 1 month (173 had validated abstinence), only 101 accepted the offer of a further
4-week supply of patches.
Birth outcomes: these were generally similar between treatment groups. The only significant difference
was that more caesarean births occurred in the NRT group than in the placebo group (20.7% vs. 15.3%).
Infant outcomes at 2 years: 72.6% (323/445) of NRT group infants survived with ‘no impairment’,
compared with 65.5% (290/443) born to participants in the placebo group (OR 1.40, 95% CI 1.05 to
1.86). Sensitivity analyses including twins or using only questionnaires returned by parents gave similar
findings. There was no significant difference between groups in infants’ reported respiratory problems;
these occurred in 132 out of 444 (29.7%) of NRT and 111 out of 444 (25%) of placebo group infants,
respectively (OR for symptoms in NRT vs. placebo 1.30, 95% CI 0.97 to 1.74).
Economic analyses: total mean costs (costs of delivering the intervention and resource-use costs) were
approximately £91 higher in the NRT group and the incremental cost-effectiveness ratio (ICER) associated
with NRT use was £4926 per additional quitter (bootstrapped 95% CI –£114,128 to £126,747), or £4156
(bootstrapped 95% CI –£65,994 to £82,059) in analyses restricted to singleton infants; however, CIs show
there was substantial uncertainty around these estimates. It was not possible to model cost–utility of NRT
owing to very similar adverse birth outcomes rates and EQ-5D scores in both trial groups and the likely
amplification in uncertainty of estimates that such analyses would have caused.
Conclusions
The SNAP trial demonstrates that at 12–24 weeks’ gestation, supplementing behavioural support with a
15mg per 16 hours nicotine patch was no more effective than placebo in promoting sustained smoking
cessation throughout pregnancy. Despite significantly higher cessation rates occurring at 1 month in
the NRT group, this effect did not persist until delivery. The quit rate was slightly, but not statistically
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significantly, higher in the NRT group at delivery and this (still non-significant) difference remained at 6, 12
and 24 months. We do not know why NRT had a large, clinically and statistically significant effect early in
pregnancy, which disappeared as gestation progressed. There was no evidence for NRT having either a
beneficial or a harmful effect on birth outcomes, apart from slightly higher caesarean rates in the NRT
group. However, as adherence was poor, birth outcome findings are difficult to interpret and could have
been different had greater adherence with trial treatments occurred.
At 2 years, infants born to participants randomised to NRT were more likely to have survived without any
impairment, but there were no significant differences in infants’ respiratory problems. The most likely
reason for better NRT group infant outcomes are the lower, albeit largely non-significant, smoking rates in
NRT group mothers.
Total mean costs were approximately £91 higher in the NRT group, representing a small (3%) difference in
costs between trial groups and these higher costs were mainly attributable to the cost of the NRT patches
(mean= £46). According to the incremental cost-effectiveness estimates, NRT would be the preferred
option if decision-makers are willing to pay more than £4926 for an additional quitter. However, there was
substantial uncertainty around the estimates and there is no accepted threshold for funding health-care
interventions based on this kind of outcome.
Recommendations for research (in priority order)
1. Randomised controlled trials (RCTs) investigating the efficacy and safety of NRT when used for smoking
cessation in pregnancy should test a higher than standard dose NRT such as (1) patches delivering more
than 15mg nicotine in 16 hours (21mg in 24 hours), (2) 4-mg gum used as required or, (3) NRT patch
combined with any ‘on demand’ short acting NRT (e.g. gum or nasal spray).
2. To investigate whether or not apparent differences in infants’ outcomes persist into childhood. RCTs
investigating NRT for smoking cessation in pregnancy should assess infants’ clinical and economic
outcomes after 2 years of age.
3. Randomised controlled trials investigating the efficacy of NRT or other interventions for smoking
cessation used in pregnancy should include an assessment of impacts on infants using outcomes similar
to those employed in SNAP.
4. Reasons for pregnant women’s low levels of adherence with NRT should be investigated; findings could
be used in future trials to enhance participants’ adherence with NRT.
5. Increases in nicotine metabolism, occurring as pregnancy progresses could explain the reduced efficacy
that NRT has in later pregnancy. Further research should investigate this hypothesis.
Implications for health care
In the UK and some other health-care systems, NRT has become an established component of cessation
support for pregnant women. Although the SNAP trial found no evidence that standard dose NRT is
effective for smoking cessation, there was also no evidence that this is less safe than smoking; indeed, the
study suggests that NRT use in pregnancy is safe in terms of infant outcomes assessed at 2 years and may
have a protective effect on infant development. Although this is the first time that a smoking cessation
intervention has been observed to have a beneficial effect on pregnant smokers’ offspring, this finding
provides support for interventions involving NRT in pregnancy. Overall, our findings provide no evidence
that NRT should not be used in pregnancy, rather that NRT might be beneficial in this setting.
Effects of NRT on infant development are likely to be mediated through the small, observed changes in
maternal smoking. There are good reasons to believe that NRT used at higher doses might affect both
maternal smoking and infant development more substantially and trials of higher-dose NRT are indicated.
Other cessation interventions delivered in pregnancy might have similar impacts on infants, but this
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requires confirmation. Choosing between interventions for use with pregnant smokers is, therefore,
difficult; both ‘self-help’ and behavioural smoking cessation support promote maternal smoking cessation
and improve birth outcomes. However, while there is no evidence that NRT has these effects, NRT does
appear to have a potentially important protective effect on infant development. Therefore, this study
supports the offering of NRT to pregnant women who smoke; however, any such offer should take
account of the rather stronger research evidence from other studies indicating that behavioural and
‘self-help’ support both have beneficial effects on smoking behaviour in pregnancy.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN07249128.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The problem
Maternal smoking during pregnancy is the most important, and preventable, cause of adverse pregnancy
outcomes including placental abruption, miscarriage, birth before 37 weeks’ gestation (pre-term birth) and
low birthweight (LBW).1 Pre-term birth is the principal cause of neonatal death and morbidity, with up to
50% of infants’ neurodevelopmental problems being attributable to this.2 Similarly, LBW births are a
marker of ill health and are associated with the future development of coronary heart disease, type 2
diabetes and obesity.3
Tobacco smoking in pregnancy is a worldwide public health problem. The UK’s estimated rate of pre-natal
smoking is 12%4 and rates are similar in most developed countries, including Australia (17%),5 Denmark
(16%),6 the USA (11%)7 and Germany (13%).8 Some other European countries, such as Spain9 and
Poland,10 have considerably higher rates of maternal smoking in pregnancy, reaching around 30%.
Although the prevalence of smoking in pregnancy appears generally to be reducing in high-income
countries, in low- and middle-income countries, rates of maternal smoking in pregnancy are believed to be
increasing.11 It is predicted that in the future, higher rates of maternal smoking in low- and middle-income
countries will substantially transfer the health burden from smoking during pregnancy to these nations.12
Additionally, in high-income countries, rates of smoking in pregnancy remain highest among younger
women and those who are more socially disadvantaged.4 As the children of mothers who smoke are twice
as likely to become smokers,13 smoking in pregnancy perpetuates cycles of deprivation and health
inequalities across generations that permanent smoking cessation initiated in pregnancy could reduce.
Treatments for smoking cessation in pregnancy
Stopping smoking in pregnancy not only benefits maternal health but has positive impacts on infant
outcomes and effective cessation interventions which are used by pregnant women reduce numbers of
LBW and pre-term births.14 Presumably, because the harms of smoking and the benefits of stopping are
widely known, many smokers stop when they are planning a pregnancy or soon after conceiving; for
example, in England and Wales, around 50% of smokers manage to stop smoking during at least part of
their pregnancy.4 For pregnant women who are unable to stop smoking without assistance, there are only
two proven cessation interventions which could help them with this: behavioural14 and self-help15 smoking
cessation support. Intensive behavioural support, which is delivered outside women’s routine antenatal
care, can reduce smoking in later pregnancy14 [pooled risk ratio (RR) for reduction in smoking prevalence
after behavioural support 0.94, 95% confidence interval (CI) 0.93 to 0.96], as can self-help cessation
interventions15 [odds ratio (OR) for cessation following self-help intervention 1.83, 95% CI 1.23 to 2.73].
Behavioural support usually involves psychologically orientated counselling that can broadly be described as
‘cognitive–behavioural therapy’. However, for this intervention to have an effect, women must attend
appointments with health professionals in addition to their routine antenatal care; however, in countries
such as England, where such support has been freely available for some time, relatively few pregnant
smokers have made use of this. Using the NHS Stop Smoking Service (SSS)16 and maternity statistics17
combined with national survey data,4 one can estimate that, in 2011, only 14% of English pregnant
smokers set quit dates using such support and as few as 6% subsequently managed to stop smoking for
at least 4 weeks. Self-help support, including books, manuals, text messaging and DVDs, involves
structured interventions that may be introduced briefly to smokers by health professionals, but are
primarily designed for motivated quitters to work through on their own. Self-help interventions are not
likely to appeal to all smokers and do require a certain level of cognitive ability for successful use.
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Outside of pregnancy there are more cessation interventions of proven efficacy available to assist smokers,
including nicotine replacement therapy (NRT),18 bupropion (Zyban®, GSK)19 and varenicline (Champix®,
Pfizer).20 NRT works by substituting the nicotine inhaled in tobacco smoke, which is accompanied by many
other toxins, for ‘clean’ medicinal nicotine (e.g. transdermal patches or lozenges). Using NRT after becoming
abstinent permits the smoker to lessen or avoid withdrawal symptoms and, eventually, as the amount or
dose of NRT reduces, these are eliminated. Bupropion is an antidepressant with an uncertain mechanism of
action, but is thought to promote smoking cessation by antagonising nicotinic acetylcholine receptors.
Varenicline is an alpha-4 beta-2 nicotinic acetylcholine receptor partial agonist; it binds to nicotinic
receptors and is thought to act by preventing the pleasurable sensations that smokers experience after
smoking, making them less likely to do so and, hence, more likely to achieve cessation. Unfortunately,
neither varenicline nor bupropion is approved for use in pregnancy. Also, possibly owing to fears that either
drug might cause fetal harm, there are insufficient studies in pregnancy to draw any conclusions about the
efficacy of safety of either drug for use by pregnant smokers.
Nicotine is the active ingredient of NRT and its impacts in pregnancy have been much more thoroughly
researched.21 Nicotine is a known neurotoxin and may be expected to affect developing fetal nerve tissues.
This may explain observed associations between behavioural problems and attention deficit disorder
among smokers’ children.22,23 However, while tobacco combustion creates and releases many potential
fatal toxins in addition to nicotine, NRT delivers nicotine alone. Consequently, there is an international,
expert consensus that maternal use of NRT in pregnancy should be safer for the fetus than continued
smoking.24 It should be noted that this consensus, while logical, is theoretically based and is not
underpinned by research evidence. Nevertheless, this consensus has had an impact internationally on the
use of NRT in pregnancy and has contributed to a relaxation in indications for NRT prescribing during
pregnancy in some countries. For example, since 2003 in the UK, the British National Formulary25 (the
manual used to guide prescribing in the UK NHS) has listed pregnancy as a ‘caution’ rather than a
‘contraindication’ to using NRT. Additionally, in 2005, the UK Medicines and Healthcare products
Regulatory Agency (MHRA) issued guidance that specifically stated that pregnant women who had not
managed to stop smoking using other means could be prescribed NRT. Many other countries take similar
approaches; the authoritative website, www.treatobacco.net, hosts all nations’ smoking cessation
guidelines and the vast majority of those written in English recommend cautious use of NRT for smoking
cessation in pregnancy.26
Current evidence for nicotine-replacement therapy use
in pregnancy
Health policy recommendations for NRT use in pregnancy have developed in the absence of scientific
evidence. In 2004, when the study described in this report [the Smoking Nicotine And Pregnancy (SNAP)
trial] was commissioned, only three trials had investigated NRT for smoking cessation in pregnancy27–29 and
the largest of these29 was excluded from a later meta-analysis30 and Cochrane review31 because its design
made it impossible to attribute treatment effects to NRT. Pooling of data from these three studies,
including the trial which was not included in later reviews, suggested that NRT used in pregnancy had
borderline effectiveness for reducing smoking in later pregnancy (pooled RR 0.94, 95% CI 0.89 to 1.00).32
In addition, one of these studies had found that slightly heavier and, therefore, potentially healthier,
infants were born to women who had been randomised to NRT.27 While the SNAP trial was running, three
further trials investigating the efficacy and safety of NRT for smoking cessation in pregnancy were
published.33–35 However, a systematic review and meta-analysis that included these three more recent trials
and also the two previous relevant studies27,28 found no evidence that that NRT was effective for smoking
cessation in pregnancy (pooled RR for cessation after NRT 1.63, 95% CI 0.85 to 3.14).30 This lack of
evidence for the use of NRT in pregnancy comes from trials conducted in Canada, the USA, Denmark and
Australia, which randomised a total of 695 women.27,28,33–35
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Unfortunately, despite the knowledge that nicotine is potentially fetotoxic, there is little evidence available
to assess whether or not using NRT in pregnancy is safe. Of the five trials above that reported before the
SNAP trial concluded, only three monitored maternal or infant birth outcomes27,34,35 and none collected
data on infants’ outcomes after delivery. Given this paucity of empirical data, meta-analyses investigating
the impact of NRT on infants’ birth outcomes have been inconclusive30 and more data are required. In
addition, as nicotine could be one of the tobacco smoke constituents responsible for the cognitive and
behavioural problems seen in infants born to smokers,22 studies that assess the impact of NRT used for
cessation in pregnancy on early infant outcomes are also needed. It remains likely that nicotine is not solely
responsible for these adverse effects; indeed, it may have no such impacts, and other toxins in tobacco
smoke could be partially, or perhaps even completely responsible for them. However, this should not
be assumed.
In summary, smoking in pregnancy is an extremely harmful behaviour and an increasing public health
problem internationally. There are only two cessation interventions of proven efficacy for use in pregnancy
and no licensed drug cessation treatments have been shown to be safe or effective in pregnancy. There is
a consensus in favour of using NRT in pregnancy, but NRT remains of unproven efficacy and its impacts on
infants born to mothers who use it in pregnancy require determining. Consequently, the SNAP trial, a
double-blind, randomised placebo-controlled trial of NRT used for smoking cessation in pregnancy, was
planned and is described within this report.
Objectives
The overall aim of the study was to investigate whether or not NRT is more effective than placebo in
achieving smoking cessation for women between 12 and 24 weeks pregnant, who currently smoke five or
more cigarettes per day and who smoked at least 10 cigarettes per day before pregnancy.
The specific study objectives were to compare:
i. the clinical effectiveness and cost-effectiveness for achieving biochemically validated smoking cessation
of 15mg per 16 hours transdermal nicotine patches with placebo patches in women at delivery
ii. the effects of maternal NRT patch use with placebo patch use during pregnancy on (1) disability,
behaviour and development and (2) respiratory symptoms in infants at 2 years of age.
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Chapter 2 Methods
Trial design
This was a phase IV, multicentre, double-blind, randomised (1 : 1 allocation and stratified by site),
placebo-controlled, parallel-group trial of standard-dose (15mg per 16 hours) NRT patches. Participants
were monitored from their recruitment at between 12 and 24 weeks’ gestation until the delivery of their
babies and then followed up by questionnaire for a further 2 years.
Participants and recruitment
Eligibility criteria
Eligible women were aged 16–50 years, between 12 and 24 weeks’ pregnant, smoked at least
10 cigarettes per day before pregnancy and continued to smoke at least five cigarettes per day.
The eligible women also had an exhaled carbon monoxide (CO) concentration of at least 8 parts per
million (p.p.m.). They were excluded if they had contraindications to the use of NRT including severe
cardiovascular disease, unstable angina, cardiac arrhythmias, recent cardiovascular accident or transient
ischaemic attack, chronic generalised skin disorders or known sensitivity to nicotine patches, chemical or
alcohol dependence, known major fetal abnormalities, or were unable to give informed consent. Women
could enrol in the trial only once but could participate in other non-conflicting research projects.
Recruiting centres
Participants were recruited from seven hospital antenatal clinics in the Midlands and north-west England.
Initially, these were at Nottingham University Hospitals NHS Trust City Hospital campus, Nottingham
University Hospitals NHS Trust Queen’s Medical Centre (QMC) campus, Sherwood Forest Hospitals NHS
Foundation Trust (King’s Mill Hospital) and University Hospital of North Staffordshire NHS Trust (City
General Site). Three further sites were added later to improve recruitment rates: Mid Cheshire Hospitals
NHS Foundation Trust (Leighton Hospital), East Cheshire NHS Trust (Macclesfield District General Hospital)
and Derby Hospitals NHS Foundation Trust (Derby City General, later to become Royal Derby Hospital).
Research midwives
In each centre, research midwives (RMs) undertook all trial-related procedures. RMs were trained in
research procedures by the trial manager with input from the chief investigator and attended monthly staff
update meetings. In addition, Clare Mannion, one of the trial co-investigators and a UK expert trainer of
smoking cessation professionals, provided the RMs with training, to English national standards, in delivery
of behavioural support to pregnant women.36
Recruitment and consent
We used three methods of identifying and recruiting eligible women who were interested in
stopping smoking.
1. Community midwives usually ask women about smoking status at their booking appointment and then
refer those who would like help to stop smoking to their local NHS SSS. In some recruiting areas,
women referred to NHS SSS were asked if they would be interested in finding out about the trial and
the RM contacted any who expressed interest. Those who were not interested or eligible for enrolment,
but who wanted to stop smoking, were seen by the NHS SSS as per normal practice.
2. Leaflets containing brief information about the trial were sent to women before their antenatal clinic or
routine ultrasonography scan appointments. Women attending these clinics were then asked to
complete a screening questionnaire to identify those who were eligible and interested (see Appendix 1).
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3. Some women who had seen information leaflets or posters advertising the study in hospitals contacted
the RMs directly.
Potentially eligible women who expressed interest in the trial were given a participant information sheet
(PIS) and, after having chance to consider this for at least 24 hours and discuss with a RM, gave their
written informed consent before trial data were collected. In addition to trial participation, women were
asked to give consent for researchers to have access to their and their child’s medical records, for
information held by the NHS to be used to keep in touch with them and to follow their health status, and
also for storage of blood samples for possible use in future research. For most trial participants, consent
and baseline data collection took place in their homes.
Interventions
The only difference in interventions delivered to trial groups was in the type of transdermal patches
allocated to women. In the intervention group, these were active nicotine patches (15mg per 16 hours
NRT transdermal patches), whereas women in the control group received visually identical placebo patches.
At enrolment, RMs delivered behavioural support lasting up to 1 hour. During counselling, RMs applied
techniques to encourage cognitive and behavioural changes among smokers such that smoking cessation
could be successfully achieved. The initial session focused on behavioural advice and tips for smokers,
including preparation for quitting and how to avoid smoking lapses once a quit attempt had begun
in addition to instruction and advice on how to use patches (which could be either placebo or nicotine).
During the session, participants were required to set a quit date within 2 weeks from which follow-up was
timed. A manual used by RMs to guide the support sessions (‘The SNAP trial’s guide to stopping smoking
during pregnancy’: see Appendix 2) was written by Clare Mannion and included some techniques from the
US ‘Smoking Cessation and Reduction in Pregnancy Treatment’ trials37 that were believed to be relevant to
UK smokers. As is consistent with good smoking cessation practice, this manual, which contained tips and
suggestions for becoming smoke-free, was left with women so that they could refer to it after their
support session. Subsequently, participants were randomised to equal-sized groups receiving either a
4-week supply of 15mg per 16 hours NRT transdermal patches or visually identical placebos (United
Pharmaceuticals, Amman, Jordan), which women were instructed to start on their quit dates. One month
after quitting, those not smoking, validated by CO measurement of < 8 p.p.m.,38 were issued with another
4-week patch supply if they wanted it. In addition to behavioural support delivered at enrolment, RMs
provided three further behavioural support sessions to all participants. Telephone behavioural support was
delivered on participants’ quit dates, at 3 days afterwards and at 1 month afterwards; those women who
collected a second month’s supply of NRT also received face-to-face support from the RM at the time this
was delivered to them. These sessions involved reinforcement of earlier behavioural sessions, with an
added focus on ways of avoiding relapse now that quit attempts had begun.
Provision of additional behavioural support and nicotine-replacement
therapy to trial participants and availability of nicotine-replacement therapy
to non-participants
Prior to starting the trial, we visited local NHS SSSs in the recruiting areas and discussed their service
provision, as it was intended that these would provide behavioural support to women enrolled onto the
trial. Primary care trusts (PCTs) in all of the trial’s recruiting areas had NHS SSSs for pregnant women, but
several PCTs had recently undergone local reorganisations and there was considerable variation in the
delivery of cessation services. Some services were already issuing NRT to pregnant women, despite the
absence of evidence for its effectiveness. We hoped to get agreement from PCTs that, for the duration of
the trial, NRT would be issued only to pregnant women within the trial, thereby ensuring that local
availability did not jeopardise recruitment and/or retention of participants or interpretation of trial findings.
The outcome of these visits meant that, in most trial areas (all except Derby), women’s contact details were
shared with their local NHS SSS, which agreed to contact participants and offer them additional
METHODS
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behavioural support. They also agreed that they would not normally offer participants any non-trial NRT
products. Women were encouraged to ask for further behavioural support as necessary, and RMs or NHS
SSS staff, guided by the manual, delivered any additional support that participants required. In Derby,
where participants’ contact details were not shared with the NHS SSS, RMs provided additional support.
The provision of additional behavioural support to participants and the availability of NRT to participants
and non-participants who contacted the NHS SSS are shown in Table 1, which illustrates the context in
which trial recruitment occurred.
TABLE 1 Provision of additional behavioural support to participants and availability of NRT to participants and
non-participants by trial centre
Trial centre
PCTs hosting
NHS SSS within
the area of each
trial centre
Provision of
additional
behavioural
support
NRT availability within PCT
Trial participants Non-participants
Nottingham
University Hospitals
NHS Trust
(City Hospital and
QMC campuses)
Nottingham City
PCT (Nottingham
City New Leaf)
Nottingham City
New Leaf (Stop
Smoking) Service
Not offered or prescribed
NRT; if any enquired about
NRT, referred back to a
trial researcher for
further discussion
NRT still offered as
judged appropriate to
non-trial pregnant
women
Nottinghamshire
County PCT
(Nottinghamshire
County New Leaf)
Nottinghamshire
County New Leaf
(Stop Smoking)
Service
NRT not prescribed to any
pregnant women through
the service for the duration
of the trial
NRT not prescribed to
any pregnant women
through the service for
the duration of the trial
Derbyshire County
PCT (few
participants only
from the
Nottingham
University Hospitals
NHS Trust centres)
By RMs No agreements made; NRT
available via local NHS SSS
No changes to NRT
provision; available via
local NHS SSS
Sherwood Forest
Hospitals NHS
Foundation Trust
(King’s Mill
Hospital)
Nottinghamshire
County PCT
(Nottinghamshire
County New Leaf)
Nottinghamshire
County New Leaf
(Stop Smoking)
Service
NRT not prescribed to any
pregnant women through
the service for the duration
of the trial
NRT not prescribed to
any pregnant women
through the service for
the duration of the trial
University Hospital
of North
Staffordshire NHS
Trust (City General
site)
Stoke PCT (North
Staffordshire
NHS SSS)
RMs until 1 month,
then passed to
North Staffordshire
NHS SSS for
further support
if required
No NRT prescribed to
women enrolled onto
the trial
NRT prescribed only to
pregnant women not
eligible or not interested
in participating in
the trial
Mid Cheshire
Hospitals NHS
Foundation Trust
(Leighton Hospital)
Central and
Eastern Cheshire
PCT (Central and
Eastern Cheshire
NHS SSS)
Central and
Eastern Cheshire
NHS SSS
All eligible women
informed and referred to
trial. NRT not offered or
prescribed to any pregnant
women enrolled in the trial
NRT initially not
prescribed to any
pregnant women; later
changed so available to
women not eligible or
interested in
participating in the trial
East Cheshire NHS
Trust (Macclesfield
District General
Hospital)
Central and
Eastern Cheshire
PCT (Central and
Eastern Cheshire
NHS SSS)
Central and
Eastern Cheshire
NHS SSS
All eligible women
informed and referred to
trial. NRT not offered or
prescribed to any pregnant
women enrolled in the trial
NRT initially not
available to any
pregnant women; later
changed so available to
women not eligible or
interested in
participating in the trial
Derby Hospitals
NHS Foundation
Trust (Derby City
General Hospital)
Derby City and
Derbyshire County
PCTs (Fresh Start)
By RMs No agreements made; trial
participants not referred to
NHS SSS
No changes to NRT
provision; available via
local NHS SSS
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Randomisation and blinding
Eligibility criteria were entered into a secure online database before internet-based randomisation that was
stratified by recruiting site and used a computer-generated, pseudorandom code using random permuted
blocks of randomly varying size, with a 1 : 1 allocation ratio, which was created by the Nottingham Clinical
Trials Unit (NCTU) and held on a secure server in accordance with their standard operating procedures.
Following randomisation, the database issued participants with a unique identifier and allocated a trial
treatment-pack number to them. Identically packaged treatments, previously prepared by one central
pharmacy (QMC pharmacy, Nottingham University Hospitals NHS Trust), were dispensed by local
pharmacies. All pharmacists, research staff and trial participants were blinded to treatment allocations.
In addition, during the follow-up period in the 2 years after ascertainment of the primary outcome at
delivery, participants and anyone involved in following them up and entering data remained blind to the
treatment allocation.
Data collection to delivery
Baseline
At baseline, RMs collected women’s demographic and contact details: ‘Heaviness of Smoking Index’,39 a
measure of nicotine addiction recorded on a scale of 0 (lower) to 6 (higher nicotine addiction); number of
daily cigarettes smoked before pregnancy; partner’s smoking status; gestation; ethnicity; age completed
full-time education; parity; use of NRT in current pregnancy; height and weight. Women were also asked
to provide an exhaled CO measurement, blood and saliva samples for cotinine estimation and a blood
sample for future deoxyribonucleic acid (DNA) extraction (any studies using the DNA samples would
require further funding and relevant ethical approvals).
One month
One month after the quit date, RMs telephoned participants and asked for details about their smoking
status. This included whether or not they had smoked since their agreed quit date and, if so, how often
this had occured and whether or not they had smoked in the previous 24 hours. RMs also asked about
the number of times they had received additional behavioural support and whether this had been face
to face, by telephone or by mobile telephone text message; the number of trial patches they had used
(i.e. adherence); and whether or not they had obtained and used any additional NRT outside of the trial.
Those who reported not smoking were visited for CO validation and a saliva sample (for cotinine
measurement) was obtained from any women who were still using trial patches and not smoking.
Non-contactable women were sent a postal questionnaire.
Delivery
When participants were admitted to hospital in established labour prior to childbirth, or as soon as possible
afterwards, as at the 1-month contact, RMs or delivery suite staff ascertained smoking status, use of trial
and ‘non-trial’ NRT, including reported numbers of patches used and additional behavioural support
received. Exhaled CO measurements and saliva cotinine samples were obtained from women who reported
not smoking for at least 24 hours before delivery. RMs telephoned those missed while in hospital, and any
who reported abstinence were visited at home for biochemical validation within a maximum of 4 weeks
after delivery. Maternal and infant birth outcomes were obtained from medical records. Maternal outcomes
included hypertension (> 140/90mmHg) measured on two or more occasions during pregnancy, miscarriage
or stillbirth, labour onset (spontaneous, induced or no labour), mode of delivery (spontaneous vaginal,
assisted vaginal or caesarean section) and antenatal or postnatal hospital admissions. Infant data and
outcomes collected at delivery or after discharge included date of birth, name, hospital and NHS numbers,
sex, birthweight, gestational age at birth, number of births (with number and birth order if multiple birth),
live birth or stillbirth, arterial cord-blood pH (either ≥ 7 or < 7), Apgar score (either ≥ 7 or < 7),
METHODS
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intraventricular haemorrhage, neonatal convulsions, admissions to neonatal intensive care units (NICUs) and
any congenital abnormalities.
Adverse event monitoring
During each contact with participants, RMs enquired about adverse events (AEs) or symptoms the
participant had experienced. RMs also obtained this information from monthly examination of medical
records. They then summarised the descriptions in the case report forms and on the study database.
Descriptions were used to code the AEs according to standard terms in the Medical Dictionary for
Regulatory Activities (MedDRA®) version 13.1 [www.meddra.org/; MedDRA is the international medical
terminology developed under the auspices of the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH). MedDRA trademark is owned by
International Federation of Pharmaceutical Manufacturers and Associations on behalf of ICH]. The
incidence of events was analysed according to the MedDRA System Organ Class categorisation and
preferred terms. Information about deaths after delivery was obtained from the NHS Health and Social
Care Information Centre’s Data Linkage Service (previously Office for National Statistics) with whom all trial
participants and their infants had been flagged. After starting the trial, it was realised that many relatively
common pregnancy-related events were being reported as serious adverse events (SAEs), including
pregnancy-related hospital admissions, premature birth and LBW and, on clinical review, none of these had
been considered to be related to the study drug. The Trial Steering Committee (TSC) and the sponsor,
therefore, advised that it would be appropriate to amend the protocol so that only maternal and
fetal/infant deaths and hospital admissions unrelated to the underlying pregnancy would be reported as
SAEs, and ethical approval was received for this. We continued to collect and monitor these along with
other AEs, and the Data Monitoring Committee (DMC) reviewed data showing the distribution of all AEs
and SAEs within trial groups at their meetings.
Figure 1 is a flow chart showing the data collection process from recruitment until delivery.
Data collection and follow-up after delivery
After primary outcome data were collected, participants were followed up by postal questionnaire at
6 months, 1 year and 2 years after delivery of their infants. Questionnaires were not sent after maternal or
infant deaths, if no birth details were available, if the participant had withdrawn consent for follow-up, or
if no contact details could be obtained for the participant and if they were not registered with a general
practitioner (GP). The NHS Health and Social Care Information Centre sent the trial office a report
including information on any participant and infant deaths every 3 months. However, because of a delay in
receiving the death report, a questionnaire was sent inadvertently to a participant whose infant had died;
we subsequently sent the NHS Health and Social Care Information Centre a list of participants and infants
who were due to be sent questionnaires for them to check every month. For non-respondents, or if
questionnaires had been returned undelivered, the trial office contacted alternative family members using
contact details that the participant had provided when they enrolled onto the trial and, if necessary, the
participant’s GP or PCT were contacted to obtain their current contact details. During the follow-up period
in the 2 years after ascertainment of the primary outcome at delivery, all those involved in following-up
participants and in entering data remained blind to the treatment allocation.
A flow chart outlining the follow-up process from delivery until the infants’ second birthdays is shown
in Figure 2.
The evidence base for questionnaire design was taken into account when composing instruments40 and the
following evidence-based methods to improve postal returns of questionnaires were used to maximise
response rates.41 At each follow-up point, participants were sent a postal questionnaire followed by
one postal reminder after 2 weeks. After a further 2 weeks, participants were telephoned and asked to
complete the questionnaire over the telephone with an appointment made to call them back when necessary.
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Before attendance for ultrasound dating scan: women
sent brief information leaflets
Eligible and interested women identified from:
screening questionnaire during ultrasound scan
appointments
or
local smoking cessation services
or
direct contact by women
RM contacts women, sends patient
 information sheet and arranges initial trial visit
Initial visit: informed consent obtained, first session of
behavioural support delivered, baseline data and samples
collected. Quit date set within next 2 weeks
Randomisation: mandatory data entered onto internet
based randomisation system. Prescription with pack number
generated for 4-week treatment of active or placebo
patches. Participant referred to local NHS SSS
for follow-up support where applicable
1-month follow-up: participants contacted by
telephone to obtain smoking status. Non-smokers visited for
CO validation and salivary cotinine (if using patches).
Further 4-week supply of treatment issued to non-smokers
if required. Non-contactable women sent postal
questionnaire
Excluded if not
interested or enrolment
criteria not met
Delivery: smoking status obtained when admitted to
hospital for delivery or as soon afterwards (within 4 weeks).
CO and salivary cotinine obtained from non-smokers for
validation. Maternal and infant birth outcomes obtained
from medical records
Further sessions of
behavioural support by
NHS SSS or RM
Adverse events
collected at contact
points and from monthly
inspection of medical
records
FIGURE 1 Trial flow from recruitment to delivery.
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To maintain contact between researchers and participants, the trial office sent greetings cards following
childbirth, at Christmas and on the child’s first and second birthdays and participants were sent cards
reminding them to inform the team of any address changes. At 1 year, a cotton shopping bag was sent to
participants on completion of the questionnaire; at 2 years, participants were given a £5 shopping voucher for
questionnaire completion and there was a colouring competition that children of respondents could enter.
The colouring competition had a £50 shopping voucher prize, with a winner chosen three times per year.
Six months after childbirth
The following information was collected from participants 6 months after delivery: current smoking status,
smoking status since childbirth, maternal use of NRT and NHS SSSs since childbirth, length of any maternal
hospital inpatient stay after delivery lasting > 24 hours, length of any infant inpatient stay in special care
after birth, numbers of additional infant hospital admissions for respiratory illness or other causes, infant
feeding method and a health status measure – the European Quality of Life-5 Dimensions (EQ-5D).42
One year after childbirth
A shorter questionnaire was sent at 1 year, primarily to maintain contact with the participant, but also to
collect the following information: current smoking status, smoking status since birth of infant, infant’s
respiratory symptoms, infant hospital admissions for respiratory illness and other causes, and infant
feeding method.
6 months after childbirth
Postal questionnaire measuring self-reported smoking
status, health economic data, infant feeding method and
participant’s health status
1 year
Birthday card, postal questionnaire measuring smoking
status, infant respiratory symptoms, hospital admissions
and feeding method
Cotton shopping bag sent for completing
2 years
Birthday card, postal questionnaire to measure child’s
behaviour, development, respiratory symptoms, hospital
admissions, medication use and maternal smoking status
£5 shopping voucher sent for completing
Colouring competition for children with prize
All participants and
infants flagged with NHS
Health and Social Care
Information Centre in
case of maternal or infant
death. Alternative family
member, GP or PCT
contacted for current
contact details for
non-respondents and
undelivered
questionnaires
Health professional questionnaire (at 2 years)
Short postal questionnaire to measure child’s disability for
completion by GP or health visitor
One postal and one
telephone reminder for
all questionnaires (one
postal reminder only
for health professional
questionnaires)
No response from
participant/not
able to contact
FIGURE 2 Trial follow-up from delivery to infants’ second birthdays.
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Two years after childbirth
At 2 years, a questionnaire sent to participants, the 2-year ‘participant questionnaire’ (PQ2) asked about
maternal smoking behaviour and infant development. The PQ2 used items from the Ages and Stages
Questionnaire®, Third Edition (ASQ-3™),43,44 which has been developed for assessing child development at
2 years and is valid for use from 23 months until 25 months and 15 days. It was designed to be completed
by parents and to distinguish between children with suspected developmental delay and those for whom
development is within the normal range. In a US population, the ASQ-3 has been reported to have a
sensitivity of 92.2% and a specificity of 71.9% for detecting developmental delay at 24-months.45 With
permission from the authors and publishers, the wording of some questions was slightly adapted for our
UK population. Items 1–30 on the PQ2 consisted of all 30 ASQ-3 items on child development covering
five domains: communication, gross motor, fine motor, problem solving and personal–social development.
Seven additional PQ2 items (i.e. PQ2 items 31–36 and 44), also taken from the ASQ-3, were mixed ‘yes’ or
‘no’/free text questions investigating both general and specific parental concerns relating to infant health
and development. The PQ2 also contained items that were not from the ASQ-3 asking about infant
hospital admissions, parental reports of infants’ respiratory symptoms and any medication taken for these.
Health professional questionnaire
If, at 2 years, participants did not respond to the PQ2 questionnaire, the health professional questionnaire
(HPQ) was posted to their GPs. This shorter questionnaire was designed to be easily completed using
medical or health visitors’ records and health professionals completing HPQs required little knowledge of
the infants. If GPs could not complete HPQs, they were asked to forward these to health visitors. The HPQ
contained items that corresponded to those on the PQ2 and were also intended to measure children’s
disability and general health in a manner consistent with the ASQ-3.46–48 This included open-response
questions that corresponded to ‘non-domain’ ASQ-3 items included on the PQ2.
For any participants for whom we received both the completed PQ2 and HPQ, only responses from PQ2
were used in analyses.
The system we used to map the question responses to outcomes is outlined in the Derivation of composite
‘impairment’ outcome for infants section and in the statistical analysis plan (SAP) (this can be accessed at
http://eprints.nottingham.ac.uk/3283/).
Outcome measures and definitions
Primary outcome to delivery
The primary outcome was self-reported, prolonged and total abstinence from smoking between the quit
date and delivery, validated by exhaled CO and salivary cotinine (COT) at childbirth. Occasional minor
lapses (no more than five cigarettes in total between the quit date and delivery) were not counted as a
return to smoking; this is consistent with standard criteria for assessing outcome in cessation studies.49
CO readings of ≤ 8 p.p.m. and COT of < 10 ng/ml indicated not smoking.38 The method used for deriving
the primary outcome from responses at 1 month and delivery is detailed in Box 1.
Secondary outcomes
(a) Smoking outcomes monitored until delivery
i. self-reported, prolonged abstinence from smoking between the quit date and 1 month
ii. self-reported, prolonged abstinence from smoking between the quit date and 1 month with
biochemical validation (exhaled CO) (this outcome was not listed in the trial protocol).
iii. self-reported, prolonged abstinence from smoking between the quit date and delivery
METHODS
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iv. self-reported, prolonged abstinence from smoking between the quit date and delivery, with
biochemical validation of this at both 1-month follow-up and delivery
v. self-reported smoking cessation for the previous 24-hour period at delivery validated by exhaled
CO and saliva cotinine estimation.
(b) Smoking outcomes monitored after delivery
i. self-reported, prolonged abstinence from smoking between the quit date and 6 months
after delivery
ii. self-reported smoking cessation for the previous 7-day period at 6 months after delivery.
(c) Birth and maternal outcomes
i. miscarriage (non-live birth prior to 24 weeks’ gestation) and stillbirth (non-live birth at 24 weeks’
gestation or later)
ii. neonatal death (i.e. from live birth to 28 days)
iii. post-neonatal death (29 days to 2 years)
iv. individualised birthweight z-score (i.e. birthweight adjust for gestational age, maternal height,
maternal weight at booking and ethnic group)
v. unadjusted birthweight and birthweight as z-score
vi. Apgar score
vii. cord blood pH
viii. gestational age at birth
ix. intraventricular haemorrhage
x. neonatal enterocolitis
xi. neonatal convulsions
xii. congenital abnormality
xiii. NICU admission
xiv. infant ventilated > 24 hours
BOX 1 Derivation of primary outcome from responses at 1 month and delivery
For a positive response (i.e. abstinent from smoking), the following were required:
at 1 month: ‘smoked since quit date’= ‘no’ or ‘missing’ or ‘how often have you smoked’= ‘five times or less’
or ‘at least weekly but less than daily’ or ‘missing’ (i.e. any response other than ‘on most days or frequently’)
and
at delivery: ‘smoked in last 24 hours’= ‘no’ and ‘smoked since quit date’= ‘no’ and CO result is between 0
and 8 and/or COTa,b < 10 ng/ml or ‘how often have you smoked’= ‘five times or less’ and CO result is
between 0 and 8 and/or COT < 10 ng/ml.
a Some participants will only have CO measurements and, for these women, readings in the stated reference
range are defined as a positive primary outcome (even without COT). Most trial participants will have both
CO and COT measurements and, for these women, BOTH readings must fall within defined ranges to count
as having a positive outcome.
b At the outset of the trial, CO only was used to validate abstinence from smoking at delivery, but at DMC/TSC
request this was changed and COT was added. Consequently, for most participants, both CO and COT were
available at delivery. Therefore, either CO or COT could be used individually for validation, but if both were
available then they both needed to indicate abstinence for a positive outcome.
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xv. elective termination
xvi. elective termination undertaken for fetal morbidity judged incompatible with fetal/infant survival
xvii. maternal mortality
xviii. mode of delivery
xix. hypertension in pregnancy (> 140/90mmHg at least twice).
Outcomes 2 years after delivery
(a) Infant impairment
Defined as presence of disability and/or behaviour and development problem(s) and categorised as:
i. survival with no impairment: two of the outcomes in the protocol at 2 years were (1) behaviour
and development and (2) disability. These outcomes were combined for analysis and reporting
purposes and the mapping of protocol outcomes on to those listed above is fully described in the
next section (see Derivation of composite ‘impairment’ outcome for infants) and the SAP
(http://eprints.nottingham.ac.uk/3283/)
ii. survival with definite impairment (this outcome was not listed in the trial protocol)
iii. survival with suspected impairment (this outcome was not listed in the trial protocol).
Survival with ‘no impairment’ was the primary outcome at 2 years.
(b) Infant respiratory symptoms
(c) Smoking outcomes
i. self-reported, prolonged abstinence from smoking between quit date and 2 years after delivery
ii. self-reported smoking cessation for previous 7-day period at 2 years after delivery.
Derivation of composite ‘impairment’ outcome for infants
Overview
Full details of how these outcomes were derived from questionnaire responses can be found in the SAP
(http://eprints.nottingham.ac.uk/3283/), but a summary follows. This process was discussed with the TSC
and the independent TSC statistician approved the SAP before analyses began.
Rationale
At the outset of the trial, we proposed two discrete infant outcomes at 2 years and these were
(1) behaviour and development and (2) disability. However, there was no expectation that infants born
within the trial would have particularly high rates of disability or developmental problems; therefore, when
preparing the SAP for the follow-up analyses, the decision was taken to amalgamate data on both
outcomes into one composite outcome. The rationale was that this would permit the trial to demonstrate
with greater confidence whether or not NRT is safe for use in pregnancy, as judged in terms of infant
development at 2 years.
Impairments were categorised in a mutually exclusive way so that all infants for whom questionnaires had
been returned were allocated to just one of the following categories: ‘survival with no impairment’,
‘definite developmental impairment’ or ‘suspected developmental impairment’. This categorisation was
based on responses to selected PQ2 and HPQ items, including the ASQ-3 domains. The scoring of the
domains is explained in the following section [Scoring of Ages and Stages Questionnaire (2-year participant
questionnaire) domain scores], followed by an explanation of how these domain scores and other
PQ2/HPQ responses were collated to form outcomes. In some cases, one or more members of the research
team inspected hard copies of questionnaires to allocate outcomes after making judgements about
free-text responses and, in all such cases, assessors were blind to participants’ treatment allocations.
METHODS
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Scoring of Ages and Stages Questionnaire (2-year participant questionnaire)
domain scores
Ages and Stages Questionnaire items from the PQ2 that are components of ASQ-3 domains were scored
and these individual item scores were summed to give overall ‘domain’ scores, as described in the ASQ-3
User Guide.45 Overall ‘domain’ scores were then compared with standard thresholds/cut-off points to
determine whether domain scores should be categorised as ‘normal’, ‘abnormal’ or ‘borderline’. In clinical
practice, any infants with ‘abnormal’ scores for any ASQ-3 domain would be considered to have ‘failed’
the ASQ-3 and would be recommended to undergo a more detailed assessment for development delay
and those with borderline scores would be closely monitored.
Primary outcome: survival with no impairment
We classified infants as having ‘survived with no impairment’ if scores were normal for all ASQ-3 domains
included on the PQ2 AND no problems were reported in PQ2 items 31–35 (i.e. free-text response
questions also taken from the ASQ-3). If the PQ2 was not completed but a HPQ had been returned, this
was used instead and ‘survival with no impairment’ was considered to have occurred when no HPQ
responses indicated potential developmental problems.
Definite and suspected impairment
1. ‘Definite’ developmental impairment: we classified infants as having developmental impairment if scores
were at or below the cut-point in any ASQ-3 domain(s) or, if no participant questionnaire had been
completed, if the HPQ indicated severe problems for any of questions 1–4 and/or severe disability was
indicated by the response to question 9 and/or severe development delay was indicated in response to
question 10.
2. ‘Suspected’ developmental impairment: we classified infants as having suspected developmental
impairment if all ASQ-3 scores were above the cut-point, but one or more domains scores fell within
the borderline range and/or this classification was used if responses to either the PQ2 or HPQ reported
concerns about developmental impairment that were judged to represent potential impairment. ‘Yes’
responses to PQ2 items questions 31–37 or HPQ questions 1–6 were examined by the research team; if
these were judged to potentially reflect valid developmental impairments, infants were placed in the
‘suspected impairment’ category and/or any response stating that a child had mild or moderate
disability on HPQ question 9 and/or mild or moderate development delay on HPQ question 10 was
classed as suspected developmental impairment.
It should be noted that HPQ/PQ2 items dealing with feeding and behaviour problems were not used in
derivation of these early child outcomes; these kinds of problems are frequently reported and have a
variety of causes. A priori, we decided not to consider reports of these problems as indicative of
impairment. In addition, as questions 1–4 were yes/no responses with free text, the severity of problems
could be difficult to establish. Therefore, we used caution and if there were doubts about the severity of
problems we classified them as ‘suspected’ impairment.
Derivation of infant respiratory problems
Infants were judged to have a respiratory problem if, at 2 years, any of questions 38–42 of the PQ2 and/or
question 7 of the HPQ indicated this. On the PQ2, these questions included hospital admissions for
respiratory problems, problems with chest or breathing (yes/no, free text), wheeze or whistling in chest
(yes/no, frequency), doctor diagnosed asthma (yes/no), asthma medications taken (yes/no, inhaler
description free text). The HPQ asked whether or not the child has problems with their chest or breathing
(yes/no, free text).
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Maternal smoking outcomes after delivery
We assessed these in a manner consistent with Russell Criteria49 and with smoking outcomes reported at
delivery. The derivation of smoking outcomes is described below:
1. Positive outcome for ‘Self-reported, prolonged abstinence from smoking between quit date and 2 years
after delivery’: the participant must have met the criteria for prolonged abstinence at delivery
(i.e. positive primary outcome), plus one of the following responses
‘smoked since 2-year-old was born’= ‘No’
or
‘how often have you smoked’= ‘five times or less’
If any participant questionnaires were completed at 6 and/or 12 months, these should all have had the
same responses as above for a positive outcome.
2. Smoked in last week (self-reported smoking cessation for previous 7-day period at 2 years
after delivery):
‘smoked since two year old was born’= ‘No’
or ‘smoked in last week’= ‘No’
3. Smoked in last 2 years (self-reported prolonged abstinence from smoking between delivery and 2 years)
(this outcome was not listed in the trial protocol)
‘smoked since two year old was born’= ‘No’
or
‘how often have you smoked’= ‘5 times or less’
If any participant questionnaires had been completed at 6 and/or 12 months, these should all have had
the same responses as above for a positive outcome.
Outcomes collected on 6-month and 1-year questionnaires
Smoking status and respiratory outcome items were included on 6-month and 1-year questionnaires.
These were not listed in the study protocol and only smoking outcomes are reported later. In addition, at
6 months, the EQ-5D questionnaire items were also used and questionnaire items asked about length of
stay in hospital and/or special care unit after delivery, infant hospital admissions and medications taken;
these data were intended for the Health economics analysis (see Chapter 4).
The 6-month and 1-year questionnaires included questions about breast and bottle-feeding and, again,
these items were not included in the original study protocol and data are not presented in this report.
Sample size
We planned to recruit 525 women into each arm of the study. A trial with 500 women in each arm would
detect an absolute difference of 9% in smoking cessation rates between the two groups immediately before
childbirth, with a two-sided significance level of 5% and a power of 93%. It was anticipated that up to 5% of
women would be lost to follow-up, and the sample size (of 500) was inflated by a factor of 1.05 to allow for
this. This size of study allowed smaller treatment effects to be detected with lower power. For example, there
would be 80% power to detect an absolute difference in cessation rates of 7%.
A Cochrane review showed that approximately 10% of women who are still smoking at the time of their
first antenatal visit stop smoking with usual care, and a further 6–7% will stop as a result of a formal
smoking cessation programme using intensive behavioural counselling.32 Therefore, in our control group
(placebo plus intensive behavioural counselling), a smoking cessation rate of around 16% was anticipated.
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The most recent Cochrane review of the efficacy of NRT outside of pregnancy had reported a treatment
effect (OR) for transdermal patches of 1.74 (95% CI 1.57 to 1.93).50 Consequently, if NRT were similarly
effective in pregnancy, one could expect a smoking cessation rate of approximately 25% in the treatment
group (NRT plus intensive behavioural counselling).
Tables in the SAP show the consequences to study power if the treatment effects in the trial were smaller
or overall quit rate was lower than expected (http://eprints.nottingham.ac.uk/3283/).
Statistical methods
The SAP for the primary analysis was finalised before any analyses started. For analyses to be conducted on
follow-up data, the analysis plan was added to and finalised during the follow-up period, before any
follow-up analyses commenced. (The SAP containing both primary and follow-up analyses can be found
at http://eprints.nottingham.ac.uk/3283/). Data cleaning and preparatory work were performed blind to
study arm allocation and all analyses of outcomes recorded at delivery were performed blind to study arm
allocation, with treatment codes revealed after these were completed. However, it was not possible to
perform all follow-up analyses blind. Statistical analyses were performed using SAS software version 9.1.3
(SAS Institute Inc., Cary, NC, USA) and Stata/SE version 11.2 (StataCorp LP, College Station, TX, USA).
Analysis to primary outcome point (delivery)
Analysis was on an intention-to-treat (ITT) basis and participants who, for any reason, had missing
outcome data were assumed to be smoking. The proportion of women who reported prolonged
abstinence from smoking immediately before childbirth was compared between treatment groups by
logistic regression and adjusted for recruitment centre as a stratification variable. Statistical significance
was assessed using the likelihood ratio test. The primary analysis adjusted for no further variables as
multivariate analysis results, and therefore overall conclusions, can be sensitive to decisions concerning
which variables to adjust for and how these are specified. Nevertheless, we planned a secondary analysis
adjusting for baseline COT (continuous variable), maternal education (in years) and partners’ smoking
status (binary variable), as adjusting for potentially important prognostic factors can improve the precision
of treatment effect estimates.51 Other smoking cessation outcomes were analysed similarly.
Fetal and maternal birth outcomes were compared on an ITT basis. For binary outcomes, ORs were
obtained using logistic regression adjusted for recruitment centre and also using the likelihood ratio test
(with Fisher’s exact test used and stratification by centre ignored when numbers of events were small).
For continuous outcomes, we compared means between groups with adjustment for recruitment centre
using multiple linear regression.
For fetal outcomes, primary analysis was of singleton births only to allow for the fact that observations will
be non-independent and that non-singleton births are likely to have different birth outcomes. However,
we undertook a sensitivity analysis including multiple births, with clustering of outcomes accounted for
using an approach previously published. This adapts the methodology previously created for use with
cluster randomised controlled trials (RCTs), assuming that each woman is regarded as the ‘cluster’ and her
number of offspring the cluster size.52
In all analyses, a p-value of < 0.05 was taken to indicate statistical significance and 95% CIs
were calculated.
Analysis at the 2-year follow-up point
The ASQ-3 does not require adjustment of an infant’s age to allow for prematurity once he or she reaches
24 months of age; therefore, as the questionnaire was sent shortly before the child’s second birthday, no
adjustment to infant ages was made in analyses.
DOI: 10.3310/hta18540 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 54
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Maternal characteristics at baseline and delivery and infant birth outcomes at delivery were compared
between those participants and infants who did and did not have outcomes ascertained at 2 years after
delivery. We also compared maternal and infant characteristics according to whether follow-up at 2 years
was by PQ2, HPQ or neither.
Analysis of early childhood outcomes was on an ITT basis with participants analysed in the treatment groups
to which they were randomised. Participants with no live birth (i.e. miscarriage, stillbirth or elective
termination) or those where the pregnancy outcome was unknown were excluded from the ITT analysis, but
postnatal infant deaths were included in the denominator for developmental outcomes. The primary analysis
was restricted to singleton births to allow for the fact that observations will be non-independent and that
multiple births may have very different outcomes. For the primary outcome, survival with no impairment, a
complete case analysis was compared with an analysis using multiple imputation to deal with missing values.
Multiple imputation was carried out using the ‘mi’ commands in Stata and in our multiple imputation we
included all of the complete baseline and the treatment code, and used 20 imputations. Using this approach,
multiple imputation was also used for the other developmental outcomes: suspected and definite
developmental impairment. The infant impairment and respiratory outcomes at 2 years were analysed as
binary indicators of presence or absence of the outcome. The ORs for the effect of treatment group were
obtained by logistic regression adjusting for centre as the stratification factor. In a subsidiary analysis, multiple
births were included and clustering accounted for by the same method as in analysis at delivery. We also
conducted sensitivity analyses comparing the results of analyses based on parental responses only and those
based on a combination of parental and health professional responses.
Smoking outcomes were also analysed on an ITT basis, with all women analysed in the treatment groups
to which they were randomised and all non-respondents assumed to be smoking. ORs for the effect of
treatment group on smoking cessation outcomes were also obtained by logistic regression. As at delivery,
the primary analysis adjusted only for centre, but we carried out sensitivity analysis that also adjusted for
baseline COT, partner’s smoking status and age at finishing education.
We tested the assumption that those missing at follow-up were smokers by exploring alternative associations
for the relationship between smoking status and ‘missingness’.53 In this analysis, we defined the OR for the
association between quitting and being missing as the informatively missing odds ratio (IMOR) and we looked
at the effect on the size of the treatment effect on smoking abstinence outcome by varying the size of this
OR between 0 and 1. In the main analysis, the assumption that those missing at follow-up are smokers is
equivalent to assuming that IMOR equals 0 (i.e. that all those who are missing are smokers). We altered this
OR up to IMOR equals 1, which is equivalent to assuming that there is no association between being missing
data and smoking status. We carried out this analysis using the mean score method to estimate the treatment
effect under the pattern mixture model, logit[E(y|r,my)]= α1+ β1r+myδ, where my is an indicator of whether
the outcome is missing or otherwise, r is the treatment effect, and exponential (δ) [the OR between outcome y
and my (IMOR)] is varied in the range 0–1.54 α1 and β1 are estimated using the subgroup with outcome data,
missing values of y (the outcome) are replaced by invlogit(α1+ β1r+ δ), the mean of this new y variable is
calculated for the intervention and control arms (say a1 and a0), and ORs calculated from these mean values
accordingly [a1/(1 – a1)]/[a0/1 – a0)].
Secondary analysis
A priori, we planned to investigate whether or not there was any relationship between self-reported nicotine
patch use in pregnancy and the presence or absence of developmental impairment in infants at 2 years.
For this, we conducted an exploratory regression analysis with absence of impairment at 2 years as the
dependent variable and the number of nicotine patches women reported having used when asked at delivery
as an explanatory variable. ‘Suspected’ and ‘definite’ impairment categories were combined into one group
representing infants who did not have impairment-free survival at 2 years. We investigated the possibility that
baseline maternal characteristics may have a confounding effect on any relationship and adjusted for
confounders as appropriate. For those in the placebo group, we set adherence with nicotine patches as zero.
Additionally, if data on adherence were not reported at delivery, we imputed 0 days use of nicotine patches.
METHODS
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Trial management and conduct
The trial was co-ordinated from a central trial office located within the University of Nottingham, with the
day-to-day running supervised and organised by a local trial management group and trial manager. The
trial was sponsored by the University of Nottingham and conducted in accordance with good clinical
practice (GCP) guidelines. All research staff received GCP and research governance training in addition to
the study-specific training. Monthly research staff meetings were held in Nottingham, which all RMs were
encouraged to attend; the aim was to keep them motivated, updated and trained, as well as to give them
the opportunity to network with each other.
In addition to GCP and research governance training, all RMs were trained to English national standards in
delivering smoking cessation advice, with particular emphasis on the issues faced by pregnant smokers.
RMs completed the 2-day training before they started recruiting, with additional refresher training during
the trial. The general aim of training was to provide RMs with an understanding of the basic epidemiology
of smoking behaviour, the motivations behind this, harm caused by smoking and environmental tobacco
smoke exposure, why people smoke and key barriers to quitting experienced by those smokers who
attempt cessation. Skills-focused sessions also aimed to equip RMs with the counselling skills required to
help smokers to begin thinking differently about their habit (cognitive change) and to apply recognised
techniques to overcoming their addiction (behavioural change). RMs were trained to put emphasis on the
value of behavioural approaches for cessation in pregnancy, on the uncertainty regarding the efficacy of
NRT and the inappropriateness of using either bupropion or varenicline in pregnancy. In addition, they
were trained to counsel participants in the appropriate use of patches (i.e. as if all were issued with
active patches) and to instruct them not to smoke or use non-trial NRT preparations in addition to
trial medications.
The NCTU provided a web-based database and randomisation system, data management reports and
MedDRA coding of AEs. The system was held on a secure server in the NCTU, had a full electronic audit
trail and full back-ups of the database were made every 24 hours. Baseline and follow-up data were
collected on paper case report forms (CRFs) or questionnaires and then inputted onto the database by the
RM or trial administrator. The database included validation checks on data fields, whereby responses not
meeting expected criteria would be flagged so that data entry errors were minimised. The trial
administrator or trial manager checked all database entries contributing to the outcomes at delivery
against the CRF and clarified any queries with RMs. In addition, 10% of follow-up questionnaires were
checked against database entries.
The independent TSC and the DMC met once or twice per year to monitor and supervise the progress and
conduct of the trial and to review any safety or data issues. The DMC received blinded outcome data each
time it met. Stopping rules were established such that if quit rates in the whole sample fell below 4%, or if
recruitment rates fell below 25% of the target, then they would consider recommending that the trial
be stopped.
Oxfordshire Research Committee A granted national research ethical approval, with additional local
approvals for each recruitment centre and Clinical Trial Authorisation (CTA) approval from the MHRA (CTA
number: 03057/0002/001-0001). The protocol was published,55 with several approved amendments made
to the original protocol after the start of recruitment; details of these amendments are given below (see
Protocol amendments) and the final protocol can be found in Appendix 3. The trial was registered on the
ISRCRN database (ISRCTN07249128) and was assigned a EudraCT number (2004-002621-46). The NHS
National Institute for Health Research (NIHR) Primary Care Research Network adopted the study.
Bulk supplies of the NRT and placebo patches were manufactured by United Pharmaceuticals, purchased at
market rates and imported into the EU via Almac Ltd, Clinical Trial Services, Craigavon, Northern Ireland.
QMC Clinical Trials Pharmacy at Nottingham University Hospitals NHS Trust managed quality control
testing, packaging and labelling of participant packs. To ensure stability for the whole study period, the
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patches needed to be stored refrigerated at 2–8 °C before being dispensed to participants. However,
as the drug was stable at temperatures of < 25 °C for 3 months, and only 1 month’s supply of patches
was issued at a time, it was not necessary for participants to store them in a refrigerator.
Baseline and 1-month saliva samples were analysed at laboratories within the Centre for Oncology and
Molecular Medicine, Division of Medical Sciences at the University of Dundee, UK, under the overall
supervision of Professor Michael Coughtrie (a co-investigator). Baseline blood samples were analysed by
ABS Laboratories Ltd, Welwyn Garden City, Hertfordshire, UK, and saliva samples taken at delivery were
analysed by Salimetrics Europe Ltd, Newmarket, Suffolk, UK.
Protocol amendments
Brief details of protocol amendments made after the start of recruitment, but prior to breaking treatment
allocation codes, are listed below.
1. We originally anticipated that women would be sent the PIS before their clinic appointments so that
they could then be recruited and consented when they attended for their antenatal scan appointment.
However, it was soon realised that, overall, this was not a practical option and that most women were
being enrolled on home visits. Therefore, rather than posting the PIS to all women, we added the
option of just sending leaflets containing brief information about the trial, with the full PIS later posted
to women who had been identified and contacted using the screening questionnaire.
2. Small changes were made to the protocol to clarify trial processes and allow for minor variations in
practice in the different centres due to different local arrangements in, for example, prescribing and
dispensing practices, local clinic arrangements, follow-up cessation support and time spent in hospital
after delivery.
3. Ambiguities in the primary outcome measure were addressed and clarified in the protocol, including the
time window in which data collected could be used for analysis, how self-report and biochemical
validation data of smoking cessation contributed to a positive primary outcome and what constitutes
‘prolonged abstinence from smoking’. Secondary outcomes were clarified to distinguish and define fetal
death at different gestations, i.e. miscarriage and stillbirth.
4. We obtained ethical approval to send a ‘congratulations on the birth of your baby’ card to women
after delivery.
5. The content of the questionnaires sent at 6 months, 1 year and 2 years after delivery was finalised and
approved, along with a questionnaire to be sent to participants when they could not be contacted
1 month after their quit date. We also decided to include incentives of shopping vouchers and a
colouring competition to help improve response rates for the 2-year questionnaires.41
6. Once the trial started, we realised that as many pregnancy-related conditions required hospital
admissions this was resulting in a large number of SAE reports, none of which were felt to be related to
the study drug. Therefore, the sponsor and TSC recommended that we should extend the list of
conditions in the protocol that did not need to be reported as a SAE (any deaths of the mother or fetus/
infant were still reported). All these AEs were still collected and reviewed by the DMC so that
unforeseen impacts of NRT could be monitored.
7. Following further stability data from the manufacturer of the nicotine and placebo patches used in the
study, the shelf life was extended from 24 to 42 months.
Trial extensions
The HTA granted two time extensions to the application, adding a total of 12 months to the original
length of the trial. This was necessary as the start of recruitment was slightly delayed and the overall
recruitment period took 10 months longer than the original estimate of 24 months. Careful budgeting of
trial resources funded the majority of this extension, but a small addition to the budget was also awarded.
METHODS
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Chapter 3 Results
Recruitment and follow-up of outcomes at delivery
Recruitment and flow of participants through the trial
Participants were recruited between May 2007 and February 2010 (Figure 3 and Table 2). We initially
estimated that recruitment would take 24 months, but after the first 6 months, target figures were revised
in line with actual recruitment figures and the recruitment period extended by 10 months.
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FIGURE 3 Cumulative trial recruitment.
TABLE 2 Recruitment numbers by study centre
Centre NRT (n) Placebo (n) Total (N= 1050), n (%)
Nottingham University Hospitals NHS Trust
(QMC campus)
61 62 123 (11.7)
Nottingham University Hospitals NHS Trust
(City Hospital campus)
62 66 128 (12.2)
Sherwood Forest Hospitals NHS Foundation Trust
(King’s Mill Hospital)
108 108 216 (20.6)
University Hospital of North Staffordshire
(City General Site)
127 130 257 (24.5)
Mid Cheshire Hospitals NHS Foundation Trust
(Leighton Hospital)
83 84 167 (15.9)
East Cheshire NHS Trust (Macclesfield District
General Hospital)
40 40 80 (7.6)
Derby Hospitals NHS Foundation Trust (Derby City
General – later to become Royal Derby Hospital)
40 39 79 (7.5)
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The Consolidated Standards of Reporting Trials (CONSORT) diagram (Figure 4) summarises the process of
recruitment and flow of participants through the study to the primary follow-up point. Approximately
21,000 women were informed of the trial by questionnaires that were distributed and completed in
antenatal clinics. The majority of these (around 18,590) were excluded without further contact either
because the screening questionnaire showed that they were not eligible (usually because they were not
smokers), or because they had no interest in joining the trial.
Of the 2410 women who expressed interest in the trial and were assessed for eligibility, 1051 (43.6%)
were randomised: 521 were assigned to receive NRT and 530 were assigned to receive placebo patches
(see Figure 4). One woman was mistakenly enrolled for a second time in a subsequent pregnancy; her
second enrolment in the placebo group was removed from all analyses, giving a final sample size of 1050
(529 in the placebo group).
Protocol breaches were discovered for 13 other participants, but after consideration of violation details it
was decided that these were not serious and would have no significant impact on trial participants or the
scientific integrity of the trial. These participants, therefore, remained in the trial and their data were used
in analyses; details of these protocol breaches are given in Appendix 4.
Two additional problems affecting 27 participants occurred within one site pharmacy, but, again,
these were judged to have no significant impact on participants or trial integrity, and details are given
in Appendix 4.
Of 1050 pregnancies, 1038 were singleton and 12 were twin.
At 1 month after their quit date, 866 women (82.5%) provided outcome data and, of these, 573 (66.2%)
responded by telephone, 19 (2.2%) responded by questionnaire and 274 (31.6%) attended face-to-face
consultations with RMs.
At delivery, 981 (93.4%) participants provided smoking outcome data, but 46 (4.4%) who could not be
contacted within the necessary time frame, 10 (1.0%) who withdrew consent and 13 (1.2%) who
experienced fetal or infant death (including one elective termination) were not asked for their
smoking status.
For most participants who reported that they were non-smokers, biochemical validation was obtained.
The validation rates at 1 month were 89% (116/131) in the NRT group and 85% (63/74) in the placebo
group. At delivery, validation rates were 89% (58/65 women) in the NRT group and 92% (45/49) in the
placebo group.
The ascertainment rate for birth outcomes was more complete than smoking outcomes as these were
obtained from participants’ hospital notes. Figure 5 summarises numbers of births within participants and
completeness of birth outcome ascertainment.
Further details on the numbers of participants who were followed up and for whom outcome data were
obtained at 1 month and at delivery are presented by study centre in Table 3.
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2410 interested and eligibility assessed
1359 excluded (see breakdown left*): 
did not meet inclusion criteria
declined to participate
other reasons
433
874
52
*Excluded (n = 1359): breakdown of reasons  
433 did not meet inclusion criteria:
3
107
219
36
5
29
24
4
2
4
outside age range
< 12 or > 24 + 6 weeks pregnant
< 5 cigarettes/day now or
< 10 before pregnancy
CO < 8
previously enrolled
contraindications to NRT
chemical or alcohol addiction
unable to give informed consent
known major fetal anomalies
not specified
874 declined to participate:
85
789
already using NRT/other cessation support
declined/DNA
52 other reasons:
39
5
8
miscarriage before enrolment/not pregnant
moved out of area
not specified
»21,000 women informed of trial
(e.g. by questionnaires)
~18,590 excluded – not
eligible or not interested
521 allocated to NRT
Follow-up at delivery
(primary outcome point) = 496 (93.8%)
22
7
4
lost to follow-up
withdrew consent
fetal/infant death
530 allocated to placebo
1 removed from primary outcome
analysis: enrolled twice;
529 included in ITT analysis
Follow-up at delivery
(primary outcome) = 485 (93.1%)
24
3
9
lost to follow-up
withdrew consent
fetal/infant death
1-month follow-up, n = 437/521 (83.9%) 1-month follow-up, n = 429/529 (81.1%)
FIGURE 4 The CONSORT diagram showing flow of participants to delivery. From Coleman et al.56 Copyright © 2012
Massachusetts Medical Society. Reprinted with permission. DNA, did not attend.
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NRT group births Placebo group births
Of 521 participants:
511 live births (single and multiple) recorded from
507 participants
517 fetuses were from singleton pregnancies:
503
8
1
1
4
8 fetuses were twins (i.e. from 4 participants) and
were live births
2 removed from birth outcome analyses
denominators: 
1 missed abortion; fetal death before randomisation
1 elective termination with normal fetus
Of 529 participants:
523 live births (single and multiple) recorded from
515 participants
521
507
4
10
16 fetuses were twins (i.e. from 8 participants) and
were live births
fetuses were from singleton pregnancies:
were live births
were non-live births
fetus died before randomisation (missed
abortion)
pregnancy was electively terminated
(normal fetus)
had missing outcome data (3 withdrew
consent, 1 lost to follow-up with no birth
record)
were live births
were non-live births
had missing outcome data (7 withdrew
consent, 3 lost to follow-up with no birth
record)
FIGURE 5 Completeness of birth outcome data. From Coleman et al.56 Copyright © 2012 Massachusetts Medical
Society. Reprinted with permission.
TABLE 3 Details of outcome ascertainment at 1 month and delivery by study centre (N= 1050)
Outcome
ascertainment
Nottingham –
QMC
Nottingham –
City
King’s
Mill
North
Staffs Leighton Macclesfield Derby Total
1-month visit, n (%)
In person 36 (29.3) 33 (25.8) 41
(19.0)
52
(20.2)
75
(44.9)
20
(25.0)
17
(21.5)
274
(26.1)
Telephone or
returned
questionnaire
71 (57.7) 80 (62.5) 123
(56.9)
156
(60.7)
68
(40.7)
41
(51.3)
53
(67.1)
592
(56.4)
No contact at
1 month
16 (13.0) 15 (11.7) 52
(24.1)
49
(19.1)
24
(14.4)
19
(23.8)
9
(11.4)
184
(17.5)
Total 123 128 216 257 167 80 79 1050
(100)
Final trial status, n (%)
Outcome
data obtained
115 (93.5) 118 (92.2) 210
(97.2)
232
(90.3)
158
(94.6)
72
(90.0)
76
(96.2)
981
(93.4)
Fetal/infant deatha 2 (1.6) 2 (1.6) 1
(0.5)
3
(1.2)
3
(1.8)
1
(1.3)
1
(1.3)
13
(1.2)
Lost to follow-up or
withdrew consent
6 (4.9) 8 (6.3) 5
(2.3)
22
(8.6)
6
(3.6)
7
(8.8)
2
(2.5)
56
(5.3)
Total 123 128 216 257 167 80 79 1050
(100)
a Fetal/infant deaths occurring before trial smoking outcome data were obtained from participants at delivery.
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Baseline characteristics
Sociodemographic characteristics, smoking behaviour, obstetric history and participants’ prior use of NRT
were similar in both trial groups (Table 4). Women had a mean age of 26 years and joined the trial at a
mean gestational age of 16 weeks. Participants were heavy smokers and around one-third smoked within
5 minutes of waking and the median number of cigarettes smoked per day at randomisation was 14.
TABLE 4 Baseline characteristics by treatment group.a From Coleman et al.56 Copyright © 2012 Massachusetts
Medical Society. Reprinted with permission
Characteristic NRT (N= 521) Placebo (N= 529)
Mean age (years), (SD) 26.4 (6.2) 26.2 (6.1)
Median number of cigarettes smoked daily before pregnancy (IQR) 20 (15–20) 20 (15–20)
Median number of cigarettes smoked daily at randomisation (IQR) 13 (10–20) 15 (10–20)
Mean gestational age at baseline (weeks) (SD) 16.2 (3.6) 16.3 (3.5)
Ethnic group, n (%) White British 503 (96.5) 515 (97.4)
Other 18 (3.5) 14 (2.6)
Mean age left full-time educationb (years) (SD) 16.2 (1.4) 16.3 (1.7)
Parity,c n (%) 0–1 356 (68.3) 363 (68.6)
2–3 129 (24.8) 142 (26.9)
≥ 4 36 (6.9) 24 (4.5)
Median baseline cotinine levels (ng/ml) (IQR) 123.1 (80.1–179.8) 121.2 (77.2–175.9)
Time to first cigarette (minutes), n (%) 0–15 281 (54.0) 285 (53.9)
> 15–60 199 (38.2) 198 (37.4)
> 60 41 (7.9) 46 (8.7)
Women with partner who smokes,d n/women with a partner, n (%) 356/481 (74.0) 360/482 (74.7)
Mean height (cm)e (SD) 163.2 (6.8) 163.0 (6.5)
Mean weight (kg)f (SD) 71.7 (18.2) 71.6 (17.2)
Previous preterm birth,g n (%) 42 (8.1) 50 (9.5)
Length of first behavioural support session (minutes), n (%) ≤ 30 84 (16.1) 81 (15.3)
31–60 428 (82.1) 433 (81.9)
> 60 9 (1.7) 15 (2.8)
Use of NRT within pregnancy and prior to enrolment,h n (%) 23 (4.4) 24 (4.5)
SD, standard deviation.
a All baseline differences between groups were non-significant (p> 0.05).
b Excludes 14 women still in full-time education at the time of recruitment.
c Defined as number of previous pregnancies that have progressed beyond 24 weeks.
d Excludes 40 in NRT group and 47 women in placebo group with no partner.
e Height was not recorded for 15 participants in the NRT group and 23 in the placebo group.
f Weight was not recorded for 12 participants in the NRT group and 11 in the placebo group.
g Defined as any previous pregnancy which lasted from 24 to 37 weeks.
h The median number of days before recruitment that women last used NRT among the 47 women who reported current
or past use was 31 days for the NRT group (IQR 15 to 38 days) and 30 for the placebo group (IQR 14 to 68 days).
DOI: 10.3310/hta18540 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 54
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Primary outcome measure at delivery
The rate of prolonged abstinence at delivery with validation was 9.4% in the NRT group and 7.6% in the
placebo group (OR for abstinence with NRT 1.26, 95% CI 0.82 to 1.96) (Table 5).
Secondary outcome measures at delivery
Smoking outcomes at delivery
For self-reported (i.e. non-validated) abstinence, there was a slightly larger but still non-significant
difference in quit rates: 12.5% with NRT compared with 9.3% with placebo (OR 1.40, 95% CI 0.94 to
2.07) (see Table 5). At 1 month, the validated abstinence rate was significantly higher in the NRT group
than in the placebo group (21.3% vs. 11.7%, respectively; OR 2.05, 95% CI 1.46 to 2.88). Similar findings
were found for adjusted analyses with all smoking outcomes.
TABLE 5 Primary and secondary smoking cessation outcomes. From Coleman et al.56 Copyright © 2012
Massachusetts Medical Society. Reprinted with permission
Outcome
n (%)
OR (95% CI)a Adjusted OR (95% CI)b
NRT
(N= 521)
Placebo
(N= 529)
Primary
Prolonged self-reported abstinence from
smoking between quit date and delivery
with COT and/or CO validationc,d
49 (9.4) 40 (7.6) 1.26 (0.82 to 1.96) 1.27 (0.82 to 1.98)
Secondary
Prolonged abstinence from quit date to
delivery without validation
65 (12.5) 49 (9.3) 1.40 (0.94 to 2.07) 1.41 (0.95 to 2.09)
Abstinence to 1 month after quit date
without validation
131 (25.1) 74 (14.0) 2.07 (1.51 to 2.85) 2.13 (1.54 to 2.95)
Abstinence to 1 month after quit date with
CO validatione
111 (21.3) 62 (11.7) 2.05 (1.46 to 2.88) 2.10 (1.49 to 2.97)
Prolonged abstinence to delivery with
validation at 1 month after quit date
and delivery
42 (8.1) 32 (6.0) 1.36 (0.84 to 2.19) 1.37 (0.84 to 2.22)
Point prevalence cessation (> 24-hour quit)
at delivery with CO validation
63 (12.1) 53 (10.0) 1.23 (0.84 to 1.82) 1.24 (0.84 to 1.85)
Point prevalence cessation (> 24-hour quit)
at delivery without validation
104 (20.0) 89 (16.8) 1.24 (0.90 to 1.70) 1.25 (0.90 to 1.72)
a Adjusted for centre only (as a stratification factor).
b Adjusted for centre, COT at baseline, partner’s smoking status (partner smokes vs. partner does not smoke/no partner)
and age at leaving full-time education.
c Either cotinine or CO values could be used for validation, but, if both were available, both were required to
reflect abstinence.
d The biochemical samples did not validate the report of not smoking (i.e. probable false reporting of cessation) in 9 out
of 58 women (16%) in the NRT group and 5 out of 45 women (11%) in the placebo group.
e This outcome measure was not included in the original protocol. The biochemical samples did not validate report of
not smoking (i.e. probable false reporting of cessation) in 5 out of 116 women (4%) in the NRT group and 1 out of
63 women (2%) in the placebo group.
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Birth outcomes at delivery
Table 6 shows outcomes for singleton births including deaths, mean birthweight and rates of preterm
birth, LBW and congenital abnormalities, and these were mainly similar in the two study groups. However,
there were significantly more deliveries by caesarean section in the NRT group than in the placebo group
(20.7% vs. 15.3%). Analyses that included twin births gave very similar findings.
TABLE 6 Birth outcomes by treatment group.a From Coleman et al.56 Copyright © 2012 Massachusetts Medical
Society. Reprinted with permission
Fetal outcomes
(singleton births only)
NRT
(N= 515)
n/N (%)
Placebo
(N= 521)
n/N (%) OR (95% CI)b
Miscarriagec 3/515 (0.6) 2/521 (0.4) 1.52 (0.25 to 9.13)
Stillbirthc 5/512 (1.0) 2/519 (0.4) 2.59 (0.50 to 13.4)
Neonatal deathc 0/507 (0) 2/517 (0.4) Not calculated
Post-neonatal deathc,d 1/507 (0.2) 0/517 (0) Not calculated
Mean (SD) Mean (SD) Mean difference (95% CI)
Birthweight, unadjusted (kg) 3.18 (0.61) 3.20 (0.59) –0.02 (–0.10 to 0.05)
Birthweight (z-score) –0.36 (0.99) –0.31 (1.02) –0.05 (–0.17 to 0.08)
Gestational age (weeks) 39.5 (2.1) 39.5 (2.1) 0.0 (–0.2 to 0.3)
n/N (%) n/N (%) OR (95% CI)b
Preterm birth
(< 37 weeks’ gestation)
40/507 (7.9) 45/517 (8.7) 0.90 (0.58 to 1.41)
LBW (< 2.5 kg) 56/507 (11.0) 43/517 (8.3) 1.38 (0.90 to 2.09)
NICU admission 33/507 (6.5) 35/517 (6.8) 0.96 (0.58 to 1.57)
Apgar score at 5 minutes < 7 16/507 (3.2) 18/517 (3.5) 0.91 (0.45 to 1.80)
Cord-blood arterial pH < 7 4/507 (0.8) 7/517 (1.4) 0.57 (0.17 to 1.97)
Intraventricular haemorrhage 2/507 (0.4) 3/517 (0.6) 0.67 (0.11 to 4.05)
Neonatal convulsions 5/507 (1.0) 5/517 (1.0) 1.02 (0.29 to 3.54)
Congenital abnormalitiese 9/507 (1.8) 13/517 (2.5) 0.70 (0.30 to 1.66)
Necrotising enterocolitis 3/507 (0.6) 6/517 (1.2) 0.50 (0.12 to 2.03)
Infant ventilated > 24 hours 10/507 (2.0) 11/517 (2.1) 0.93 (0.39 to 2.22)
Assisted vaginal delivery 38/507 (7.5) 43/517 (8.3) 0.95 (0.59 to 1.50)
Caesarean delivery 105/507 (20.7) 79/517 (15.3) 1.45 (1.05 to 2.01)
SD, standard deviation.
a Using an ITT analysis, we calculated an overall total of 1036 women after the exclusion of 12 women with multiple
pregnancies and two from the NRT group [one missed abortion (i.e. the retention in the uterus of a dead fetus) before
randomisation and one with elective termination of a normal fetus].
b Odds ratios were adjusted for recruitment centre (as a stratification factor).
c These outcomes were defined a priori as SAEs. There were no maternal deaths and no SAEs were judged to be related
to NRT. The denominators for individual fetal outcomes are as follows: miscarriage – number randomised minus number
of elective terminations; stillbirth – number randomised minus number of elective terminations and miscarriages. For all
other outcomes, the denominator is the number of singleton live births, including those births for which outcome data
were missing (507 in NRT group and 517 in placebo group).
d Post-neonatal deaths known about when birth outcomes were analysed.
e Congenital abnormalities in NRT group: congenital cystic kidney disease, congenital heart disease, multiple congenital
abnormalities, tetralogy of Fallot, cleft lip and palate, congenital musculoskeletal anomaly, syndactyly, congenital
deafness, talipes (all n= 1). Congenital abnormalities in placebo group: atrial septal defect (n= 2), talipes (n= 2),
gastroschisis, neural tube defect, cardiac septal defect, congenital acrochordon, hypoplastic left heart syndrome,
congenital cystic lung, hip dysplasia, kidney malformation, cleft palate (all n= 1).
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Adverse events
Other AEs are shown in Table 7 and, apart from skin reactions at the patch site (97 participants in NRT
group reported skin reactions compared with 28 in placebo group), rates were similar in the two groups.
In total, 46 participants in the NRT group and 32 in the placebo group stopped using the patches
permanently owing to AEs. Further information on the distribution and nature of AEs is in Appendix 5.
Adherence with patches and use of smoking cessation support
Adherence with trial patches was low in both groups and rates are shown in Table 8. Only 7.2% of
women (35/485) assigned to receive NRT and 2.8% (14/496) assigned to placebo reported using trial
medications for more than 28 days. Additionally, although 111 NRT group participants were abstinent at
1 month and had this validated by a RM (see Table 5), only 72 of these (65%) accepted a second month’s
supply of patches. The corresponding figure for the placebo group was 47% (29/62). Only 2.5% of NRT
group participants (12/485) and 2.2% (11/496) of placebo group participants reported using ‘non-study’
NRT for ≥ 20 days.
As per protocol, RMs attempted to contact participants and provide behavioural support on the quit
date, 3 days after their quit date and 1 month after their quit date. In the NRT group, 368 (70.6%) were
successfully contacted via a telephone call from a RM on their quit date and 386 (74.1%) 3 days after their
quit date. A total of 69 (13.2%) were not successfully contacted on either day, while 302 (58.0%) had a
call on both days. In the placebo group, 378 (71.5%) were successfully contacted on their quit date and
381 (72.0%) 3 days after their quit date. A total of 67 women (12.7%) were not successfully contacted on
either day, while 297 (56.1%) received a call on both days. At 1 month, 428 (82.1%) participants in the
NRT group received support from a RM either face to face [164 (31.5%)] or by telephone [264 (50.7%)].
In the placebo group, 419 (79.2%) participants received RM support [110 (20.8%) face to face, 309
(58.4%) telephone only]. The lower rate of face-to-face support delivered to the placebo group at
1 month reflects the fact that this was delivered at consultations arranged to validate abstinence from
smoking. Support was received by participants on all three occasions (i.e. quit date, 3 days after their
quit date and 1 month after their quit date) for 268 participants (51.4%) in the NRT group and
250 participants (47.3%) in the placebo group (see Table 8). Support was not received on any of these
occasions for 27 participants (5.2%) in the NRT group and 28 participants (5.3%) in the placebo group.
Participants also reported little additional face-to-face or text message contact with, or support from,
smoking cessation advisors who worked for local NHS SSS (see Table 8). Support by telephone was more
common and both groups reported receiving a median of two telephone contacts from advisors.
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TABLE 7 Adverse eventsa by treatment group. From Coleman et al.56 Copyright © 2012 Massachusetts Medical
Society. Reprinted with permission
AE NRT (N= 521) Placebo (N= 529)
SAEs, n (%)
Maternal mortality 0 0
Other SAEsb 9 (1.7) 6 (1.1)
Maternal AEs potentially related to treatment, n (%)
Patch stopped permanently owing to AEc 46 (8.8) 32 (6.0)
Skin reactions at patch site (but no treatment discontinuation)d 97 (18.6) 28 (5.3)
Maternal AEs as probable complications of pregnancy, n (%)
Blood pressure > 140/90mmHg on at least two occasions 24 (4.6) 25 (4.7)
Nausea or vomiting 16 (3.1) 19 (3.6)
Headache 25 (4.8) 16 (3.0)
Abdominal pain 54 (10.4) 50 (9.5)
Vaginal bleeding or haemorrhage 35 (6.7) 38 (7.2)
Premature rupture of membranese 6 (1.2) 10 (1.9)
Uterine contractions during pregnancye 24 (4.6) 30 (5.7)
Gestational diabetes 3 (0.6) 3 (0.6)
Pre-eclampsia or eclampsia 3 (0.6) 5 (0.9)
Hospital admission for other pregnancy complicationf 44 (8.4) 41 (7.8)
Other less frequent maternal AEsg 63 (12.1) 73 (13.8)
Fetal AEs as probable complications of pregnancy, n (%)
Decreased fetal movements (fetal hypokinesia)e 58 (11.1) 46 (8.7)
Other AEs affecting fetusg 5 (1.0) 5 (0.9)
Neonatal AEsg 32 (6.1) 29 (5.5)
Total AEs, nh 535 450
a AEs were coded using the MedDRA, version 13.1. For each treatment group, percentages were calculated as the
number of women who experienced the specified AE at least once, divided by the number of women who were
randomised. Column totals may add up to over 100% as participants may have experienced AEs in more than one
category (row).
b Other SAEs included miscarriage, stillbirth, neonatal and post-neonatal deaths reported as pre-specified trial outcomes.
c Reasons for patch discontinuation are summarised in Appendix 5.
d AEs included pruritus, swelling, erythema, rash, blistering or vesicles, pain and other local reactions.
e Symptoms required hospital admission or assessment.
f Overnight admission for less frequent events (< 3% of participants); full breakdown available in Appendix 5.
g Events occurring in < 3% of women or infants; full breakdown available in Appendix 5.
h The total numbers of women or their infants who had at least one SAE or AE were 316 (61%) in the NRT group and
269 (51%) in the placebo group.
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TABLE 8 Cessation support and adherence with NRT by treatment group. From Coleman et al.56 Copyright © 2012
Massachusetts Medical Society. Reprinted with permission
Adherence and support NRT, n (%) Placebo, n (%)
p-value (by chi-squared
test for trend)
Measures reported at 1 month N = 437a N = 429a
Reported days trial patch use in first month 0–7 180 (41.3) 220 (51.5) p< 0.001
8–14 82 (18.8) 108 (25.3)
15–21 74 (17.0) 58 (13.6)
> 21 100 (22.9) 41 (9.6)
Days of non-trial NRT use 0 425 (97.3) 406 (94.6) p< 0.05
1–4 8 (1.8) 11 (2.6)
5–9 1 (0.2) 5 (1.2)
≥ 10 3 (0.7) 7 (1.6)
Additional face-to-face contacts with NHS SSS
advisorb (n)
0 409 (93.6) 407 (94.9) NS
1 22 (5.0) 17 (4.0)
≥ 2 6 (1.4) 5 (1.2)
Additional telephone contacts with NHS SSS
advisorb (n)
0 146 (33.4) 139 (32.4) NS
1 122 (27.9) 114 (26.6)
2 95 (21.7) 94 (21.9)
3 41 (9.4) 43 (10.0)
≥ 4 33 (7.6) 39 (9.1)
Additional SMS ‘text’ contacts with NHS SSS
advisorc (n)
0 332 (76.0) 329 (76.7) NS
1 50 (11.4) 53 (12.4)
2 30 (6.9) 31 (7.2)
3 10 (2.3) 8 (1.9)
≥ 4 15 (3.4) 8 (1.9)
Measures reported at delivery N = 485c N = 496c
Days of non-trial NRT use 0 459 (94.6) 449 (90.5) p< 0.05
1–4 7 (1.4) 16 (3.2)
5–19 7 (1.4) 20 (4.0)
≥ 20 12 (2.5) 11 (2.2)
Additional face-to-face contacts with NHS SSS
advisorb (n)
0 429 (88.5) 448 (90.3) NS
1 36 (7.4) 32 (6.5)
2 15 (3.1) 11 (2.2)
≥ 3 5 (1.0) 5 (1.0)
Additional telephone contacts with NHS SSS
advisorb (n)
0 141 (29.1) 156 (31.5) NS
1–2 186 (38.4) 203 (40.9)
3–4 93 (19.2) 86 (17.3)
5–9 57 (11.8) 49 (9.9)
≥ 10 8 (1.7) 2 (0.4)
Additional SMS ‘text’ contacts with NHS SSS
advisorb (n)
0 347 (71.6) 365 (73.6) NS
1–2 87 (17.9) 85 (17.1)
3–4 24 (5.0) 27 (5.4)
5–9 24 (5.0) 17 (3.4)
≥ 10 3 (0.6) 2 (0.4)
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Follow-up after delivery
Follow-up of participants and infants after delivery
Follow-up of participants and infants began after the first birth in July 2007 and continued until
December 2012.
Two CONSORT diagrams are presented for the follow-up period from delivery until infants were 2 years
old; participants indicated as withdrawn in either diagram were not sent further questionnaires after
their withdrawal.
Participants’ follow-up
The first diagram (Figure 6) is for all participants and summarises questionnaire distribution and response
rates at the three follow-up time points, plus reasons for withdrawal. This provides denominators and
follow-up data that are relevant to participant outcomes (e.g. smoking behaviour). By the final follow-up
point, 150 participants [14.3% of the original study population: 73 out of 521 (14.0%) NRT, 77 out of
529 (14.6%) placebo] had withdrawn from the study, or a completed 2-year questionnaires had not been
received from either the participant or their GP. This includes the 122 participants whose reasons for
withdrawal are shown in Figure 6, plus 28 participants with fetal deaths or for whom no birth details were
obtained. These are described in Infants’ follow-up.
Infants’ follow-up
The second diagram (Figure 7) provides similar details for the 1010 live infants that were known to be born
from singleton pregnancies and provides information on follow-up that is relevant to the assessment of
infant outcomes at 2 years. This shows the 14 fetal deaths recorded when birth outcome data were
analysed (also described in Figure 5), plus 14 participants for whom no infant birth details were obtained.
TABLE 8 Cessation support and adherence with NRT by treatment group. From Coleman et al.56 Copyright © 2012
Massachusetts Medical Society. Reprinted with permission (continued )
Adherence and support NRT, n (%) Placebo, n (%)
p-value (by chi-squared
test for trend)
Participants issued with a second month’s
supply of patchesd (n)
72 29
Reported days of trial patch use by participants
issued with 2 months’ worth of patchesd
0–7 3 (4.3) 1 (3.6) NS
8–14 12 (17.1) 8 (28.6)
15–28 20 (28.6) 5 (17.9)
≥ 29 35 (50.0) 14 (50.0)
Behavioural support from RMs N = 521 N = 529
Successful contacts with RMs (n)e 0 27 (5.2) 28 (5.3)
1 74 (14.2) 74 (14.0)
2 152 (29.2) 177 (33.5)
3 268 (51.4) 250 (47.3)
NS, not significant; SMS, short message service.
a On occasions, at the 1-month visit, when responses to individual questions were missing (always n≤ 12), women were
assumed to have had no contact with cessation advisors, to have never used non-trial NRT and to be in the lowest
compliance category.
b These were contacts for additional behavioural support provided by local NHS SSS advisors.
c There were no missing responses to individual questions at delivery.
d A total of 101 women (29 placebo and 72 NRT) were issued with a further 28 days’ supply of NRT. Out of these,
98 women provided data on compliance at the time of delivery and were included in the analysis of trial patch use
at the time of delivery.
e Contact attempts were made with participants for behavioural support on their quit dates, 3 days after quit date
and at 1 month after quit date.
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Total participants:
N = 1050
Placebo: n = 529 (50.4%)
Participant questionnaires returned at 6 months
    Postal: n = 120 (22.7%)
    Telephone: n = 218 (41.2%)
Participant questionnaires sent at 1 year: n = 506 (95.7%)
Participant questionnaires returned at 1 year
    Postal: n = 137 (26.3%)
    Telephone: n = 151 (29.0%)
PQ2 returned at 2 years
    Postal: n = 156 (29.9%)
    Telephone: n = 146 (28.0%)
NRT: n = 521 (49.6%)
Participant questionnaires returned at 6 months
    Postal: n = 126 (24.2%)
    Telephone: n = 209 (40.1%)
Participant questionnaires sent at 1 year: n = 500 (96.0%)
Participant questionnaires returned at 1 year
    Postal: n = 135 (25.5%)
    Telephone: n = 165 (31.2%)
PQ2 returned at 2 years
    Postal: n = 148 (28.0%)
    Telephone: n = 156 (29.5%)
Withdrawal
Consent withdrawn: n = 1
Postnatal infant death: n = 1
Infant taken into care: n = 1
Withdrawal
Consent withdrawn: n = 1
Postnatal infant death: n = 2
Infant taken into care: n = 1
Withdrawal
Consent withdrawn: n = 4
Postnatal infant death: n = 1
Withdrawal
Consent withdrawn: n = 4
Postnatal infant death: n = 0
Withdrawal
Consent withdrawn: n = 1
Lost to follow-up: n = 1
Withdrawal
Consent withdrawn: n = 2
Lost to follow-up: n = 0
Outcomes to delivery have been previously reported
HPQ sent at 2 years: n = 208 (39.9%)
HPQ returned at 2 years: n = 158 (30.3%)
HPQ sent at 2 years: n = 222 (42.0%)
HPQ returned at 2 years: n = 162 (30.6%)a
Outcome data at 2 years (PQ2 or HPQ): n = 448 (86.0%)a Outcome data at 2 years (PQ2 or HPQ): n = 452 (85.4%)a
Withdrawal
Consent withdrawn: n = 4
Infant adopted: n = 0
Lost to follow-up: n = 1
No questionnaire completed: n = 44
Withdrawal
Consent withdrawn: n = 1
Infant adopted: n = 1
Lost to follow-up: n = 3
No questionnaire completed: n = 48
Participant questionnaires sent at 6 months:
n = 504 (96.7%)
Participant questionnaires sent at 6 months:
n = 511 (96.6%)
PQ2 sent at 2 years: n = 497 (95.4%) PQ2 sent at 2 years: n = 505 (95.5%)
a
FIGURE 6 The CONSORT diagram showing flow of all trial participants during the 2-year follow-up period.
a, 26 HPQs were returned in participants who had already returned a PQ2 (n= 12 NRT, n= 14 placebo) and these
were not included in subsequent analyses. Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N,
Dickinson A, Whitemore R, et al. Effect of nicotine patches in pregnancy on infant and maternal outcomes at
2 years: follow-up from the randomised, double-blind, placebo-controlled SNAP trial [published online ahead of
print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/S2213-2600(14)70157-2.
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Total participants: N = 1050
Placebo: n = 507
Participant questionnaires sent at 6 months:
n = 503 (99.2%)
Participant questionnaires returned at 6 months
    Postal: n = 118 (23.3%)
    Telephone: n = 213 (42.0%)
Participant questionnaires sent at 1 year: n = 498 (98.2%)
Participant questionnaires returned at 1 year
    Postal: n = 137 (27.2%)
    Telephone: n = 151 (30.0%)
PQ2 sent at 2 years: n = 493 (98.0%)
PQ2 returned at 2 years
    Postal: n = 156 (31.0%)
    Telephone: n = 145 (28.8%)
HPQ sent at 2 years: n = 217 (42.8%)
HPQ returned at 2 years: n = 159 (31.4%)a
HPQ sent at 2 years: n = 205 (40.8%)
HPQ returned at 2 years: n = 156 (31.0%)a
NRT: n = 503
Participant questionnaires returned at 6 months
    Postal: n = 126 (25.1%)
    Telephone: n = 208 (41.4%)
Participant questionnaires sent at 1 year: n = 496 (98.6%)
Participant questionnaires returned at 1 year
    Postal: n = 134 (26.4%)
    Telephone: n = 161 (31.8%)
PQ2 sent at 2 years: n = 497 (98.0%)
PQ2 returned at 2 years
    Postal: n = 148 (29.2%)
    Telephone: n = 153 (30.2%)
Withdrawal
Consent withdrawn: n = 1
Postnatal infant death: n = 1
Infant taken into care: n = 1
Withdrawal
Consent withdrawn: n = 1
Postnatal infant death: n = 2
Infant taken into care: n = 1
Withdrawal
Consent withdrawn: n = 4
Postnatal infant death: n = 1
Withdrawal
Consent withdrawn: n = 4
Postnatal infant death: n = 0
Withdrawal
Consent withdrawn: n = 1
Lost to follow-up: n = 1
Withdrawal
Consent withdrawn: n = 2
Lost to follow-up: n = 0
Withdrawal
Consent withdrawn: n = 4
Infant adopted: n = 0
Lost to follow-up: n = 1
No questionnaire completed: n = 43
Withdrawal
Consent withdrawn: n = 1
Infant adopted: n = 1
Lost to follow-up: n = 3
No questionnaire completed: n = 46
Outcomes to delivery have been previously reported
Singleton live-birth pregnancies: n = 1010
Twin pregnancies: n = 12
Lost to follow-up: n = 4
Withdrew consent: n = 10
Included in ITT analyses
for infant outcomes: n = 1010
Total participants eligible for infant follow up: n = 1036
Fetal deaths: n = 14
Participant questionnaires sent at 6 months:
n = 500 (99.4%)
Outcome data at 2 years (PQ2 or HPQ): n = 445 (88.5%)a Outcome data at 2 years (PQ2 or HPQ): n = 446 (88.0%)a
FIGURE 7 The CONSORT diagram showing flow of participants with live singleton births. These data were used for
birth outcome analyses during the 2-year follow-up period. a, 26 HPQs were returned in participants who had
already returned a PQ2 (n= 12 NRT, n= 14 placebo) and these were not included in subsequent analyses.
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of
nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised,
double-blind, placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med
2014. doi:10.1016/S2213-2600(14)70157-2.
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Of those with no birth details, 10 withdrew consent before delivery (three NRT, seven placebo) and four
were lost to follow-up (one NRT, three placebo); for ITT analyses of infant outcomes, it has been assumed
that 14 live singleton infants were born to these participants. Four singleton infant deaths occurred
between birth and the 2-year follow-up (two NRT, two placebo), of which one was known about and
recorded when outcomes at delivery were analysed (see Table 6). For simplicity, and as primary analyses for
infant outcomes did not include infants carried in multiple birth pregnancies, twin infants are excluded from
Figure 5. However, sensitivity analyses included twins and either PQ2 or HPQ responses for 18 twin infants
(6 NRT, 12 placebo) from nine of the 12 twin pregnancies were obtained and used in these.
Discrepancies in questionnaire follow-up
One participant in the placebo group was sent neither the 6-month nor the 1-year questionnaire as her
birth details were not obtained until 18 months after delivery (i.e. it was not known that a live birth had
occurred). Two participants were inadvertently sent questionnaires: one in the placebo group was sent a
6-month questionnaire as the trial team had not been informed that the child had been taken into care at
delivery, and one participant in the NRT group whose infant had died was sent a 1-year questionnaire due
to a delay in receiving the death report from the NHS Information Centre. There were 26 participants
(12 NRT, 14 placebo), all with singleton births, for whom both PQ2 and HPQs were completed and
returned, and for these respondents PQ2 responses were used.
Completeness of follow-up for early childhood outcomes
For the 1010 known singleton live births, there were 891 (445 NRT, 446 placebo) (88.2%) responses to
either the PQ2 or the HPQ, which could be used in analyses contributing to the primary outcome at the
2-year follow-up (see Figure 7).
Completeness of follow-up for participants’ smoking outcomes
From the full trial cohort of 1050 participants, 606 (302 NRT, 304 placebo) (57.7%) responded to the PQ2
questionnaire providing data that could be used in the analysis of participants’ smoking outcomes at the
2-year follow-up (see Figure 6).
Overall follow-up rates were similar in both groups; the response rates for all follow-up time points can
be seen in Figure 6 and Table 9, and in chart form in Figure 8. Most participants required a reminder
questionnaire and approximately half of those who provided data did so by completing the questionnaire
over the telephone. Around three-quarters of health professionals returned the questionnaire by post,
TABLE 9 Response rates to questionnaires sent during the follow-up period
Questionnaire
Questionnaire
sent (N)
Reminder sent
n (% of
questionnaires
sent)
Returned by
post n (% of
questionnaires
sent)
Completed by
telephone n (% of
questionnaires
sent)
Total
response
n (% of
questionnaire
sent)
Participant
6-month
1015 886 (87.3) 246 (24.2) 427 (42.1) 673 (66.3)
Participant 1-year 1006 875 (87.0) 272 (27.0) 316 (31.4) 588 (58.4)
PQ2 1002 864 (86.2) 304 (30.3) 302 (30.1) 606 (60.5)
HPQ 430 306 (71.2) 320 (74.4) NA 320a (74.4)
Combined 2-year
response
(i.e. PQ2 or
HPQ returned)
1002 NA NA NA 900 (89.8)
NA, not applicable.
a This includes 26 HPQs that were returned for participants who had already returned a PQ2.
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although most needed a postal reminder. The total combined response for participant or HPQs at 2 years
was 900 (89.8% of those sent questionnaires at 2 years; 85.7% of all randomised participants). This figure
excludes the 26 HPQs that were received for participants who subsequently returned their PQ2.
Characteristics of participants and infants who were followed up
after delivery
Table 10 shows the maternal baseline characteristics and singleton birth outcomes for the 900 participants
who had 2-year outcome data in the NRT and placebo groups. As with the whole trial cohort, these two
groups had similar demographic characteristics at enrolment. Singleton infant birth outcomes were also
similar in the two groups, apart from delivery by caesarean section, which, as found in the full cohort at
primary outcome, was similarly slightly higher in the NRT group than in the placebo group (20.2%
compared with 15.5%). The proportion of the participants providing data at 2 years who had prolonged,
validated abstinence from smoking at delivery was 10.3% in the NRT group and 8.2% in the placebo
group (see Table 10), which compares with 9.4% and 7.6% for NRT and placebo groups, respectively, for
the full cohort (see Table 5).
Table 11 shows the same characteristics within those participants who provided 2-year follow-up data on
the PQ2, those for whom a HPQ was completed instead and those for whom no data was obtained.
Most of the demographic data are similar in these three groups; however, those with no follow-up data at
2 years had a slightly higher mean index of multiple deprivation (IMD) score (36.8, compared with 32.3 in
those with PQ2 data and 32.2 in those with HPQ data). Their first behavioural support session may also
have been slightly shorter (21.3% of this group had a behavioural support session of < 30 minutes,
compared with 14.4% and 15.7% of those with PQ2 and HPQ data, respectively). Median COT levels at
enrolment appear to be slightly higher in those who were followed up by HPQ (131.6 ng/ml, compared
with 119.1 ng/ml in the other two groups).
Participants who completed a PQ2 were more likely to have validated abstinence between quit date and
delivery (10.9%, compared with 5.8% of those with HPQ data and 4.0% of those with no 2-year data)
(see Table 11).
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FIGURE 8 Numbers of questionnaires sent and returned during the follow-up period.
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TABLE 10 Comparison of maternal characteristics and birth outcomes for participants who provided data at 2 years
NRT (N= 448)a Placebo (N= 452)a
Maternal characteristics at study enrolment
Mean age (years) (SD) 26.5 (6.2) 26.3 (6.1)
Median number of cigarettes smoked daily before pregnancy (IQR) 20 (15–20) 20 (15–20)
Median number of cigarettes smoked daily at baseline (IQR) 13 (10–20) 15 (10–20)
Mean gestational age at baseline (weeks) (SD) 16.2 (3.5) 16.3 (3.5)
Ethnic group, n (%)
White British 434 (96.9) 442 (97.8)
Other 14 (3.1) 10 (2.2)
Age left full-time education (years)
Mean (SD) 16.2 (1.4) 16.3 (1.7)
Missing data (n) 5 8
Index of multiple deprivation
Mean (SD) 32.1 (16.7) 32.4 (16.9)
Missing data (n) 13 9
Parity, n (%)
0–1 306 (68.3) 311 (68.8)
2–3 111 (24.8) 121 (26.8)
≥ 4 31 (6.9) 20 (4.4)
COT at baseline (ng/ml)
Median (IQR) 123.7 (80.2–185.4) 120.9 (75.6–175.9)
Missing data (n) 35 33
Time to first cigarette, n (%)
0–15 minutes 245 (54.7) 243 (53.8)
16–60 minutes 169 (37.7) 168 (37.2)
> 60 minutes 34 (7.6) 41 (9.1)
Women with partner who smokes
n (%) 306 (68.3) 306 (67.7)
Missing data (n, %) 34 (7.6) 38 (8.4)
Height (cm)
Mean (SD) 162.9 (6.8) 163.1 (6.4)
Missing data (n) 12 13
Weight (kg)
Mean (SD) 71.2 (17.8) 72.3 (17.1)
Missing data (n) 8 8
Previous preterm birth, n (%) 38 (8.5) 42 (9.3)
RESULTS
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TABLE 10 Comparison of maternal characteristics and birth outcomes for participants who provided
data at 2 years (continued )
NRT (N= 448)a Placebo (N= 452)a
Length of first behavioural support session, n (%)
< 30 minutes 66 (14.7) 67 (14.8)
31–60 minutes 376 (83.9) 371 (82.1)
> 60 minutes 6 (1.3) 14 (3.1)
Use of NRT earlier in pregnancy, n (%) 19 (4.2) 23 (5.1)
Maternal smoking outcomes at delivery
Met primary smoking cessation outcome, n (%) 46 (10.3) 37 (8.2)
Infant birth outcomes at delivery (singleton pregnancies) NRT (n = 445)b Placebo (n = 446)b
Mean birthweight, unadjusted (kg) (SD) 3.2 (0.6) 3.2 (0.6)
Mean gestational age (weeks) (SD) 39.5 (2.1) 39.5 (2.2)
Preterm birth, n (%) 36 (8.1) 40 (9.0)
LBW (< 2.5 kg), n (%) 49 (11.0) 37 (8.3)
NICU admission, n (%) 29 (6.5) 32 (7.2)
Apgar score at 5 minutes < 7, n (%) 12 (2.7) 13 (2.9)
Congenital abnormalities, n (%) 7 (1.6) 12 (2.7)
Infant on ventilator > 24 hours, n (%) 8 (1.8) 10 (2.2)
Assisted vaginal delivery, n (%) 33 (7.4) 37 (8.3)
Delivery by caesarean section, n (%) 90 (20.2) 69 (15.5)
SD, standard deviation.
a All pregnancies (i.e. includes twins).
b Singleton pregnancies only.
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine
patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind,
placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/
S2213-2600(14)70157-2.
TABLE 11 Maternal and infant characteristics: comparison of participants and singleton infants for whom outcome
data were and were not available at 2 years
All participants at randomisation
(N= 1050)
Followed up: PQ2
(N= 606)
Followed up: HPQ
(N= 294)a
Not followed up
(N= 150)b
Maternal characteristics at enrolment/randomisation (all pregnancies)
Mean age (years) (SD) 26.9 (6.3) 25.5 (5.6) 25.7 (6.3)
Median number of cigarettes smoked daily
before pregnancy (IQR)
20 (15–20) 20 (15–20) 20 (15–20)
Median number of cigarettes smoked daily at
baseline (IQR)
15 (10–20) 15 (10–18) 12 (10–15)
Mean gestational age at baseline (weeks) (SD) 16.2 (3.5) 16.4 (3.5) 16.2 (3.6)
Ethnic group, n (%)
White British 588 (97.0) 288 (98.0) 142 (94.7)
Other 18 (3.0) 6 (2.0) 8 (5.3)
Mean age left full-time education (years) (SD) 16.3 (1.7) 16.2 (1.3) 16.3 (1.5)
continued
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TABLE 11 Maternal and infant characteristics: comparison of participants and singleton infants for whom outcome
data were and were not available at 2 years (continued )
All participants at randomisation
(N= 1050)
Followed up: PQ2
(N= 606)
Followed up: HPQ
(N= 294)a
Not followed up
(N= 150)b
Mean index of multiple deprivation (SD) 32.3 (17.1) 32.2 (16.2) 36.8 (16.0)
Parity, n (%)
0–1 424 (70.0) 193 (65.7) 102 (68.0)
2–3 144 (23.8) 88 (29.9) 39 (26.0)
≥ 4 38 (6.3) 13 (4.4) 9 (6.0)
Median COT level at baseline (ng/ml) (IQR) 119.1 (72.1–179.5) 131.6 (88.7–184.7) 119.1 (80.0–161.3)
Time to first cigarette, n (%)
0–15 minutes 329 (54.3) 159 (54.1) 78 (52.0)
16–60 minutes 231 (38.1) 106 (36.1) 60 (40.0)
> 60 minutes 46 (7.6) 29 (9.9) 12 (8.0)
Women with partner who smokes, n (%) 408 (67.3) 204 (69.4) 104 (69.3)
Mean height (cm) (SD) 162.9 (6.8) 163.2 (6.3) 163.7 (7.0)
Mean weight (kg) (SD) 72.4 (16.6) 70.5 (19.1) 71.0 (18.9)
Previous preterm birth, n (%) 47 (7.8) 33 (11.2) 12 (8.0)
Length of first behavioural support session, n (%)
< 30 minutes 87 (14.4) 46 (15.7) 32 (21.3)
31–60 minutes 505 (83.3) 242 (82.3) 114 (76.0)
> 60 minutes 14 (2.3) 6 (2.0) 4 (2.7)
Use of NRT earlier in pregnancy, n (%) 33 (5.5) 9 (3.1) 5 (3.3)
Maternal smoking at delivery (all pregnancies)
Met primary smoking cessation outcome, n (%) 66 (10.9) 17 (5.8) 6 (4.0)
Infant birth outcomes (singleton
pregnancies, N = 1010)
(N = 602) (N = 289)a (N = 119)
Mean birthweight, unadjusted (kg) (SD) 3.2 (0.58) 3.1 (0.62) 3.2 (0.60)
Mean gestational age (weeks) (SD) 39.5 (2.1) 39.4 (2.3) 39.6 (2.1)
Preterm birth, n (%) 46 (7.6) 30 (10.4) 9 (7.6)
LBW (< 2.5 kg), n (%) 46 (7.6) 40 (13.8) 13 (10.9)
NICU admission, n (%) 39 (6.5) 22 (7.6) 7 (5.9)
Apgar score at 5 minutes < 7, n (%) 13 (2.2) 12 (4.2) 9 (7.6)
Congenital abnormalities, n (%) 8 (1.3) 11 (3.8) 3 (2.5)
Infant on ventilator > 24 hours, n (%) 11 (1.8) 7 (2.4) 3 (2.5)
Assisted vaginal delivery, n (%) 51 (8.5) 19 (6.6) 11 (9.2)
Delivery by caesarean section, n (%) 118 (19.6) 41 (14.2) 25 (21.0)
SD, standard deviation.
a Twenty-six participants who provided both HPQ and PQ2 data were excluded from this analysis (n= 12 NRT, n= 14
placebo, all singleton pregnancies).
b Includes participants who were lost to follow-up and those who did not return questionnaires at 24 months.
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine
patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind,
placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/
S2213-2600(14)70157-2.
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Outcome measurements after delivery
Infant outcomes at 2 years
Infants’ developmental outcomes and any reports of respiratory problems at 2 years after delivery are
shown in Table 12, separated by treatment group for all those with known outcomes, including four
postnatal deaths. In Table 13, these results are broken down further to show outcomes by questionnaire
and, for comparison purposes, postnatal deaths are not included in the denominators in this table.
Of the 1010 singleton infants, 891 (445 NRT, 446 placebo) had information about them returned on
either the PQ2 or the HPQ questionnaire; however, owing to missing data, it was not possible to allocate
developmental outcomes on one PQ2 (from placebo group) and six returned HPQs (two NRT, four
placebo). Within these 891, infants born to women who had been allocated to the NRT group in
pregnancy were significantly more likely to have survived with no impairment than those born to women
allocated to placebo [323/445 (72.6%) of NRT group infants and 290/443 (65.5%) in the placebo group].
The OR for ‘survival with no impairment’ in the NRT compared with the placebo group obtained in the
primary analysis (ITT with multiple imputation analysis) was 1.40 (95% CI 1.05 to 1.86, p= 0.023). Similar
statistically significant differences in survival without impairment were also found for other analyses
including the clustered analysis with twin births (OR 1.43, 95% CI 1.08 to 1.91, p= 0.013) (see Table 12)
and the analysis of singleton infants using just the PQ2 responses (OR 1.52, 95% CI 1.09 to 2.11,
p= 0.012) (see Table 13).
There were no significant differences between groups for any of the other infant outcomes (see
Tables 12 and 13). Using definitions of developmental impairment described in the methods, ‘definite’
impairment was identified in 48 (10.8%) of the NRT and 64 (14.5%) of the placebo groups, and
‘suspected’ impairment in 72 (16.2%) of NRT and 87 (19.6%) of placebo groups. A greater number of
questionnaires that were returned by participants reported potential child development problems than the
health professional ones; 253 (42.0%) of the 602 returned PQ2s were categorised with definite or
suspected impairment, compared with only 18 (6.2%) of the 289 HPQ responses.
A detailed breakdown of infant developmental outcomes from the PQ2 and HPQs, including ASQ-3
domain scores and problems reported in the supplementary questions, is shown in Table 14. Overall,
participants were most likely to report problems with their infant’s talking (23.1%), followed by behaviour
(10.3%), but these showed no differences between groups. However, there were significant differences in
the number of infants for whom all five ASQ-3 domain scores were normal: 190 (63.1%) in the NRT group
compared with 163 (54.2%) in placebo (OR 1.47, 95% CI 1.06 to 2.05, p= 0.02) (see Table 14). For
specific items that contributed to ‘survival with no impairment’, the only significant difference between
groups was in the ASQ-3 ‘personal-social’ domain; 254 (84.4%) had normal scores in the NRT group
compared with 231 (76.7%) in the placebo group. However, although not significantly different, for
infants in the NRT group, both the mean scores and the number of infants with normal scores were
consistently higher in every ASQ-3 domain. The only other difference was with feeding problems (see
Table 14), for which fewer participants allocated to NRT reported problems with their infants’ feeding
[18 (6.0%) NRT, 36 (12%) placebo (OR 0.47, 95% CI 0.26 to 0.85, p= 0.011)]. This outcome is not one
used by the ASQ-3 questionnaire and did not contribute to ‘survival with no impairment’.
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TABLE 14 Comparison of ASQ-3 domain scores and supplementary questions in PQ2 and HPQ at 2 years by
trial group
NRT Placebo OR (95% CI)a p-value
ASQ-3 domain scoresb
Number providing data 301 301
Number (%) of mothers
providing data for at least
one domain
301 (100) 301 (100)
Fine motor skills (mean, SD) 51.3 (8.0) 50.5 (7.5)
Fine motor skills normal, n (%) 264 (87.7) 255 (84.7) 1.30 (0.82 to 2.08) 0.2668
Gross motor skills (mean, SD) 55.1 (8.9) 53.4 (11.1)
Gross motor skills normal, n (%) 263 (87.4) 251 (83.4) 1.40 (0.87 to 2.22) 0.1469
Communication (mean, SD) 52.3 (13.2) 51.0 (14.4)
Communication normal, n (%) 265 (88.0) 259 (86.1) 1.21 (0.75 to 1.96) 0.4273
Problem solving (mean, SD)a 45.6 (10.6) 44.3 (11.1)
Problem solving normal, n (%) 247 (82.1) 231 (76.7) 1.34 (0.90 to 2.01) 0.1479
Personal-social (mean, SD)a 51.3 (9.7) 49.1 (10.4)
Personal-social normal, n (%) 254 (84.4) 231 (76.7) 1.64 (1.08 to 2.48) 0.0184
All ASQ-3 domains normal 190 (63.1) 163 (54.2) 1.47 (1.06 to 2.05) 0.0201
Below normal cut-off score in
≥ 1 domains, n (%)
47 (15.6) 64 (21.3) 0.67 (0.44 to 1.02) 0.0588
Below normal cut-off score in
≥ 2 domains, n (%)
19 (6.3) 30 (10.0) 0.59 (0.32 to 1.08) 0.0811
ASQ-3 supplementary questions [n (%) reporting problem]
Hearing
n (%) 6 (2.0) 11 (3.7) 0.54 (0.20 to 1.51) 0.2326
Missing data 1 (0.3) 1 (0.3)
Speech (talking)
n (%) 72 (23.9) 67 (22.3) 1.11 (0.76 to 1.63) 0.5789
Missing data 1 (0.3) 1 (0.3)
Speech (understanding)
n (%) 21 (7.0) 22 (7.3) 0.93 (0.50 to 1.73) 0.8119
Missing data 1 (0.3) 1 (0.3)
Neuromotor (walking, running, climbing)
n (%) 10 (3.3) 17 (5.7) 0.59 (0.27 to 1.33) 0.1990
Missing data 1 (0.3) 1 (0.3)
Vision
n (%) 11 (3.7) 18 (6.0) 0.59 (0.27 to 1.28) 0.1784
Missing data 1 (0.3) 1 (0.3)
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TABLE 14 Comparison of ASQ-3 domain scores and supplementary questions in PQ2 and HPQ at 2 years by
trial group (continued )
NRT Placebo OR (95% CI)a p-value
Behaviourc
n (%) 30 (10.0) 32 (10.6) 0.91 (0.54 to 1.55) 0.7362
Missing data 2 (0.7) 1 (0.3)
Feedingc,d
n (%) 18 (6.0) 36 (12.0) 0.47 (0.26 to 0.85) 0.0107
Missing data 1 (0.3) 1 (0.3)
HPQ
Number of health professionals
providing data
144 145
n (%) reporting problems
Hearing 3 (2.1) 2 (1.4) 1.52 (0.25 to 9.24) 0.649e
Speech
n (%) 6 (4.2) 9 (6.2) 0.57 (0.19 to 1.70) 0.3110
Missing data 0 (0) 5 (3.5)
Neuromotor
n (%) 3 (2.1) 5 (3.5) 0.54 (0.12 to 2.44) 0.4167
Missing data 1 (0.7) 0 (0)
Vision 7 (4.9) 4 (2.8) 1.93 (0.54 to 6.86) 0.2988
Behaviourc
n (%) 8 (5.6) 4 (2.8) 2.12 (0.62 to 7.21) 0.229e
Missing data 3 (2.1) 0 (0)
Feedingc
n (%) 6 (4.2) 4 (2.8) 1.52 (0.42 to 5.51) 0.523e
Missing data 0 (0) 1 (0.7)
Current health status, n (%)
No disability 136 (94.4) 137 (94.5)
Mild disability 3 (2.1) 5 (3.5)
Moderate disability 2 (1.4) 0 (0)
Severe disability 1 (0.7) 0 (0)
Missing data 2 (1.4) 3 (2.1)
Concerns about development
n (%) 2 (1.4) 5 (3.5)
Missing data 1 (0.7) 1 (0.7)
Formal development assessment carried out (if yes)
n (%) 1 (50.0) 4 (80.0)
Missing data 1 (50.0) 1 (20.0)
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Respiratory problems at 2 years were reported in 132 (29.7%) and 111 (25.0%) of infants born in the NRT
and placebo groups, respectively (OR 1.30, 95% CI 0.97 to 1.74, p= 0.083) (see Table 12). As with the
development questions, more respiratory problems were reported on participant-completed questionnaires
[194 (32.2%) of returned PQ2s compared with 49 (17.0%) of HPQs included reports of respiratory
symptoms]. A more detailed breakdown of singleton infants’ respiratory problems is given in Table 15,
including outcomes that were collected 1 year after delivery. The only significant difference was in the
number of participants reporting at 2 years that their child had ever experienced any wheeze or whistling
in their chest [74 (24.6%) NRT, 49 (16.3%) placebo (OR 1.72, 95% CI 1.14 to 2.59, p= 0.0099)].
Maternal smoking outcomes after delivery
After delivery, both point prevalence and prolonged abstinence from smoking was low and relapse to
smoking gradually increased (Table 16). During the 2-year follow-up, the numbers of participants in the
NRT and placebo groups reporting abstinence from smoking since their quit dates were 28 (5.4%) and 17
(3.2%), respectively, at 6 months, and 19 (3.7%) and 11 (2.1%), respectively, at 1 year. By 2 years after
delivery, 15 (2.9%) allocated to NRT and nine (1.7%) allocated to placebo remained abstinent (OR 1.71,
95% CI 0.74 to 3.94, p= 0.20). Table 17 shows that participants who did not provide any smoking data
at the three postnatal follow-up time points were more likely to have been smokers at delivery, which is
consistent with the assumption used in analyses of smoking behaviour, i.e. that participants who were lost
to follow-up should be counted as smokers.
Additionally, the sensitivity analysis that further investigated this assumption found that varying the
relationship between missingness and smoking status had almost no impact on ORs that compared
smoking cessation rates between trial groups at 2 years. Varying the IMOR between 0 and 1 (in an
unadjusted analysis) altered the OR for the effect of treatment group on self-reported prolonged
abstinence since delivery from 1.117 (IMOR= 0) to 1.107 (IMOR= 1), the OR for self-reported 7-day
cessation from 1.068 to 1.059, and the OR for prolonged abstinence from smoking between quit date and
2 years after delivery from 1.713 to 1.707. This provides added reassurance that treating those with
missing outcome data as smokers had no substantial impact on the study findings for smoking outcomes.
TABLE 14 Comparison of ASQ-3 domain scores and supplementary questions in PQ2 and HPQ at 2 years by
trial group (continued )
NRT Placebo OR (95% CI)a p-value
Overall development delay (if yes), n (%)
Mild 0 (0) 3 (75.0)
Moderate 1 (50.0) 0 (0)
Severe 0 (0) 0 (0)
Missing data 1 (50.0) 1 (25.0)
SD, standard deviation.
a Missing data for problem-solving (placebo n= 2), personal-social (placebo n= 1).
b ASQ-3 domain cut-off scores: fine motor skills= 35.16, gross motor skills= 38.07, communication= 25.17, problem
solving= 29.78, personal-social= 31.54.
c Responses from these questions were not used for primary outcome ‘survival with no impairment’, but did contribute to
the ‘suspected developmental impairment’.
d Item not from ASQ-3, but added to PQ2.
e Unadjusted analyses and Wald test p-value used owing to small cell sizes (all other multivariate analyses adjusted for site
and likelihood ratio test used).
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine
patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind,
placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/
S2213-2600(14)70157-2.
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TABLE 15 Infant respiratory outcomes between 6 months and 2 years after delivery
Infant respiratory outcomes
(singleton pregnancies)a
NRT
(n= 503)
Placebo
(n= 507)
OR
(95% CI)b p-value
Adjusted OR
(95% CI)c p-value
1 year after deliveryd
Number (%) of respondents 288 (57.3) 295 (58.2)
Wheeze or whistling
n (%) 62 (21.5) 57 (19.3) 1.18
(0.78 to 1.77)
0.4356 1.00
(0.65 to 1.55)
0.9820
Missing data 0 (0) 1 (0.3)
If yes, how many attacks in last year? n (%)
0 6 (9.7) 8 (14.0)
1–3 41 (66.1) 33 (57.9)
4–12 12 (19.4) 10 (17.5)
> 12 1 (1.6) 4 (7.0)
Missing data 2 (3.2) 2 (3.5)
How often has sleep been disturbed due to wheezing? n (%)
Never 38 (61.3) 38 (66.7)
< 1 night/week 14 (22.6) 12 (21.1)
≥ 1 night/week 7 (11.3) 5 (8.8)
Missing data 3 (4.8) 2 (3.5)
Doctor diagnosed asthma, n (%)e 13 (4.5) 15 (5.1) 0.95
(0.44 to 2.06)
0.9005 0.97
(0.42 to 2.24)
0.9421
Dry cough at night
n (%) 27 (9.4) 20 (6.8) 1.46
(0.79 to 2.69)
0.2219 1.26
(0.65 to 2.42)
0.4906
Missing data 1 (0.4) 1 (0.3)
Seen by paediatrician or chest specialist about chest or breathing problems
n (%) 28 (9.7) 28 (9.5) 1.06
(0.61 to 1.86)
0.8263 0.99
(0.55 to 1.78)
0.9680
Missing data 1 (0.4) 1 (0.3)
2 years after delivery (maternal questionnaire: PQ2)
Number (%) of respondents 301 (59.8) 301 (59.4)
Respiratory related hospital admissions
n (%) 39 (13.0) 34 (11.3) 1.22
(0.74 to 2.01)
0.4340 1.47
(0.85 to 2.53)
0.1615
Missing data 0 (0) 1 (0.3)
Problems with chest or breathing
n (%) 53 (17.6) 48 (16.0) 1.21
(0.78 to 1.88)
0.3881 1.22
(0.76 to 1.95)
0.4079
Missing data 1 (0.3) 1 (0.3)
Wheeze or whistling
n (%) 74 (24.6) 49 (16.3) 1.72
(1.14 to 2.59)
0.0087 1.79
(1.14 to 2.79)
0.0099
Missing data 0 (0) 2 (0.7)
continued
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TABLE 15 Infant respiratory outcomes between 6 months and 2 years after delivery (continued )
Infant respiratory outcomes
(singleton pregnancies)a
NRT
(n= 503)
Placebo
(n= 507)
OR
(95% CI)b p-value
Adjusted OR
(95% CI)c p-value
If yes, how frequently? n (%)
Every day 5 (6.8) 3 (6.1)
Every week 10 (13.5) 3 (6.1)
≤ once/month 58 (78.4) 42 (85.7)
Missing data 1 (1.4) 1 (2.0)
Doctor diagnosed asthmae
n (%) 31 (10.3) 19 (6.3) 1.79
(0.98 to 3.28)
0.0547 1.74
(0.91 to 3.32)
0.0889
Missing data 0 (0) 1 (0.3)
Medicines taken for cough/wheeze/chest problems
n (%) 51 (16.9) 39 (13.0) 1.43
(0.90 to 2.27)
0.1231 1.42
(0.86 to 2.32)
0.1653
Missing data 0 (0) 2 (0.7)
2 years after delivery (HPQ)f
Number (%) of respondents 144 (28.6) 145 (28.6)
Problems with chest or breathing
n (%) 26 (18.1) 23 (15.9) 1.04
(0.57 to 1.89)
0.8953 1.05
(0.56 to 1.98)
0.8730
Missing data 1 (0.7) 1 (0.7)
a The denominators for respiratory outcomes are based on participants with singleton births who responded at each
follow-up time point (i.e. the outcomes for twin pregnancies have been excluded).
b Adjusted for centre only (as a stratification factor).
c Adjusted for centre, COT at baseline, partner’s smoking status and age at leaving full-time education.
d Respiratory symptoms were collected at 1 year but were not listed as outcomes in the protocol.
e Diagnosed defined as a doctor ever having said your child has asthma.
f Twenty-six participants have been excluded who responded to the HPQ, as they had already provided PQ2 data
(n= 12 NRT, n= 14 placebo).
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine
patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind,
placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/
S2213-2600(14)70157-2.
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TABLE 16 Maternal smoking outcomes between 6 months and 2 years after delivery
Maternal smoking outcomesa
NRT
(n= 521)a
Placebo
(n= 529)a OR (95% CI)b p-value
Adjusted OR
(95% CI)c p-value
6 months after delivery
Number (%) of respondents 335 (64.3) 338 (63.9)
Self-reported prolonged abstinence
since delivery, n (%)d
57 (10.9) 50 (9.5) 1.18
(0.79 to 1.76)
0.4254 1.23
(0.81 to 1.87)
0.3251
Self-reported 7-day cessation, n (%) 56 (10.8) 52 (9.8) 1.11
(0.74 to 1.65)
0.6228 1.15
(0.76 to 1.74)
0.5032
Prolonged abstinence from smoking
between quit date and 6 months after
delivery, n (%)e
28 (5.4) 17 (3.2) 1.71
(0.92 to 3.17)
0.0836 1.84
(0.98 to 3.46)
0.0547
1 year after delivery
Number (%) of respondents 288 (55.3) 300 (56.7)
Self-reported prolonged abstinence
since delivery, n (%)d,f
33 (6.3) 29 (5.5) 1.16
(0.70 to 1.95)
0.5640 1.18
(0.69 to 2.04)
0.5437
Self-reported 7-day cessation, n (%)f 55 (10.6) 37 (7.0) 1.57
(1.01 to 2.43)
0.0413 1.55
(0.98 to 2.46)
0.0574
Prolonged abstinence from smoking
between quit date and 1 year after
delivery, n (%)e,f
19 (3.7) 11 (2.1) 1.78
(0.84 to 3.78)
0.1273 2.20
(0.98 to 4.92)
0.0475
2 years after delivery
Number (%) of respondents
(PQ2 only)g
302 (58.0) 304 (57.5)
Self-reported prolonged abstinence
since delivery, n (%)d
23 (4.4) 21 (4.0) 1.11
(0.61 to 2.04)
0.7274 1.03
(0.53 to 1.98)
0.9409
Self-reported 7-day cessation, n (%) 45 (8.6) 43 (8.1) 1.06
(0.69 to 1.65)
0.7789 0.98
(0.62 to 1.56)
0.9483
Prolonged abstinence from smoking
between quit date and 2 years after
delivery, n (%)e
15 (2.9) 9 (1.7) 1.71
(0.74 to 3.94)
0.2036 1.96
(0.82 to 4.70)
0.1204
a For the smoking outcomes, participants who did not provide data or were lost to follow-up are assumed to be smokers
and included in the denominator.
b Adjusted for centre only (as a stratification factor).
c Adjusted for centre, COT at baseline, partner’s smoking status and age at leaving full time education.
d Self-reported prolonged abstinence since delivery defined as having smoked ≤ 5 times since the baby was born.
e Participant met criteria for prolonged abstinence at delivery (i.e. positive primary outcome) plus self-reported smoking
≤ 5 times since the baby was born.
f Cessation information was collected at 1 year but was not listed as an outcome in the protocol.
g Smoking status was only ascertained in the PQ2.
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine
patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind,
placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/
S2213-2600(14)70157-2.
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Secondary analysis: adherence with nicotine patches and impairment
Data on the presence or absence of impairment at 2 years of age were available for 884 singleton infants
and this was the sample size for analysis. Reported adherence with nicotine patches was heavily skewed
and skewness was increased by coding placebo group participants’ adherence with nicotine patches as
zero. We analysed adherence with nicotine-containing patches in three categories: 0 days’ use and, for
participants reporting at least use of one patch (1 day’s use), we used a median split within these
participants (median= 10 days’ use) to create two categories of ‘up to median use’ (1–10 days) and ‘above
median use’ (11–56 days). Table 18 shows the numbers in each adherence category, the distribution of
survival with no impairment within these categories and crude and adjusted OR for the association
between adherence categories and survival with no impairment, using 0 days’ adherence as a reference
category. Adjustment was made for partner’s smoking status, which was found to be associated with
outcome in the multivariable model. Results in Table 18 suggest that participants in the highest category
of adherence with nicotine-containing patches were more likely to have infants who had survived without
impairments (adjusted OR 1.72, 95% CI 1.22 to 2.57).
TABLE 17 Sensitivity analyses of smoking outcomes: association between smoking status at delivery and smoking
outcomes reported by participants at the three follow-up time points
Smoking status at delivery Smoking data reporteda No smoking data reportedb p-valuec
6-month follow-up N = 656 N = 325
Smoking at delivery, n (%) 579 (88.3) 313 (96.3) < 0.001
Abstinent at delivery, n (%) 77 (11.7) 12 (3.7)
1-year follow-up N = 571 N = 410
Smoking at delivery, n (%) 511 (89.5) 381 (92.9) 0.065
Abstinent at delivery, n (%) 60 (10.5) 29 (7.1)
2-year follow-up N = 589 N = 392
Smoking at delivery, n (%) 523 (88.8) 369 (94.1) 0.004
Abstinent at delivery, n (%) 66 (11.2) 23 (5.9)
This table is based on the 981 participants who provided primary outcome data at delivery.
a Smoking data reported: any smoking question with a response (smoked in the last week, smoked since delivery and
smoking frequency).
b No smoking data reported: missing data for all three smoking questions.
c Chi-squared test p-value.
TABLE 18 Secondary analyses of smoking outcomes: associations between maternal adherence with
nicotine-containing patches and infants’ survival with no impairment
Reported number of
days on which
nicotine patches used
(adherence category)
Number (%)
participants in
adherence category
(N= 884a)
Number (%) infants from
each adherence category
that survived with no
impairment (N= 613)
Crude OR
(95% CI)
Adjusted OR
(95% CI)b
0 474 (53.6) 313 (66.0) 1.00
(not estimable)
1.00
(not estimable)
1–10 (≤median) 197 (22.3) 136 (69.0) 1.15
(0.80 to 1.64)
1.12
(0.78 to 1.60)
11–56 (>median) 213 (24.1) 164 (77.0) 1.72
(1.19 to 2.50)
1.77
(1.22 to 2.57)
a Excludes four infants who died before follow-up and for whom there were no outcome data.
b Adjusted for partner smoking status.
Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine
patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind,
placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/
S2213-2600(14)70157-2.
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Chapter 4 Health economics analysis report
Introduction
The cost-effectiveness of NRT use by the general population has been established57,58 and a number of
studies have investigated the potential cost saving of smoking cessation interventions in pregnancy,59
but few have used empirical data on costs to calculate the incremental cost-effectiveness of
smoking interventions.60
This chapter reports on an economic evaluation conducted alongside the SNAP trial, addressing the value
for money and cost-effectiveness of NRT patches and behavioural support compared with behavioural
support alone.
The objectives were:
i. to compare the costs associated with the control and intervention strategies
ii. to estimate the consequences of these alternatives
iii. to assess cost-effectiveness of NRT patches used in addition to behavioural support on smoking
cessation at delivery
iv. to use EQ-5D data collected at 6 months after delivery to model longer-term cost–utility of NRT used for
smoking cessation in pregnancy
v. to explore the potential for providing monetary estimates of the long-term impacts on the child of their
differential birth outcomes.
Methods
Overview
A cost-effectiveness analysis was undertaken to compare NRT patches and behavioural support to
behavioural support only, for women who were smoking during pregnancy. The main outcome for the
economic evaluation was biochemically validated abstinence from smoking between a quit date and
delivery. As recommended by the National Institute for Health and Care Excellence (NICE),61 analyses were
conducted from a NHS and personal-social services viewpoint, including direct health effects (maternal
smoking cessation) and costs (or cost savings) to the NHS. Mothers were eligible for inclusion in the SNAP
trial if they were between 12 and 24 weeks’ gestation and outcomes were collected at delivery (up to
42 weeks’ gestation); therefore, the time horizon of the trial was up to 7 months.
Cost estimation
There were two main components to the costing of the control and intervention strategies: first, the costs
of the inputs required for the interventions and second, the resources used to care for each woman and
her infant during the period between randomisation and delivery.
Intervention costs
The cost inputs for the interventions included training and staff time to deliver the behavioural support
(band 7 midwives), CO monitors (breath testing equipment), consumables (NRT patches and consumables
associated with CO breath testing) and overheads for premises.
Training costs were calculated for 2 days of training for 10 midwives (salary costs at a mid-point of band 7),
provided by an NHS SSS advisor (salary costs an average of band 5 and 6) at an NHS SSS, including
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overheads62 and the cost of 1060 15-page manuals that were used both to guide intervention delivery and
as information for participants.
At baseline, participants were given a 4-week supply of NRT patches at a dose of 15mg per 16 hours.
Participants in the placebo arm were given identical patches, without the active ingredients; however,
these placebo patches represent a research cost and were therefore excluded from the costing. The
placebo group will therefore be referred to as the control group throughout Chapter 4. At the baseline
hospital antenatal visit, midwives also provided up to 1 hour of behavioural support. The time midwives
spent providing face-to-face behavioural support was recorded and multiplied by salary and overhead costs
to calculate a cost per session. All women provided a CO reading at baseline.
Three sessions of behavioural support were provided over the telephone on the quit date and at 3 days
and 1 month after this. For each woman, successful calls were logged and these varied in length and
although call times were not recorded, call lengths were estimated by a trial midwife to be the following:
2 minutes for the quit date call, 3.5 minutes for the call 3 days after the quit date, 4 minutes for the call
1 month after the quit date to self-reported smokers and 2 minutes for 1 month calls to self-reported
non-smokers. The call for self-reported non-smokers was shorter as, during this, midwives would arrange
a home visit to validate smoking cessation and provide face-to-face behavioural support. Midwives would
try to contact participants several times if they did not get through; therefore, the cost of failed call attempts
was also estimated. Failed calls were assumed to be 30 seconds per call attempt, with three call attempts per
woman who did not speak to the midwife on the appropriate day, and for each successful call we also
assumed a 30 second failed call attempt.
Women who self-reported not smoking at 1 month after the quit date were visited at home to have a
session of behavioural support and for CO validation. Women biochemically verified as abstinent at
1 month were offered a second 4-week supply of patches. At delivery, midwives used CO monitors to
verify smoking status, which took approximately 10 minutes of midwife time.
To calculate the costs of CO monitoring per use at baseline, 1 month and delivery, the costs of the
equipment and associated consumables were totalled and divided by the total number of uses. The cost
of four CO monitors was not depreciated as the life expectancy was estimated to be around 5 years
(the length of the trial). One calibration kit was required for every two monitors. Based on usage evidence
from the trial we assumed semidisposable mouthpiece adaptors were changed after 60 uses, batteries
were changed every 240 uses and one disposable mouth piece and alcohol-free wipe was required for
each use.
Resource-use costs
Resource-use data were collected from trial participants and from medical records. We collected data from
participants on their use of NHS SSS (either face to face or by telephone). Information about antenatal
hospital admissions and mode of delivery was collected from maternal medical records and data on
admissions to neonatal special care came from infant medical records.
Valuation of costs
All data were valued in monetary terms and unit costs were reported in pounds sterling for the financial
year 2009–10 (representing the mid-point of the trial). Any costs occurring in prior or later price years were
inflated or deflated using the Hospital and Community Health Services pay and prices index.63 As for the
economic evaluation, we considered trial follow-up until to 7 months post randomisation only and no
discounting was required. For standard NHS health care, UK unit costs were applied from national sources,
increasing the generalisability of the results. Table 19 presents a summary of resource use and unit costs,
with the calculation of the costs detailed in Calculating costs.
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Calculating costs
In order to calculate the costs of face-to-face NHS SSS sessions, a weighted average cost of individual and
group sessions was calculated based on information from a NICE costing report.62 Salary and overheads
information from the same report were used to calculate the cost per minute of a phone call (assumed to
be the same length as the calls reported for providing behavioural support).
The cost of mode of delivery was established by calculating a weighted average of unit costs of the
different modes of delivery activities recorded in NHS reference costs. A similar method was used to
calculate an average cost of a maternal antenatal admission, based on antenatal observations
and investigations.
To calculate the cost of the admission of a baby to neonatal care, a weighted average of bed-day costs for
neonatal critical care from NHS reference costs (£618) was multiplied by a weighted average length of stay
for neonates with major diagnoses (12.2 days) according to Hospital Episode Statistics for 2009–10.69
Quantities of services used were multiplied by the relevant unit costs to estimate overall cost profiles for
women in the trial.
Outcome measures
The measure of health benefit for the economic evaluation was the same as the primary measure of
clinical effectiveness in the SNAP trial: self-reported and biochemically validated maternal smoking
TABLE 19 Unit costs (2009–10 prices)
Unit cost (£) Unit Source of unit cost
Interventions
15mg per 16 hours NRT patches 1.28 Patch The Health and Social Care
Information Centre64
Dispensing cost 2.14 Prescription www.psnc.org.uk/pages/
archive.html65
Band 7 midwife time (including overheads) 35.28 Per hour The NHS Staff Council,66 Curtis63
Antenatal midwife home visit 45.00 Visit Department of Health67
CO monitors and consumables 0.47 Per use Estimated from the SNAP trial
Printing 0.96 15-page manual Estimated from the SNAP trial
Resource use
NHS SSS
Face to face (individual or group session) 11.69 Session NICE62
Telephone call (4-minute call) 1.27 Call NICE62
Text message 0.16 Message NHS Connecting for Health68
Maternal antenatal admission 1180.48 Admission Department of Health67
Mode of delivery
Unassisted vaginal delivery 1454.28 Obstetric delivery Department of Health67
Assisted vaginal delivery 2095.06
Caesarean section 3028.66
Baby admission to neonatal unit 7532.31 Admission Department of Health,67
The Health and Social Care
Information Centre69
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cessation from quit date to immediately before delivery. Temporary smoking lapses of up to a total of five
cigarettes (on up to five occasions) were permitted.
The National Institute of Health and Care Excellence (2008)61 recommend that health outcomes should be
measured in quality-adjusted life-years (QALYs) to facilitate comparisons between different health-care
programmes. However, QALYs, commonly calculated from the generic health-related quality-of-life tool
the EQ-5D,70 may be inappropriate in a study including pregnant women. Generic quality of life studies
have shown poorer quality-of-life in early pregnancy compared with population norms for women of
child-bearing age71 and substantial changes in quality of life, particularly declining physical functioning and
vitality, occur over the course of pregnancy.72 These dramatic changes in quality of life between pregnancy
and the post-partum period would likely mask any potential short-term quality-of-life gains from smoking
cessation. Nevertheless, EQ-5D data were collected at 6 months after delivery, within the postal
questionnaire sent to participants, which is described in Chapter 2, Methods.
Analysis
An incremental cost-effectiveness analysis was undertaken, following the NICE guidance for health-care
evaluations,61 comparing the additional costs of NRT patches with behavioural support alone, as well as
the additional benefits, to give a cost per additional quitter.
The incremental cost-effectiveness ratio (ICER) calculates the mean cost of the intervention group over and
above the control and divides by the mean difference in health benefits. The following formula is for ICER,
for which Δ represents change, C represents the costs, E represents the effects and subscript I and C refer
to the intervention and control, respectively.
ICER ¼ ΔC
ΔE
¼
CI−CC
EI−EC
ð1Þ
All analyses were conducted on an ITT basis in which all randomised participants were included and
analysed in the groups to which they were randomised. Analyses were conducted in Microsoft Excel, 2010,
version 14.0.7113.5005 (32-bit) (Microsoft Corporation, Redmond, WA, USA).
There were no missing data on the effectiveness outcome (validated smoking cessation from quit date to
delivery), as any women without validated cessation were assumed to be smokers. Missing data for cost
items were imputed using average costs for the appropriate arm of the trial, allowing the base-case
analysis to be completed for all women in the trial and, therefore, with the same quit rate as the main
effectiveness analyses in Chapter 3.
Cost data were bootstrapped to account for skewness, sampling with replacement observations
1000 times to generate a new population of sample means with an approximate normal distribution.
Bootstrap results were presented graphically using a cost-effectiveness plane73 to show the uncertainty
around the mean estimates of incremental costs and effects.
The EQ-5D data collected at 6 months after delivery were converted into a single index summary score
after applying UK population values.74 Descriptive statistics for EQ-5D data are presented by trial group.
We planned to use 6-month EQ-5D data in conjunction with smoking status utility values based on quit
rates at 2 years after delivery to calculate the longer-term costs and benefits of differential quit rates
between the intervention and the control arms.
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Results
A total of 1050 women were recruited to the SNAP trial: 521 and 529 in the NRT and placebo
arms, respectively.
Costs
The breakdown of intervention costs for the trial arms are presented in Table 20. Costs for providing
behavioural support and CO monitoring were relatively equal in both arms, although costs of the 4-week
home visits were slightly higher in the NRT group than the control group (£14.31 compared with £9.46,
respectively) because rates of self-reported smoking cessation were higher in the NRT group at 4 weeks
(25.1% compared with 14.0%). The mean total intervention cost in the control group was £47.75. The
comparative cost of providing behavioural support and CO monitoring was £52.24 in the NRT group, and
the total mean cost including NRT patches was £98.31.
Table 21 reports the resources utilised in the two arms of the trial. Use of NHS SSS, maternal antenatal
hospital admissions and admissions to neonatal care were similar in the two groups, although more women
had a caesarean section in the NRT group than in the control group: 20.9% and 16.1%, respectively.
Quantities of services used were multiplied by the relevant unit costs in Table 19 to calculate the cost
of resources used for each woman and total costs were calculated by adding resource-use costs to
intervention costs. Table 22 summarises total mean costs for the trial groups. Mean intervention costs were
significantly higher in the NRT group, at a mean difference of £50.56. Total mean resource-use costs were
£40.26 higher in the NRT group and overall costs were, therefore, £90.81 higher for this group; however,
these differences were not statistically significant.
TABLE 20 Intervention costs by allocated group (prices in £ 2009–10)
Intervention
NRT group,
n= 521, mean (SD)
Control,
n= 529, mean (SD)
Training cost (per face-to-face session)
Training costs for midwives
(per hospital behavioural support session)
4.18 4.18
Treatment cost (per participant)
NRT patches 46.07 (15.57) 0.00
Behavioural support session at hospital
(including CO monitoring)
21.72 (4.18) 22.00 (4.62)
Telephone callsa
Calls on quit date 1.30 (0.27) 1.30 (0.27)
Calls on quit date+ 3 days 1.97 (0.64) 1.94 (0.66)
Calls on quit date+ 1 month (self-reported smokers) 1.78 (0.88) 1.91 (0.87)
Calls on quit date+ 1 month (self-reported non-smokers) 1.07 (0.27) 1.00 (0.24)
Home visit at 4 weeks for behavioural support for
self-reported non-smokers (including CO monitoring)
14.31 (21.14) 9.46 (18.47)
10 minutes to monitor CO levels at delivery 5.92 (1.61) 5.96 (1.54)
Average intervention costs (per participant) 98.31 (35.21) 47.75 (19.03)
SD, standard deviation.
a Calls include the cost of failed attempts.
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Outcomes
Any women without biochemical validation of quitting were assumed to be smokers. In the NRT group,
49 out of 521 women (9.4%) were abstinent with biochemical validation from quit date to delivery and in
the control group this was true for 40 out of the 529 women (7.6%), a non-significant difference of 1.8%
(see Chapter 3).
Cost-effectiveness analysis and uncertainty
Table 23 presents the ICER, combining the differential costs of the treatment groups, with the differential
quit rates. NRT plus behavioural support was found to be somewhat more costly than behavioural support
alone, but with a slightly higher quit rate. This generates an ICER of £4926 per quitter. If decision-makers
are willing to pay > £4926 for an additional quitter, then NRT would be the preferred option; otherwise,
behavioural support alone should be adopted.
TABLE 21 Health-care service utilisation
NRT, N= 521 Placebo, N= 529
NHS SSS
Missing data, mean n (%) 36 (6.9) 33 (6.2)
Face-to-face session, mean n (SD) 0.18 (0.6) 0.16 (0.6)
Telephone call, mean n (SD) 2.06 (2.3) 1.84 (2.0)
Text message, mean n (SD) 0.80 (1.8) 0.71 (1.7)
Maternal antenatal hospital admission
Missing data, mean n (%) 10 (1.9) 12 (2.3)
Admissions, mean n (%) 79 (15.2) 82 (15.5)
Mode of birth
Missing data, mean n (%) 10 (1.9) 14 (2.7)
Unassisted vaginal birth, mean n (%) 362 (69.5) 386 (73.0)
Assisted vaginal birth, mean n (%) 40 (7.7) 44 (8.3)
Caesarean section, mean n (%) 109 (20.9) 85 (16.1)
Baby admitted to neonatal unit
Missing data, mean n (%) 10 (1.9) 14 (2.7)
Admissions,a mean n (%) 37 (7.1) 39 (7.3)
SD, standard deviation.
a Including multiple births (four twin births in the NRT group and eight in the control group. N= 1062 babies).
TABLE 22 Total costs (prices in £ 2009–10)
Type of cost
NRT group,
n= 521, mean (SD)
Control group,
n= 529, mean (SD) Differencea (95% CI)
Intervention costs £98.31 (35.21) £47.75 (19.03) £50.56 (47.13 to 53.99)
Resource-use costs £2571.56 (2393.63) £2531.31 (2384.34) £40.26 (–248.76 to 329.27)
Total costs £2669.87 (2394.09) £2579.06 (2385.68) £90.81 (–198.31 to 379.94)
SD, standard deviation.
a Difference= cost in the intervention group minus cost in the control group.
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A cost-effectiveness scatter plot was produced based on the bootstrapping, including 1000 resamples of
the costs and effects data. The bootstrapped results were plotted on a cost-effectiveness plane, visually
displaying the uncertainty around the mean differences in costs and benefits between the trial arms
(Figure 9). The majority of the plots in the scatter plot fall in the north-east quadrant, indicating that NRT is
likely to be more effective but more costly than behavioural support alone. However, the scatter plot also
shows the uncertainty around the cost estimates.
TABLE 23 Results of the incremental cost-effectiveness analysis (prices in £ 2009–10)
NRT group, n= 521 Control group, n= 529
Cost (SD) £2669.87 (£2394.09) £2579.06 (£2385.68)
Quit rate 9.4% 7.6%
ICER £4926 per quitter
Bootstrapped 95% CI of ICER –£114,128 to £126,747
SD, standard deviation.
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FIGURE 9 Cost-effectiveness plane.
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Sensitivity analyses
To allow for uncertainty in our estimates of costs and consequences, we conducted a sensitivity analysis
excluding 12 women who had multiple births (four twin births in the NRT group and eight in the control
group) who are more likely to have complicated pregnancies and deliveries. Table 24 shows the total costs
and quit rates in the singleton-only analysis. Quit rates were very similar (+ 0.08% in the NRT group and
–0.46% in the control group); total costs were lower in the singleton-only analysis, but by a similar
amount in both groups (–£64.37 in the NRT group and –£72.32 in the control group). The corresponding
ICER generated for singleton births was £4156 per quitter.
Projecting longer-term costs and benefits (objectives 4 and 5)
We had planned to use EQ-5D data collected 6 months after delivery in conjunction with smoking status
utility values based on quit rates at 2 years to calculate the longer-term costs and benefits of differential
quit rates between the intervention and control arms. These longer-term analyses were impeded for a
number of reasons. First, there was only a small, non-significant difference in quit rates between groups.
Second, there was no difference in EQ-5D scores between the groups at 6 months (Table 25). Third, there
was great uncertainty in cost estimates in the alongside trial economic analysis, which would be amplified
in any longer-term projections, generating non-robust estimates. Fourth, there were no significant
differences in birth outcomes, precluding monetary estimates of the long-term impacts on the child.
TABLE 25 Mean EQ-5D index scores at 6 months
NRT group, n= 335 Control group, n= 338
Missing data 3 11
Mean (95% CI) 0.896 (0.875 to 0.917) 0.894 (0.873 to 0.916)
TABLE 24 Results of the incremental cost-effectiveness analysis (singleton births only) (prices in £ 2009–10)
NRT group, n= 517 Control group, n= 521
Cost (SD) £2604.73 (£2198.98) £2505.97 (£2184.43)
Quit rate 9.48% 7.10%
ICER £4156
Bootstrapped 95% CI of ICER (–£65,994 to £82,059)
SD, standard deviation.
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Summary
l Total mean costs were £90.81 higher in the NRT group, representing around a 3% difference in costs
between trial groups. The higher costs in the NRT group were mainly attributable to the cost of the
NRT patches (mean= £46.07).
l The ICER associated with NRT patch use was estimated at £4926 per quitter. Sensitivity analyses
including only singleton births resulted in an ICER of £4156 per quitter; however, there were very wide
CIs around these estimates, indicating a high level of uncertainty. This uncertainty occurred because
there were only small differences in total costs between the groups, but the total cost for each group
was affected by high within-group variability, which was particularly influenced by costs attributable to
antenatal or neonatal admissions. For example, in both groups, approximately 7% of babies were
admitted to neonatal care and each had an admission cost of £7532, compared with an average
between-group difference in costs of only £91. Therefore, as between-group cost differences are small,
if women with these high resource-use costs happen to fall in one arm by chance, this could change
the result of the ICER.
l If decision-makers are willing to pay > £4156 for an additional quitter, then NRT should be adopted;
otherwise, behavioural support alone should be adopted.
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Chapter 5 Discussion
Principal findings
Smoking outcomes
This trial demonstrates that, at 12–24 weeks’ gestation, supplementing behavioural support with a 15mg
per 16 hours nicotine patch was no more effective than a placebo in promoting sustained smoking
cessation throughout pregnancy. Clinically and statistically significant higher biochemically validated
cessation rates were obtained with NRT at 1 month, but this effect did not persist into later pregnancy.
After childbirth, self-reported, prolonged cessation since quit dates agreed in pregnancy were between
1% and 2% higher in women who had been randomised to NRT, but these small differences were
not statistically significant.
Maternal and fetal birth outcomes
Maternal and fetal birth outcomes were generally very similar with almost no statistically significant
differences between groups. Caesarean section births were more frequent in the NRT group and this
difference was statistically significant (OR 1.45, 95% CI 1.05 to 2.01).
Infant outcomes at 2 years
At 2 years of age, singleton infants born to trial participants who had been allocated NRT were significantly
more likely to have no developmental impairment than those born to participants in the placebo group.
Very similar findings occurred whether using data obtained from only participant-completed questionnaires
(PQ2) or data from both PQ2 and HPQ questionnaires combined. Additionally, very similar findings were
noted in pre-specified analyses, which (1) included twin births and adjusted for clustering of outcomes and
(2) applied multiple imputation methods to investigate the assumption that data missing were missing at
random (i.e. that missingness was associated with baseline characteristics but not with the outcome itself).
No significant difference in reported rates of infants’ respiratory problems was noted.
Economic outcomes
Total mean costs were £90.81 higher in the NRT group, with the excess largely attributable to the cost
of NRT patches (mean cost of patches= £46.07). For singleton births only, an ICER of £4156 per quitter
was derived; therefore, if decision-makers are willing to pay this amount for each additional quitter, then
NRT, used in addition to behavioural support, would be the preferred option. The results showed no
differences between groups in birth outcomes or health status as measured by EQ-5D at 6 months
postnatal. Therefore, it was not possible to estimate a cost per QALY or model long-term QALYs.
There has been little research investigating the cost-effectiveness of smoking cessation interventions in
pregnancy. Although a number of studies have investigated the potential cost saving of smoking
interventions for pregnant women,59 these studies have mainly been conducted in the USA with restricted
perspectives, particularly omitting data relating to infant outcomes. Only two studies have thus far
reported QALYs: one being a simple model based on an American trial60 and another a hypothetical model
constructed for NICE guidance.75 Although these studies suggest that smoking cessation in pregnancy may
be cost-effective, they are mainly poor quality and the settings and methods used preclude comparison
with our results. Furthermore, with the exception of the NICE model,75 none of the studies has explored
the cost-effectiveness of NRT.
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Adherence
Adherence to both types of patch was low. Although adherence was not a trial outcome, the pattern of
adherence may be related to, and at least partially explain, smoking cessation and birth outcomes and,
consequently, requires discussion.
Limitations and strengths
Overall comments
This study is by far the largest of its type. Prior to the SNAP trial being completed, in the five previous RCTs
of NRT for smoking cessation in pregnancy, only 695 women had been randomised.30 We believe that this
is the first trial to test whether or not a smoking cessation intervention delivered in pregnancy can affect
infant outcomes. The study is also original in that in previous trials of NRT in pregnancy, maternal smoking
behaviour has been investigated for only up to 3 months after childbirth,34,35 whereas we followed up
participants and infants until 2 years after birth. We can find only one trial testing any smoking cessation
intervention (i.e. a non-NRT intervention) for pregnant women that attempted to monitor smoking
behaviour up to and beyond 2 years after childbirth.76 However, in this study, smoking data were not
sought from all trial participants at predetermined time points, but was obtained opportunistically at
multiple, different times between 8 and 54 months after childbirth, rendering smoking behaviour data
difficult to interpret.
Outcomes recorded at and before delivery
By carefully implementing a double-blind, placebo-RCT design, most of the biases that could have
influenced outcomes at these time points have been minimised. However, we did not ask women which
treatment they perceived they had been allocated to and hence have no data to confirm whether
participants remained blinded to their treatment allocations or, indeed, guessed their allocation.
Consequently, it is possible that some participants may have correctly determined their treatment
allocation and, if this had occurred, we would be unable to quantify its extent. However, unblinded trials
of NRT in pregnancy tend to overestimate the treatment effect from NRT30 and we found no effect at
delivery. Additionally, loss of blinding among trial participants would not explain the very different pattern
of findings with respect to efficacy at 1 month and delivery.
The strengths of the study appear to outweigh its weaknesses and overall findings reported are likely to be
valid. Target sample size was achieved; therefore, the study was adequately powered to detect the
anticipated 9% difference in cessation rates between trial arms. However, it remains possible that NRT
could work for smoking cessation in pregnancy, but with a lesser impact because smaller treatment effects
(i.e. < 9% absolute difference) would not necessarily have been detected by a trial of this size. At baseline,
groups were well balanced for all variables recorded, including those with potential to influence findings;
therefore, chance differences between groups are unlikely to explain these. Additionally, the high outcome
ascertainment rates, which were very similar in both groups, reduce the likelihood that ascertainment bias
influenced study outcomes. Birth outcome ascertainment rates were particularly high and, as RMs who
extracted data on birth outcomes and AEs from medical records were blinded to patch allocation, these
data are particularly likely to be free from bias. Similarly, when participants reported abstinence from
smoking, equally high biochemical verification rates were obtained from participants in both trial groups,
minimising any bias in the reporting of outcomes that may have occurred.
The validity of trial findings could have been affected by unintentional variation in treatments provided for
participants, or in any support or treatment sought by them that was additional to trial interventions. For
example, differences between NRT and placebo group outcomes would have been minimised if trial
participants had also been prescribed NRT from their GPs, issued with it by local NHS SSSs or had bought it
from pharmacies. However, only 2.2% in the placebo group (and 2.5% allocated NRT) reported using NRT
obtained outside of the trial for more than 20 days and it seems unlikely that this level of usage, which
was very similar in both trial arms, would have unduly affected findings. Finally, if participants were
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inadequately prepared for, or inadequately instructed about using, NRT, then this could have affected their
ability to use NRT sufficiently well for any impacts of this treatment to become apparent. However, the trial
RMs, trained to English national cessation standards, provided accompanying behavioural support and, in
both trial groups, participants’ rates of accessing subsequent additional support were similarly low. This
low level of additional support may have affected overall quit rates. However, the level of behavioural
support was comparable with that used in ‘low intensity support’ nicotine patch trials conducted among
non-pregnant subjects in which NRT has been found effective (RR 1.78, 95% CI 1.49 to 2.12),18 for which
NRT caused a near doubling of cessation at the 1-month follow-up point. Taken together, these points
suggest that the behavioural support delivered in the trial probably gave women appropriate instruction in
using NRT and, as no differences were seen between groups in additional support received by trial
participants, this is unlikely to explain trial findings.
Infant outcomes at 2 years
Key strengths are that no previous trials have tested the impact of a smoking cessation intervention in
pregnancy on infant outcomes and we achieved high (around 88%) outcome ascertainment rates
combined with low withdrawal and missing data rates at 2 years. Follow-up rates were very similar in both
trial groups, reflecting the fact that staff conducting follow-up were blind to participants’ treatment
allocations. Additionally, we used caution when classifying questionnaires reporting infants’ development
and respiratory symptoms and manually checked individual questionnaire responses, when necessary.
We were cautious when categorising open-response questionnaire items, generally allocating infants as
experiencing ‘suspected’, rather than ‘definite’ impairment, based on responses to these. A similar
approach was also taken with open response items on respiratory problems. Consequently, it is unlikely
that infants classed as having ‘no impairment’ were actually impaired or that infants categorised as
experiencing ‘respiratory problems’ had not had these. Finally, with respect to the primary outcome
monitored at 2 years, ‘survival with no impairment’, we obtained the same pattern of findings in all
pre-planned analyses, irrespective of whether or not parental or health professional reports of infant health
were used, or whether or not twins were included. This consistency of findings suggests that the overall
finding, that NRT used in pregnancy has a beneficial effect on child development as measured by ASQ-3,
is likely to be valid and unlikely to have occurred by chance.
A limitation is that the ASQ-3 is generally used as a screening tool to identify potential impairments that
are subsequently confirmed or refuted by detailed face-to-face assessment.43 We cannot, therefore,
be certain that the parent-reported ‘snapshot’ of child development obtained via completed ASQ-3
questionnaires is perfectly valid for allocating infants as experiencing ‘definite’ or ‘no impairment’.
However, a previous UK obstetric trial used 30-item ASQ questionnaires to detect neurosensory disability
and, in a subgroup of infants, compared a range of failed and non-failed ASQ scores with outcomes from
‘gold standard’ face-to-face developmental assessments.77 This found that, when used for detecting
neurodevelopmental problems in a cohort of participants and infants that was similar to those in this
study, the 30-item ASQ compared well with standard face-to-face assessments and had a negative
predictive value of 99.5% (95% CI 98.3% to 99.9%).77 If, in our study, the ASQ-3 performed similarly
and if we had employed gold standard face-to-face assessments, one would expect very few infants
categorised by ASQ-3 as having no impairment to then be diagnosed with developmental problems in
face-to-face assessments. Our use of a self-report questionnaire completed by health professionals to help
decide whether or not infants had developmental impairments could also be criticised. Using this method
of data collection, we do not know whether or not those completing questionnaires did so with reference
to medical records or other knowledge of infants. However, very similar questionnaires have been used in
previous authoritative cohort studies78 and incorporation of such health professional data into analyses
in this trial did not affect outcomes.
Smoking outcomes at 2 years
This was the first trial of a smoking cessation intervention to monitor longitudinal smoking rates within
pregnant trial participants for as long as 2 years after delivery; therefore, the data are novel. Although data
were self-reported and we obtained no information on smoking behaviour for around 40% of participants,
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sensitivity analysis suggested that our assumption that non-respondents at 2 years were smokers
was appropriate.
Economic analyses
We present a within trial incremental cost-effectiveness analysis, calculating the cost per additional quitter
associated with NRT patch use. Owing to the issues around measuring the EQ-5D in a population of
pregnant women, we did not propose to calculate QALYs, which reduces the comparability of our
cost-effectiveness outcome with different health-care programmes. The trial did not find a difference in
outcomes that would have enabled the projection of longer-term costs and benefits of NRT use, thus
precluding conclusions about the long-term cost-effectiveness of NRT patch use in pregnancy.
Interpretation and generalisability
Smoking outcomes
In contrast to the negative primary outcome recorded at delivery, the increased cessation until 1 month
after randomisation was of a similar magnitude to that seen following NRT use by non-pregnant
smokers.18 The lack of a statistically significant longer-term effect from NRT may be explained by the low
adherence rates in the trial. One reason for the apparently low adherence is that many participants were
specifically instructed to not use NRT when smoking and many failed to quit and restarted smoking.
However, this does not explain why only 58% (101/173) of participants who were abstinent at 1 month
accepted a second month’s supply of NRT. Other NRT trials in pregnancy have reported similarly low rates
of adherence: two studies of NRT patches found median durations of NRT use of 2 weeks34 and 3 weeks,27
and, in a trial that tested 2-mg nicotine gum, this was used for just over 5 weeks.35 Outside pregnancy,
most smokers who attempt to quit with NRT discontinue this within 1 month because they either start
smoking again or they believe it is not working.79 Nevertheless, despite such reports of adherence with
NRT being lower than recommended,79 trials18 and cohort data from routine clinical care80 both
demonstrate that NRT used by non-pregnant smokers is effective for smoking cessation. Adherence with
NRT is potentially an important influence on the efficacy of this treatment in pregnancy; NRT cannot have
an effect if it is not used and reduced adherence with NRT in later pregnancy could explain the lack of
effect shown at delivery. Therefore, potential influences on adherence in the trial require
further exploration.
Trial participants often discontinue treatments after experiencing AEs or side effects; however, only
8.8% of women in the NRT group reported stopping patches after AEs. In previous similar trials, the
discontinuation rate was 12% for nicotine gum35 and 4.4% for nicotine patches or placebos.27 These AE
rates are much lower than participants’ rates of early treatment discontinuation and hence can only
partially explain this. Treatment discontinuation could be explained by increases in maternal nicotine and
cotinine clearance in pregnancy; increases of 60% and 140%, respectively, have been reported to occur by
25 weeks’ gestation.81 Such increases would be expected to reduce NRT-generated nicotine levels and
increase users’ withdrawal symptoms. It is possible that, for NRT to consistently ameliorate women’s
nicotine withdrawal symptoms and be effective throughout pregnancy, a higher dose is required.82
However, this trial did not include assessment of nicotine metabolism and did not assess withdrawal
symptoms. In addition, factors other than increases in metabolism may explain low NRT adherence rates in
this and previous trials.
In summary, this trial provides no evidence that NRT, as the 15mg per 16 hours transdermal patch, is
effective for smoking cessation in pregnancy. Women used the patches for shorter periods than
recommended and this could explain negative trial findings. It is possible that, even with the low
adherence displayed by trial participants, NRT actually does have a positive effect and, with a larger sample
size, the 1.8% absolute difference in favour of treatment with NRT would have become statistically
significant. However, a recent meta-analysis of this trial’s findings with all previous similar studies
(n= 1745) does not suggest this. In this analysis, the RR for cessation in later pregnancy after using NRT
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compared with control was 1.33 (95% CI 0.93 to 1.91).31 Even if the small difference between groups in
this trial does represent a real effect of NRT that has not been statistically proven, it seems unlikely that,
based solely on this small effect on maternal smoking behaviour, NRT used in pregnancy would be
considered clinically useful. The number needed to treat (calculated using trial data) is 54, which means
that if the magnitude of effect observed in this trial were to be found statistically significant (e.g. in a
future meta-analysis), 54 women would require treatment with NRT to produce one successful quitter. This
success rate would be unlikely to impress clinicians who would probably be inclined to use other methods
of cessation support for pregnant smokers.
Other outcomes measured at delivery
Rates of adverse outcomes were similar between groups with the exception of caesarean deliveries, which
were unexpectedly more frequent in the NRT group. This is difficult to explain and is likely to be a chance
occurrence. However, caution is warranted when interpreting the overall similarity in birth outcomes
between trial groups. Because many adverse birth outcomes are quite rare, some comparisons may have
limited power and the low rate of treatment adherence makes it difficult to attribute the presence or
absence of differences in birth outcomes to NRT.
Outcomes measured after delivery
This study has provided the first evidence that a smoking cessation intervention delivered to pregnant
women can influence the development of their offspring. We found that NRT, used in pregnancy for
smoking cessation, without having any statistically significant, long-term effect on maternal smoking in
pregnancy, had a positive impact on subsequent child development. The most likely explanation for this
impact lies in the altered smoking behaviour of women who were randomised to NRT. For example, the
transient doubling of quit rates in the first month after trial enrolment and until around 20 weeks’
gestation could have occurred at a crucial time for infants’ brain maturation, resulting in the greater
survival to 2 years of age with no developmental impairment. The slightly higher, but non-significant, quit
rates observed from delivery until 2 years and the reduced accompanying exposure of infants to domestic
environmental tobacco smoke may also have had additional positive effects. If the impact of NRT on
infants is mediated through increased maternal smoking cessation, any effective smoking cessation
intervention used by pregnant women would be expected to have similar effects. However, it remains
possible that any protective impact of NRT on infants’ development arises directly from the impact of
nicotine itself and is not mediated by reduced fetal or infant exposure to tobacco smoke toxins. Irrespective
of whether the impact of NRT on infants is direct or mediated (indirect), this trial is reassuring about NRT
use in pregnancy. Although in controlled laboratory studies, nicotine has been shown to cause fetal
tachycardia, albeit to a lesser extent than smoking,21,83,84 this trial provides no evidence that NRT is
harmful. Similarly, as nicotine is a neurotoxin and can cause behavioural problems in young rodents,21,83
there has previously been concern that NRT might harm infants’ developing nervous systems and that it
could cause behavioural problems and poorer academic achievement in smokers’ children.22 However,
study findings clearly suggest that nicotine is unlikely to be responsible for these problems.
As mentioned above, findings from this trial require confirmation; future studies of NRT and other smoking
cessation interventions in pregnancy should follow-up infants and trial participants for at least 2 years after
delivery to facilitate this. Additionally, the cohort of trial infants from this trial should be followed after
2 years, to determine whether or not impacts on child development attributable to NRT persist into
childhood. If further studies can replicate findings or confirm that these benefits persist later into childhood,
then this would provide reassurance that these findings did not occur by chance, which is important both
scientifically and economically. Intervention costs were relatively low (< £100 per participant) and, should
the impacts on infants identified in this study be confirmed, it is likely that NRT used in pregnancy for
smoking cessation would be viewed as cost-effective, potentially generating cost savings for the NHS.
The trial had a relatively pragmatic design, with reasonably broad inclusion and few exclusion criteria,
therefore, results are likely to be generalisable to most pregnant smokers. However, women recruited to
the trial were between 12 and 24 weeks’ gestation and, therefore, our results may be less applicable to
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those trying to quit using NRT earlier or later in their pregnancy. For example, at earlier gestations, nicotine
metabolism may not yet have increased and so the dose of NRT used in this trial may be sufficient to help
such women to quit successfully. Our 1-month findings suggest that this could be likely and as we found
no safety issues, future studies could consider including women earlier in pregnancy. Similarly, as we only
included women who smoked at least 5 cigarettes a day, the results cannot necessarily be extrapolated to
those who are very light smokers and less addicted to nicotine and they may also be more likely to be able
to successfully quit with the dose of NRT used in this trial.
Conclusions
The NRT transdermal nicotine patches (15mg per 16 hours) used in pregnancy for smoking cessation
caused a transient, doubling of cessation that disappeared by delivery. Infants born to women in the NRT
group were more likely to survive without impairment to 2 years of age, but there were no differences in
the experience of respiratory symptoms between groups.
Recommendations for research (in priority order)
1. Randomised controlled trials investigating the efficacy and safety of NRT when used for smoking
cessation in pregnancy should test higher than standard dose NRT such as:
i. patches delivering more than 15mg nicotine in 16 hours (e.g. 21mg in 24 hours)
ii. 4-mg gum used as required or
iii. a NRT patch combined with any ‘on demand’ short-acting NRT (e.g. gum or nasal spray).
2. To investigate whether or not apparent differences in infants’ outcomes persist into childhood. RCTs
investigating NRT for smoking cessation in pregnancy should assess infants’ clinical and economic
outcomes after 2 years of age.
3. RCTs investigating the efficacy of NRT or other interventions for smoking cessation used in pregnancy
should include an assessment of impacts on infants using outcomes similar to those employed in SNAP.
4. Reasons for pregnant women’s low levels of adherence with NRT should be investigated; findings could
be used in future trials to enhance participants’ adherence with NRT.
5. Increases in nicotine metabolism, occurring as pregnancy progresses, could explain the reduced efficacy
that NRT has in later pregnancy. Further research should investigate this hypothesis.
Implications for health care
In the UK and some other health-care systems, NRT has become an established component of cessation
support for pregnant women. Although the SNAP trial found no evidence that standard dose NRT is
effective for smoking cessation, there was also no evidence that this is less safe than smoking; indeed, the
study suggests that NRT use in pregnancy is safe in terms of infant outcomes assessed at 2 years and may
have a protective effect on infant development. Although this is the first time that a smoking cessation
intervention has been observed to have a beneficial effect on pregnant smokers’ offspring, this finding
provides support for interventions involving NRT in pregnancy. Overall, our findings provide no evidence
that NRT should not be used in pregnancy and instead suggest that NRT might be beneficial in this setting.
Effects of NRT on infant development are likely to be mediated through the small, observed changes in
maternal smoking. There are good reasons to believe that NRT used at higher doses might affect both
maternal smoking and infant development more substantially and trials of higher-dose NRT are indicated.
Other cessation interventions delivered in pregnancy may have similar impacts on infants, but this requires
confirmation. Choosing between interventions for use with pregnant smokers is, therefore, difficult; both
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‘self-help’ and behavioural smoking cessation support promote maternal smoking cessation and improve
birth outcomes. However, while there is no evidence that NRT has these effects, NRT does appear to have
a potentially important protective effect on infant development. Therefore, this study supports offering
NRT to pregnant women who smoke; however, any such offer should take account of the somewhat
stronger research evidence from other studies indicating that behavioural or ‘self-help’ support both have
beneficial effects on smoking behaviour in pregnancy.
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Appendix 1 Antenatal screening questionnaire
Ante-natal Questionnaire 
Dear Madam 
We are looking at ways to improve the lifestyle and health of pregnant women 
and babies in the womb. As one part of this study we are asking all women 
attending for routine ultrasound examinations to fill in a 5-minute questionnaire. 
We would like to invite you to participate in this study. If you are happy to fill in 
this 6-question questionnaire then tick the box marked ‘YES’ and then complete 
the form, following the instructions on it. If you do not wish to complete the 
questionnaire then just tick the box marked ‘NO’. 
YOUR ANSWERS WILL BE TOTALLY CONFIDENTIAL AND SEEN ONLY BY 
THE RESEARCH MIDWIFE AND RESEARCHERS AT THE UNIVERSITY OF 
NOTTINGHAM.
Many thanks for your help. 
Best wishes 
Dr Tim Coleman 
Division of Primary Care, University of Nottingham, QMC Medical School, 
Nottingham. NG7 2RD. 
For most questions, just tick the relevant box, like this 
CONSENT FORM 
I am happy to fill in the antenatal questionnaire. I understand that I am under no 
obligation to take part and can withdraw at any stage. 
Yes No
Signed: …………………………………………………..…  Date: …………………………………… 
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Ante-natal Questionnaire 
ID 
Centre number:  
 
Date ....../....../200....... 
 
     (tick one box) 
1. Have you smoked any cigarettes or tobacco in the last week? Yes 1 
  
No 2 
2. Are you between 12 and 25 weeks into your pregnancy? Yes 1 
  
No 2 
  
Don’t know 3 
If you answered ‘No’ to either of the two questions above, you have finished and can hand back the 
questionnaire.  If you answered ‘Yes’ or ‘Don’t know’, continue below. 
(tick one box) 
3. How often do you usually smoke cigarettes or tobacco? 
Every day 1 
  
On most days 2 
  
Less than most days 3 
 
If you answered: ‘less than most days’ to question 3 above you have finished and may hand the 
questionnaire back.  If not, please continue. 
(tick one box) 
 
4. 
Before you became pregnant, how often did you 
usually smoke cigarettes or tobacco? 
Every day 1 
  
On most days 2 
  
Less than most days 3 
If you answered: ‘less than most days’ to question 4 above you have finished and may hand the 
questionnaire back.  If not, please continue. 
APPENDIX 1
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You have now finished. 
THANK YOU FOR YOUR HELP 
(tick one box) 
5. Are you interested in stopping smoking during this 
pregnancy? 
Yes 1 
  
No 2 
  
Not sure 3 
If you answered ‘No’ to question 5 above, you have finished and can hand back the questionnaire.  If 
you answered ‘Yes’ or ‘Not sure’, please read on and continue. 
Nicotine patches help smokers to stop smoking and smokers who use patches are twice as 
likely to manage to stop for good. Experts recommend that pregnant women who smoke 
should use patches to try to stop smoking because they believe that these are safer for 
expectant mothers and their babies than continuing to smoke. 
 
Researchers from your hospital have teamed up with Nottingham University and are running a 
research project to find out if nicotine patches help pregnant women to stop smoking. 
6. Are you interested in taking part in this project? Yes 1 
  
No 2 
IF YOU ARE INTERESTED and answered ‘Yes’ to question 6 above, please COMPLETE YOUR CONTACT 
DETAILS BELOW AND TELL THE PERSON WHO IS COLLECTING THIS QUESTIONNAIRE. 
Name  
Address  
Telephone Day  
 Evening  
 Mobile  
Best time to contact  
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Appendix 2 Smoking cessation manual
 
 
 
THE SNAP TRIAL‛S 
GUIDE TO 
STOPPING SMOKING DURING 
PREGNANCY 
 
 
 
 
 
 
 
Written by 
 
Clare Mannion  
Stop Smoking Service Manager/ Co investigator 
March 2007
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Introduction
Stopping smoking at any stage during your pregnancy will help your baby to have 
the best start in life and the benefits for you and your baby will start the day 
you stop. So congratulations on taking the first step to stopping for good. We 
will be supporting you through the whole process and we hope this guide will help 
support you in your stop attempt.
So what are the benefits?
Benefits of Quitting Smoking for Mum and Baby
For Mum
☯ Less likely to feel sick during pregnancy
☯ Less likely to be admitted to hospital
☯ More likely to have a successful pregnancy
☯ Less likely to miscarry the baby
☯ Reduce the risk of bleeding
☯ Reduce the risk of still birth
☯ Reduce the risk of a complicated delivery
For Baby
☯ More likely to grow and develop normally
☯ Have a better chance of surviving the first year of life
☯ Less likely to be delivered too early
☯ Less likely to have complications at delivery
☯ Less likely to develop chest infections, asthma and ear problems including 
glue ear and possible hearing loss
☯ Less likely to have behavioural problems
☯ Less likely to become a smoker later on in life
Breathing in secondhand smoke will
☯ Double the risk of cot death
☯ Double the risk of breathing problems
☯ Double the chance of your child being admitted to hospital
APPENDIX 2
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So, what kind of smoker are you?
Is smoking “just a habit” or are you addicted? To quit successfully you will need 
to understand your addiction, the more you understand the easier it will be for 
you.
Please complete the following with your advisor and it will help you to 
understand your level of addiction to nicotine.
Fagerstrom Test for Nicotine Dependence 
1. How soon after you wake up do you smoke your first cigarette?
☯ After 60 minutes (0)
☯ 31-60 minutes (1)
☯ 6-30 minutes (2)
☯ Within 5 minutes (3)
2. Do you find it difficult to refrain from smoking in places where it is 
forbidden?
☯ No (0)
☯ Yes (1)
3. Which cigarette would you hate most to give up?
☯ The first in the morning (1)
☯ Any other (0)
4. How many cigarettes per day do you smoke?
☯ 10 or less (0)
☯ 11-20 (1)
☯ 21-30 (2)
☯ 31 or more (3)
5. Do you smoke more frequently during the first hours after awakening 
than during the rest of the day?
☯ No (0)
☯ Yes (1)
6. Do you smoke even if you are so ill that you are in bed most of the day?
☯ No (0)
☯ Yes (1)
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0-2  Very low dependence  
3-4  Low dependence  
5  Medium dependence
6-7  High dependence 
8-10  Very high dependence 
 
Scores under 5: “Your level of nicotine dependence is still low. You should act 
now and stop smoking before your level of dependence increases. “ 
 
Score of 5: “Your level of nicotine dependence is moderate. If you don‛t quit 
soon, your level of dependence on nicotine will increase until you become 
seriously addicted.  Act now to end your dependence on nicotine.” 
 
Score over 7: “Your level of dependence is high. You aren‛t in control of your 
smoking – it is in control of you! When you start to quit, the skin patches that 
you are issued with could help you to break your addiction.” 
 
Understand what triggers your smoking: control your habit 
Every smoker has a regular pattern of smoking and many have smoked this way 
for years. You probably smoke at particular times in situations which give you 
strong urges for cigarettes.  For example, some smokers always light up after a 
meal. 
 
Your ‘Smoking Diary‛ can help you to find out when you are most likely to want a 
cigarette and what triggers your urges to smoke.   
 
Fill in the first couple of diary days now with your stop smoking advisor and 
see if any of the tips provided in this manual can help you fight your urges to 
smoke.  
 
Fill in more diary days before you stop smoking.  Find out all of your triggers to 
smoking and think carefully about how you can avoid these and resist your urges 
to smoke.  
Your score was: ______  
 
Your level of dependence on nicotine is: ______
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Your Smoking Diary – Day 2 
 
Time Place With Mood Need No of Cigs 
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Your smoking diary 
 
Time Place With Mood Need No of Cigs 
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Your smoking diary  
 
Time Place With Mood Need No of Cigs 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
My ‘triggers‛    How to deal with my triggers 
1…………………………………………..  1……………………………………………………… 
2…………………………………………..  2……………………………………………………… 
3……………………………………………  3……………………………………………………… 
4…………………………………………..  4……………………………………………………… 
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Before you quit, remember to look at your diary.  Think about the difficult or 
tempting situations in which you find it difficult not to smoke (your ‘triggers‛) 
and try to work out how you are going to deal with these situations / triggers. 
We‛ve listed some tips below, but you may want to go through your diary with 
your advisor to get more ideas for avoiding smoking at these times. 
 
 
TIPS 
Tip 1. Think about when you enjoy a cigarette and when you need one and then 
think again about how you are going to cope and not smoke at these times.  
Example: If you always have a cigarette in the morning with a coffee, then stop 
having coffee – if you have fruit juice or water instead, you should not want to 
smoke as much.   
 
Tip 2. If you feel the need to eat something instead of having a cigarette why 
not try a healthy food like sugar free gum or fruit. Research shows that taking 
dextrose (sugar) tablets regularly throughout the day (one pack per day) for 
the first 2 weeks after quitting reduces your urge to smoke. NB Please do not 
use these if you are a diabetic or have pregnancy related diabetes! 
Tip 3. Identify diversions or distractions that can replace your desire to smoke.  
Examples: Physical exercise (e.g. fast walking or swimming), texting a friend or 
even brushing your teeth can all take your mind off smoking. 
 
Tip 4. Remember cravings increase in intensity for up to 3 minutes and then 
subside. Plan how you will distract yourself – ask your advisor about relaxation 
techniques. 
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Pro‛s and Con‛s 
To help you prepare to stop smoking here‛s another exercise you may like to do.  
List what you think the benefits are to continuing to smoke and give them a 
score out of 10, with 10 being very important to you.  Next list the reasons why 
you want to stop smoking and again give them a score out of 10.  Then add up 
each column, if the column on the right has a higher score then you are ready to 
stop smoking.   
Benefits of Smoking Score Reasons why I want to 
stop smoking 
Score 
    
    
    
    
    
    
    
    
    
If you score the benefits of smoking score more highly than your reasons for 
stopping, then you can talk about this with your advisor. 
 
What is the cost of smoking to me and how much will I save? 
Fill in the chart below and you might be surprised at how much you are spending 
on cigarettes.  Work out the amount that you spend on smoking each week and, 
more importantly, how much you could save.  
Time Quit Amount Saved What could I buy 
1 week     
2 weeks   
1 month   
3 months   
1 year   
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Are you ready to quit yet??? 
 
You‛ve spent some time now planning and preparing for your quit attempt and 
this is really important. The more ready you are the more likely you are to 
succeed. Keep focused on your reasons for stopping and plan changes to your 
routine to help you through some of the difficult situations you may come 
across. 
 
So all you need to do now is to set a date!!! Talk this through with your advisor 
and pick a day which suits you best. Pick a day that is no longer than 2 weeks 
away so that you don‛t lose your motivation. 
 
 
 
 
 
 
 
 
Complete the list below the day before you quit  
 
 Set up your house and car as a smoke free zone  
 Get rid of all your ashtrays, lighters, matches, and cigarettes 
 Put up smoke free signs around the house to remind friends and family 
 Buy some sugar free gum and dextrose tablets 
 Keep your advisor‛s number nearby 
 Plan some treats for yourself with the money that you will save 
 
Ongoing support: Regular contacts with your stop smoking advisor in the early 
stages of your stop attempt have been proven to increase your chances of 
quitting forever. Please make sure we have the right contact details for you so 
that your advisor can ring/email/text you to offer you the support and advice 
you need to quit and to answer any questions you may have. 
 
 
 
 
  
MY QUIT DATE IS 
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Secondhand Smoke (breathing in other peoples smoke!) 
 
Did you know that?  
 
· Non smokers who are exposed to secondhand smoke in the home, have a 
25% increased risk of heart disease and lung cancer and is a cause of 
respiratory disease, cot death, middle ear disease and asthmatic attacks 
in children. 
 
· More than 17,000 children under 5 are admitted to hospital every year 
because of secondhand smoke. 
 
· Breathing in other peoples smoke will also increase your risk of relapsing 
back to smoking  
 
 
What can you do? 
 
· It will help you to stop smoking if your friends and family help you.   
 
· If they smoke, one way that friends and family can help is by stopping too 
or at least not smoking in front of you.   
 
· If no one smokes in your company, then you and your baby will not be 
exposed to any cigarette or tobacco smoke poisons and you will find it 
easier to stop for good.   
 
· Tell friends and family that you are stopping smoking and ask them to 
help you and your baby by stopping themselves or not lighting up in front 
of you. 
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More Top Tips 
 
☯ Make sure you have your patches ready by the bedside so that you can 
put one on as soon as you wake up. We would suggest you have some 
scissors nearby too, so that you can get your patch out the pack without 
any trouble or panic! 
 
☯ Don’t use any moisturisers or shower gels with added moisturiser on the 
area where you put your patches.  You need to keep your skin here dry to 
make sure that the patches will stick. Choose a non hairy site too! 
 
☯ Change the site where you stick your patch every day. The skin here may 
be irritable for the first 20 minutes after putting on the patch, but this 
should settle. If skin irritation continues for longer than 20 minutes, 
remove it and contact your stop smoking advisor 
 
☯ Take your patch off each night and replace with a fresh patch each 
morning 
 
☯ Take each day at a time, don’t think too far ahead, short term goals will 
be more achievable 
 
☯ Stay away from those triggers and keep yourself busy  
 
☯ Count the number of cigarettes you have not had since stopping, it soon 
mounts up!! 
 
☯ Start planning treats for yourself – 20 cigarettes per day can cost 
£1,820 per year. What could you do with all that cash? 
 
☯ Think about yourself as a non smoker 
 
☯ Do a crossword 
 
☯ Send an email or text to a friend to tell them how well you’re doing 
 
☯ Drink juice instead of tea or coffee 
 
☯ Brush your teeth and remind yourself how horrible cigarettes tasted 
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☯ If you are stressed, write down what’s stressing you out, and then tear 
the piece of paper up into tiny pieces 
 
☯ Compile a list of things that you have been meaning to do for ages and do 
them! 
 
☯ Go to the cinema or watch a DVD 
 
☯ Ring your stop smoking advisors and tell them how well you’re doing 
 
☯ Remind yourself of why you wanted to stop smoking 
 
 
 
And Finally……… 
 
The Snap Trial team would like to thank you for participating in this very 
important study and wish you a great success in stopping smoking. 
 
 
 
Thank You!!! 
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Useful Contact Details 
 
 
NHS Pregnancy Smoking Helpline  
0800 169 9 169 
 
Textphone 
0800 169 0 171 
 
For Online Support and Information  
gosmokefree.co.uk 
 
NHS Asian Tobacco Helplines 
0800 169 0 881 URDU 
0800 169 0 882 PUNJABI 
0800 169 0 883 HINDI 
0800 169 0 884 GUJARATI 
0800 169 0 885 BENGALI 
 
For general information visit 
www.ash.org.uk 
 
 
If you change your contact details or have any questions about the SNAP 
Trial please contact us – thank you 
 
Smoking, Nicotine and Pregnancy (SNAP) Trial Office 
Academic Division of Obstetrics and Gynaecology 
Maternity Unit (First Floor) 
Nottingham University Hospitals NHS Trust 
City Hospital Campus 
Hucknall Road 
Nottingham 
NG5 1PB 
 
Trial Manager: Sue Cooper  
Tel: 0115 8231898 
 
Email: snap@nottingham.ac.uk 
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Appendix 3 Smoking, Nicotine and Pregnancy
Trial protocol
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Summary 
 
The HTA-funded smoking, nicotine and pregnancy (SNAP) trial will investigate 
whether or not nicotine replacement therapy (NRT) is effective, cost-effective and 
safe when used for smoking cessation by pregnant women.  Over two years, in 5 
trial centres, we will randomise 1050 pregnant women who are between 12 and 
24 weeks pregnant as they attend hospital for ante-natal ultrasound scans.  
Women will receive either nicotine or placebo transdermal patches with 
behavioural support.  The primary outcome measure is biochemically-validated, 
self-reported, prolonged and total abstinence from smoking between a quit date 
(defined before randomisation and set within two weeks of this) and delivery. At 
six months after childbirth self-reported maternal smoking status will be 
ascertained and two years after childbirth, self-reported maternal smoking status 
and the behaviour, cognitive development and respiratory symptoms of children 
born in the trial will be compared in both groups.  
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1. Background 
 
Maternal smoking during pregnancy harms unborn children and, as up to 30% of 
pregnant women smoke1, it is a significant public health problem.  The adverse 
effects of smoking during pregnancy include an increased risk of miscarriage and 
stillbirth, accounting for 4000 deaths annually, and of pre-term birth and low 
birth weight leading to increased perinatal morbidity2;3. Children of mothers who 
smoke whilst pregnant are at increased risk of neo-natal mortality, sudden infant 
death syndrome and asthma2.  Maternal smoking whilst pregnant is also 
associated with an increased risk of attention deficit and learning problems in 
childhood.3;4  Currently only around 25% of pregnant smokers stop for even part 
of their pregnancy and, of these, around two thirds re-start post-natally1.     
 
Effective methods for promoting smoking cessation by pregnant women are 
required.  The most effective smoking cessation therapy in non-pregnant smokers 
is a combination of behavioural support and pharmacotherapy with either nicotine 
replacement therapy (NRT)5 or bupropion.6  Behavioural support alone can 
increase smoking cessation rates by up to 7%7  and the addition of 
pharmacotherapy increases this further by 1.5 to 2-fold.  Behavioural support is 
usually provided without pharmacotherapy, however, because of concerns that 
drug therapy may harm the fetus.8  This is understandable for bupropion, but is 
far less logical for nicotine. 
 
Pregnant women who smoke will already expose their unborn children to nicotine.  
Nicotine has well documented potential adverse effects in pregnancy, since it is a 
vasoconstrictor and nicotine from cigarettes causes dose-related increases in 
maternal blood pressure and heart rate and has lesser effects on the fetal heart 
rate.9  In rats chronic nicotine exposure is associated with dose-dependant 
alterations in behavioural and cognitive responses, CNS toxicity and a diminished 
adrenal response to hypoxia that, in humans, could pre-dispose to sudden infant 
death syndrome.9  Consequently, nicotine may also be responsible for the 
attention deficit and learning problems that are described above.4  Cigarette 
smoke, however, contains numerous other toxins in addition to nicotine and it is 
not known which of these actually cause harm, though the fetal effects of nicotine 
have been most widely studied. The cardiovascular effects of nicotine from NRT 
are less than those observed from smoking and regular NRT use generates lower 
plasma nicotine concentrations (when body weight is accounted for) than those in 
the animal experiments described above.9  There is also no evidence that NRT 
use in pregnancy results in higher plasma nicotine concentrations than smoking9.  
For these reasons, and because using NRT in pregnancy results in exposure to 
only nicotine and no other toxins, there is expert consensus that NRT use is safer 
than smoking in pregnancy as long as pregnant women using NRT do not receive 
more nicotine from NRT than they would have done by smoking10; 11.  It is 
difficult, though, for health professionals to give clear guidance to pregnant 
women on using NRT when the safety of NRT in pregnancy is justified primarily 
on theoretical grounds and its efficacy has not been established. 
 
To date, evidence on the effectiveness of NRT in pregnancy comes from 3 studies 
and is inconclusive.12-14  Two of these studies were trials investigating   NRT as 
transdermal patches12;13 but one13 was stopped after only 40 patients had been 
randomised.  The other12, however, randomised 250 women but produced no 
clear evidence that NRT was effective, since the odds ratio for smoking cessation 
using NRT versus placebo was 1.1 with a 95% CI of 0.7 to 1.8.  This odds ratio is 
much lower than that obtained from meta-analysis of trials of NRT patches in 
non-pregnant subjects (OR, 1.74) 5 and raises questions about whether using 
NRT in pregnancy is effective for smoking cessation.  The third study was not 
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placebo controlled and randomised women to intensive behavioural support with 
an additional option to use NRT patches and / or gum14 or a ‘normal care’ group 
which received only very minimal smoking cessation advice. Although, 75 women 
in this trial opted to use NRT, this design makes it difficult to disentangle any 
effect of NRT from that of intensive behavioural support. Where reported, no 
harmful effects of NRT were demonstrated in these 3 studies.  In the larger patch 
trial12, babies born in the NRT group were significantly heavier than others [mean 
birth weight (adjusted for prematurity) difference = 186g (95%CI 35,336g)], 
suggesting that pure nicotine as NRT has less impact on fetal growth in utero 
than smoking. Additionally, in the trial which allowed a group of women to use 
either NRT patches or gum or a combination of these, mean birth weights in 
fetuses born after 37 weeks were not statistically different between the 2 trial 
groups [non-significantly lighter (by 32g) in NRT group].  In both trials that 
reported the distribution of low birth weight infants between groups12;14, no 
significant differences were noted. 
 
It has recently become apparent that conventional doses of nicotine contained in 
NRT may be insufficient for pregnant women and this may explain the negative 
findings from the one trial of NRT in pregnancy.  In pregnancy, the metabolic 
clearances of nicotine and cotinine (the principal metabolite of nicotine) are 
increased by 60% and 140% respectively15. Accordingly, even when pregnant 
women take standard doses of NRT for adequate periods, these may still be 
ineffective because they may require higher doses of NRT to replace the nicotine 
they would have received via smoking.  Higher doses of NRT might, therefore, be 
needed in pregnancy, but because there is very little human-subject research into 
the effects of nicotine on the developing fetus, it is not known whether these 
might increase the risk of fetal damage.  Until the effectiveness of the current 
conventional dose of NRT is established, it is hard to justify trials of higher ones.  
 
In summary, although consensus opinion suggests that taking NRT during 
pregnancy is likely to be safer than smoking10; 8;11;16, there is little direct trial 
evidence to support this and we do not know if NRT is actually effective in 
promoting smoking cessation amongst pregnant smokers.  The SNAP trial will 
produce direct evidence on these important questions. 
 
2. Hypothesis 
 
The SNAP trial will investigate whether or not NRT is more effective than placebo 
in achieving smoking cessation for women who and are between 12 and 24 weeks 
pregnant, who currently smoke 5 or more cigarettes daily and who smoked 10 or 
more cigarettes daily before pregnancy.   
 
3. Interventions 
 
Treatment group: Pregnant women will receive an eight week course of 15mg / 
16hr NRT transdermal patches.  Although many studies have used longer 
courses, there is no evidence that these are more effective.5  Patches will be 
issued in conjunction with individual behavioural support (Section 10) which is an 
effective smoking cessation intervention in pregnancy.7  Four weeks after their 
quit dates, women who are not smoking will be issued with a second four week 
supply of patches if required.  
 
Control group:  Women in the control arm of the trial will receive an identical 
placebo NRT patch and the same behavioural support as those in the treatment 
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group.  In both control and intervention groups, participants will be blind to their 
group allocation. 
 
4. Randomisation procedure 
 
After collecting pre-randomisation baseline data (section 9), exhaled carbon 
monoxide readings will be taken from women and assuming that readings 
indicate that women do smoke [cut off 8 ppm17], informed consent for trial entry 
will be sought.  After consenting to trial entry, women will receive an initial 
behavioural support session (section 10) before being randomised.    
 
Randomisation will be via the Nottingham Trials Unit web-based database and 
randomisation service.  In each centre the recruiting research midwife (RM) will 
have a username and password.  (S)he will log on to the trial website that hosts 
the trial database (https://ctsu.nottingham.ac.uk/snap/login.asp), confirm that 
the patient eligibility criteria are all met and enter an agreed minimum amount of 
registration data about the participant and centre before randomisation is 
possible. Data to be entered at this stage are found in section 9.  The computer 
will then issue a trial number which will be the unique identifier for the trial 
participant and a trial pack number which will reflect the treatment allocated. 
Randomisation will be stratified by trial centre only.  
 
Numbered packs of active and placebo patches will be distributed by Queen’s 
Medical Centre pharmacy and stored in either the local pharmacy or the 
participating ante-natal/ultrasound clinics, depending on local agreements or 
arrangements. After randomisation, a prescription with a container number will 
be generated by the database. The local pharmacy or research midwife will select 
the patch pack with the appropriate container number and issue this to the 
participant. The research midwife and the trial participant will both be blind to 
group allocation. When research midwives visit women at home to enrol them 
into the trial, immediate internet randomisation will not be possible.  In this 
circumstance the research midwife will return to her / his hospital base to 
randomise the enrolled woman and the appropriate trial pack will be posted to 
the trial participant.  
 
5. Outcome measures 
 
Primary end point:  Self-reported, prolonged and total abstinence19 from 
smoking or the use of any non-pharmacological 
nicotine containing substances between a quit date 
set within two weeks of randomisation and 
immediately prior to childbirth and validation of 
abstinence from smoking at this point by both 
exhaled CO measurementa  and salivary cotinine 
estimationa. 
 
Permitted timing and rules of data collection:  
 
Self reported smoking data will be used if this is collected within i) eight weeks of 
the one month follow up point and ii) within one month of delivery.  
 
Biochemical validation data will be used if this is collected within one month of 
any data collection point. Biochemical validation of self reported, prolonged 
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smoking cessation will use exhaled CO measurement (at one month) and, 
additionally, salivary cotinine estimationa at delivery.   
 
Prolonged abstinence from smoking will be considered to have occurred when no 
smoking is reported between the quit date and delivery (or other follow up point). 
For the purposes of attributing positive or negative primary outcomes, very 
occasional, minor lapses during reported abstinence will not be counted as a 
return to smoking unless women report smoking more than 5 cigarettes in total 
between their quit date and delivery. 
 
 
  
Secondary end points: 
 
a) Smoking 
 
1. Self reported, prolonged abstinence from smoking between quit date and 
one month.  
2. Self reported, prolonged abstinence from smoking between quit date and 
delivery. 
3. Self reported, prolonged abstinence from smoking between quit date and 
delivery, with biochemical validation of this at both one month follow up 
and delivery. 
4. Self reported smoking cessation for previous 24hr period at delivery 
validated by exhaled CO and saliva cotinine estimation. 
5. Self reported, prolonged abstinence from smoking between quit date and 
6 months after delivery. 
6. Self reported smoking cessation for previous 7 day period at 6 months 
after delivery.  
7. Self reported, prolonged abstinence from smoking between quit date and 
2 years after delivery. 
8. Self reported smoking cessation for previous 7 day period at 2 years after 
delivery.  
 
 
b) Fetal loss and morbidity 
 
1. Miscarriage (less than 24 weeks gestation) and stillbirth (24 weeks 
gestation and over) 
2. Neonatal death (i.e. from birth to 28 days) 
3. Post-neonatal death (29 days to 2 years) 
4. Individualized birth weight Z score (i.e. birth weight adjust for gestational 
age, maternal height, maternal weight at booking and ethnic group). 
5. Apgar score 
6. Cord blood ph 
7. Gestational age at birth 
8. Intraventricular haemorrhage 
9. Neonatal enterocolitis 
10. Neonatal convulsions 
11. Congenital abnormality  
 
c)  Maternal morbidity and mortality 
 
1. Maternal mortality 
2. Mode of delivery  
                                           
a cut offs are 8 ppm for exhaled CO and 10ng/ml for salivary cotinine17 
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3. Proteinuria 
4. Hypertension in pregnancy 
 
d) Early childhood outcomes 
 
1. Behaviour and development at 2 years  
2. Disability at 2 years  
3. Respiratory symptoms at 2 years  
 
e)  Health economic data  
 
1. Duration of maternal hospital admission for childbirth 
2. Duration of any admission (of baby) to special care 
3. Health status at 6 months (EQ5D)20 
 
 
6. Number of patients required 
 
Sample size:  We need to recruit 525 women into each arm of the study. A trial 
with 500 women in each arm would detect an absolute difference of 9% in 
smoking cessation rates between the two groups immediately before childbirth 
with a two-sided significance level of 5% and a power of 93%.  We anticipate that 
up to 5% of women will be lost to follow up and inflate our sample size (of 500) 
by a factor of 1.05 to allow for this.  This size of study would allow us to detect 
smaller treatment effects with lower power.  For example, we would have 80% 
power to detect an absolute difference in cessation rates of 7%.   
 
Justification:   A Cochrane review has shown that approximately 10% of women 
who are still smoking at the time of their first antenatal visit will stop smoking 
with usual care and a further 6% to 7% will stop as a result of a formal smoking 
cessation program using intensive behavioural counselling15.  This means that in 
our control group (placebo plus intensive behavioural counselling) we can expect 
a smoking cessation rate of around 16%. The most recent Cochrane review of 
NRT, reports a treatment effect (odds ratio) for transdermal patches of 1.74 
95%CI (1.57-1.93)5.  Consequently, if we were to find NRT as effective in 
pregnancy as it is generally, we could expect a smoking cessation rate of 
approximately 25% in our treatment group (NRT plus intensive behavioural 
counselling).   
 
 
7. Eligibility criteria 
 
Inclusion criteria:  Eligible women are aged 16 to 50, between 12 and 24 
weeks pregnant, who report smoking at least ten cigarettes daily before 
pregnancy and who still currently smoke at least five cigarettes daily.  They also 
must have an exhaled CO reading at least 8 ppm. Women may only enrol into the 
trial once and may participate in other non-conflicting research projects. 
 
Exclusion criteria:  Women with the following contraindications to the use of 
NRT will be excluded: severe cardiovascular disease, unstable angina, cardiac 
arrhythmias, recent cerebrovascular accident or TIA, chronic generalized skin 
disorders or known sensitivity to nicotine patches, chemical dependence / alcohol 
addiction problems.  Also, women who cannot give informed consent and those 
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with known major fetal anomalies will be excluded.  IUGR is not an exclusion 
criterion. 
 
8. Trial process 
 
Diagrams in Appendix A summarise the trial process. 
All trial materials (e.g. PIS and questionnaires) appear in Appendix B. 
 
Recruitment:  All pregnant women between 12 and 24 weeks into pregnancy 
who smoke and are interested in stopping smoking are potentially recruits to the 
study.  Three methods of recruitment will be used:  
a) It is usual practice in most areas for the community midwives to routinely 
ask women at their booking appointment about smoking status and 
whether they would like help to stop smoking. This information is then 
passed to the local smoking cessation service. These referred women will 
be sent a patient information sheet by the smoking cessation service and a 
letter asking whether they would be interested in participating in the trial. 
Women who were eligible and interested would be seen by the research 
midwife for consent and data collection as below. If they were not 
interested or eligible they would be seen by the smoking cessation service 
as per normal practice. 
b) Brief information about the trial and patient information sheets (PIS) will 
be posted to all women who attend trial site hospitals for ante natal care 
with their routine antenatal ultrasound scan appointment letters (scans 
are usually performed at between 12 and 20 weeks gestation). In each 
trial hospital, a research midwife (RM) working with a clerical assistant will 
use a systematic method to identify smokers who are interested in 
participating from all women attending for ultrasound examinations.  
During piloting a questionnaire was used for this (example in Appendix B) 
and a similar instrument could be used in any or all of the trial centres. 
The final method of identifying eligible patients will be agreed with the 
Chief Investigator.  Research midwives will also agree a method for 
monitoring the numbers of women identified as potentially eligible to join 
the trial and the proportion of these that eventually enrol. 
c) As an alternative to b) above, a leaflet advertising the trial and/or a 
questionnaire which identifies women who are interested in participating in 
the trial will be posted to all women who attend trial site hospitals for 
antenatal care with their routine antenatal ultrasound scan appointment 
letters or given to women by their community midwife at an antenatal 
appointment.  Women who are interested in joining the trial will be invited 
to contact the research midwife directly or when they attend hospital for 
their ultrasound scans.  These women will be sent / given a PIS to 
consider and will be contacted again after 24 hours to ascertain whether or 
not they want join the trial.  After this, consent and other trial procedures 
will be followed as described below.  
 
Consent:  Women who are interested in participation will be asked to discuss this 
with the research midwife.  The research midwife will ascertain if women are 
eligible to join the study and have read the PIS at least 24 hours earlier.  If they 
have read the PIS, the research midwife will answer any questions that women 
have about trial enrolment and seek informed consent to: 
    
i)  trial participation 
ii)  collection of follow up data on materno-fetal outcomes from medical  
records   
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iii) participants' registration with the Office for National Statistics  
iv)  collection of a blood sample for cotinine estimation and DNA extraction &  
storage  
v) collection of saliva samples for cotinine estimation  
vi) potential future contact for follow up studies by University of Nottingham 
based investigators 
 
If women have not read the PIS, but express an interest in the study, they will be 
given a copy.  These women will be contacted after 24 hrs and if they are still 
interested in enrolling in the study, informed consent will be sought.  
 
Once consent is recorded, baseline data, saliva, blood samples and exhaled CO 
readings are obtained.  Next the research midwife delivers the first session of 
behavioural support to the participant during which a quit date which is within 2 
weeks when they will start using transdermal patches is agreed.  
 
Registration & randomisation:  Immediately after the behavioural support 
session, the research midwife uses a PIN to log on to the University of 
Nottingham internet randomisation service and enters the mandatory 
enrolment data (section 9), without which randomisation will not be permitted.  
The participant is automatically allocated a trial number (i.e. unique ID) and a 
trial treatment pack number which identifies the treatment required and the RM 
issues the corresponding trial treatment pack.   
 
Many trial participants will need a home visit for consenting, intensive behavioral 
counseling and subsequent randomization.  In this situation, the research midwife 
(RM) will ensure that all base line data including the mandatory enrolment 
data is collected whilst visiting the participant.  The RM will return to base and 
randomise the participant via the internet before posting an appropriate 
treatment pack to the study participant. 
 
The research midwife then sends letters to the participant’s general practitioner 
and hospital obstetrician to inform them that she is enrolled in the trial.  One 
copy of the consent form is placed in the hospital medical records, another 
accompanies the letter to the GP and the third is sent to the Trial Office. 
 
Further behavioural support:  The research midwife will contact the participant 
on their quit day and three days afterwards. The research midwife will give the 
participant contact details for the local NHS stop smoking service and also pass 
the participants’ details to this service.  Participants will receive further 
behavioural support sessions from the NHS stop smoking service according to an 
agreed format, or from the research midwife if other local support is not available 
or not wanted by the participant. 
 
Data handling:  RMs will enter the data which they collect on to a secure 
database hosted by the University of Nottingham via an internet connection and 
will also make paper copies of data collection to allow audit.  Once data collection 
at any one time point (e.g. baseline or one month) is complete, the research 
midwife will post a copy of the data collection sheet to the Trial Office. Infant 
records within the database will be created from within maternal ones and will 
automatically be linked to maternal and sibling trial records. 
 
Biological samples 
i) For DNA extraction, 2x5ml EDTA blood samples are required. These can be 
refrigerated or frozen (if later than 24 hrs elapses between collection and 
dispatch).  If frozen, this needs to be to -20◦ centigrade. Samples will be 
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dispatched to Professor Ian Hall at the University of Nottingham for long term 
archiving.  Frozen samples require non-glass tubes.  
 
ii) Blood for serum cotinine estimation (5ml sample minimum) need to be placed 
in BD Gold top tubes (or equivalent).  These need to be frozen as per i) above 
before transport to the Nottingham Trial Coordination Team prior to dispatch to 
Professor Michael Coughtrie at the University of Dundee. 
 
iii) Saliva for salivary cotinine estimation is also transported to Dundee after 
collection.  
 
All frozen samples need to be transported on ice in non-glass containers labelled 
with: 
 
· Trial number  
· Hospital number 
· Subject’s initials 
 
Withdrawal from patch treatment: If for any reason, a participant terminates 
patch treatment, every effort must still be made to collect follow up data. 
 
Follow-up at one month after agreed quit date:  If required, participants will 
be seen by the research midwife (RM) for further supplies of patches.  To allow 
some flexibility this follow up will occur between 3 and 6 weeks after 
randomisation.  The RM will contact participants to ascertain women’s smoking 
status and those who report not smoking regularly (confirmed by exhaled CO 
measurement) and who wish to receive a further supply of patches will be issued 
with a new trial treatment pack number (obtained by the RM from the online 
database) and will receive a corresponding treatment pack (containing 4 weeks’ 
patches).  A saliva sample to measure cotinine levels on treatment will be taken if 
women are not smoking and are still wearing the patches at one month. The Trial 
Office will send one postal questionnaire asking about smoking status to women 
whom the research midwife has been unable to contact at one month.  When 
women report continued smoking cessation but do not wish to receive further 
NRT, the research midwife will arrange CO validation of this, visiting them at 
home, if necessary. 
 
Follow-up immediately before childbirth:  When participants are admitted to 
hospital whilst in established labour prior to childbirth, Delivery Suite staff will be 
asked to contact the research midwife who will visit participants to ascertain their 
self-reported smoking status and use of transdermal patches.  Women who report 
abstinence from smoking in the previous 24 hours will be asked by the research 
midwife to perform exhaled CO testing and provide a saliva sample for cotinine 
estimation.  The RM will have overall responsibility for data collection and will 
arrange with Delivery Suite staff for this to be obtained in her / his absence.    
The RM will telephone those missed whilst in hospital as soon as possible 
afterwards (within 4 weeks maximum) to collect smoking behaviour data.  Where 
participants report smoking cessation, the research midwife will measure their 
exhaled CO readings and obtain a saliva sample for cotinine estimation, visiting 
women at home if necessary.   
 
Further infant, fetal and maternal data will be obtained from medical records 
(section 9c) 
 
Data monitoring by RM between data collection points: These data are 
required to ensure that the Data Monitoring and Ethics Committee is provided 
with adequate information to form an opinion concerning trial safety: 
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Development of major fetal abnormality between randomisation and labour onset 
Miscarriage and stillbirth between randomisation and labour onset 
Maternal death between randomisation and labour onset 
Hospital admission 
 
Each month the Trial Office will provide RMs in the centres with a list of trial 
numbers for participants who are still pregnant.  The RM will use these to access 
subjects’ computer records to obtain the information listed above. In the event of 
a hospital admission the RM will assess whether or not a serious adverse event 
has occurred and act accordingly (Section 12).  If the RM enters a miscarriage or 
stillbirth into the database, this will automatically prevent further infant follow up 
and the RM will liaise with the mothers’ obstetrician to determine whether or not 
asking for follow up information concerning smoking behaviour around the 
anticipated time of delivery is acceptable. Major fetal abnormalities will also be 
reported to the trial office who will review these individually before deciding 
whether or not the participant should be allowed to continue within the trial. 
 
Registration with Office for National Statistics:  The Trial Office will “flag” 
participants (women and babies) with the Office for National Statistics (ONS) 
[now called the NHS Information Centre] at birth to facilitate follow up. Each 
week during the 2 year follow up period, the ONS will inform the trial team of any 
post-neonatal (i.e. between 29 days and 2 years) or maternal deaths. 
 
Procedure for administering postal follow up questionnaires:  Appendix A 
summarises the procedure for follow postal up after delivery.  After infant deaths, 
questionnaires will not be sent and, where maternal deaths are reported, infants’ 
general practitioners will be consulted about the appropriateness of continued 
follow up.  The Trial Office will send questionnaires directly to study participants 
using contact details provided at study recruitment.  For non-respondents or 
where questionnaires are returned labelled “not at this address”, the office will 
check participants’ addresses by contacting infants’ grandparents and, if 
necessary, the ONS / NHS Information Centre (NHSIC).  ONS / NHSIC will trace 
the infant or mother and provide details of the Primary Care Trust (PCT) which 
provides their NHS health services and the Trial Office will then contact the 
infant’s general practitioner so that a questionnaire can be sent. To maintain 
contact between researchers and participants, study infants will be sent 
Christmas cards and birthday cards.   
 
Immediately following childbirth: When appropriate, mothers will be sent or 
given a simple “Congratulations on the birth of their baby” card. 
 
Follow-up 6 months after childbirth:  A postal questionnaire, with one postal 
and one telephone reminder, will be used to collect the data items specified in 
Section 9d, below.  
 
Follow-up 1 year after childbirth:  Before infants’ 1st birthdays, parents will 
be sent a 1st birthday card  and a questionnaire to collect the data items specified 
in Section 9e, below.  Non-respondents will be sent a questionnaire reminder and 
then followed up by telephone. 
 
Follow-up 2 years after childbirth  
 
i) Parent questionnaire:  Four weeks before infants’ 2nd birthdays, we will 
dispatch to parents a questionnaire and two weeks later, all participating infants 
will be sent a 2nd birthday card, with questionnaire non-respondents being sent a 
reminder . Parents who do not respond after two questionnaires will be followed 
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up by telephone. The questionnaire will measure child behaviour, development, 
hospital admissions, respiratory symptoms and maternal smoking behaviour and 
will use standard questions to record parents’ reports of infants’ respiratory 
symptoms21 and behaviour22, the appropriate ‘Ages and Stages’ questionnaire35, 
with reference to the evidence base for questionnaire design24.  It will also include 
simple questions designed to measure children’s disability according to a standard 
definition.25 Three methods that have been demonstrated to improve postal 
returns of questionnaires will be used.36 Before the questionnaire is sent a card 
will be sent to the parent reminding them that they will be receiving a 
questionnaire shortly, and asking them to inform us of any change of address. 
When the questionnaire is sent, a £5 voucher will be enclosed along with a 
colouring competition for the child. The colouring competition will have a £50 
voucher prize, with a winner chosen 3 times per year.    
 
ii) Health professional questionnaire: When parents do not respond to the 2 
year follow up questionnaire described above, we will attempt to obtain responses 
to items measuring children’s disability from health professionals. To do this, we 
will post to participants’ general practitioners (GPs) a very short questionnaire 
containing only items to measure children’s disability which correspond to those 
that were on the questionnaire sent to parents.  These items are designed to be 
easily completed using medical or health visitors’ records.  Health professionals 
completing these questionnaires require relatively little knowledge of the patient 
and GPs will be asked to complete them.  If GPs cannot complete questionnaire, 
they will be asked to forward these to children’s’ health visitors (HV).  We will use 
an initial postal and subsequent telephone reminder to GPs to obtain the required 
information.  Items used will be based on those included in a previously-used 
questionnaire which has been validated and used with GPs and HVs 26;27’.     
 
Expected start date:     1st   April       2006  
Expected completion date:    31th March          2013 
 
9. Data collection 
 
This section specifies the items of data collect at different points during the trial. 
a) Baseline (i.e. pre-randomisation) data collection 
Although online forms will allow data to be inputted to an online database, a 
paper copy of data will be kept for audit purposes.  
i) Mandatory enrolment data (i.e. required for randomisation): The 
RM will collect the following data from participants immediately after obtaining 
informed consent.  The RM must enter the following data items about 
participants to the online database before randomisation is permitted: 
 
DoB (valid range equiv to age 16-50) 
participant’s initials 
hospital number 
daily number of cigarettes smoked before pregnancy28 
daily number of cigarettes smoked currently28 
agreed gestational age at time of randomisation (valid range 120-246) [estimated 
delivery date will be calculated automatically within database] 
time elapsed since last cigarette 
exhaled CO reading of at last 8ppm 
blood sample requested (for cotinine assay, DNA extraction & storage) 
indication that patient has signed consent form 
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indication that participant’s contact details have been recorded on paper (see 
below) 
agreed quit date 
 
ii)  Remaining baseline data for online entry:  The following data will be 
collected with above data and the RM will also enter this on to the online 
database but entering these variables will not be mandatory before online 
randomisation is permitted.  
 
NHS number (for ONS registration) 
ethnic group 
age left full time education 
number of previous births beyond 24 weeks (valid range 0-12) 
time to first cigarette of day29 
partner’s smoking status 
maternal height 
maternal weight at booking appointment 
saliva sample 
 
 
iii) Baseline data stored on paper and secure database:   
Participant name and contact details (including landline / mobile telephone 
number & postcode) 
previous surname(s) – for ONS registration 
Participant’s general practitioner and / or name of practice plus practice address 
grandparents’ contact details, including phone numbers 
 
 
b)  One month after quit date:  RM collects data from those who return.  
Postal questionnaires sent from NTCT to those who do not. The following data are 
collected: 
 
RM notes whether or not follow up occurs and the date of any follow up.  RM also 
inspects participants’ supply of patches to calculate the number used. 
 
Smoked at all in the previous 24 hrs 
Smoked since quit date (further details on outcomes form 1) 
Exhaled CO reading 
On how many days have patches been used? 
On how many days (if any) have non-trial patches been used? 
How many behavioural support sessions with NHS stop smoking services used 
(telephone & face to face)? 
Saliva sample for cotinine estimation taken if not smoking and patches still used 
 
 
c)  Upon admission for childbirth or as soon as possible afterwards:  
The following data are recorded by the RM or delivery suite staff: 
 
Date of follow up / exhaled CO reading or saliva sample 
Smoked at all in the 24 hrs prior to delivery 
Smoked between quit date and delivery 
Both of,  i) exhaled CO reading & ascertainment date ii) saliva   
  sample (for cotinine) if not smoking at delivery 
On how many days have patches been used? 
On how many days (if any) have non-trial patches been used? 
How many behavioural support sessions with NHS stop smoking services used 
(telephone & face to face)? 
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i) These data obtained by RM from maternal or infant medical records:  
 
maternal  
hypertension (>140/90) on 2 occasions (excluding labour) 
miscarriage ( between randomisation and 24 weeks) 
labour onset (spontaneous, induced, no labour) 
mode of delivery (SVD, instrumental, caesarean) 
ante natal or post natal maternal hospital admission 
infant 
baby initials 
D.O.B 
Gender 
Baby NHS number 
Prompt for RM to confirm full name and address and contact details of baby and 
to record these on paper (see below) 
Prompt for RM to make a new record of contact details if these have differed from 
previous (i.e. maternal) ones 
baby hospital number 
birth weight 
Number of births 
if multiple birth, indicate number and birth order 
live or stillbirth? 
cord ph < 7.0 
Apgar <7 at 5min 
Gestational age at birth -   to be calculated within database from gestation at 
      recruitment  
 
These infant personal details will be recorded on paper and secure database: 
 
baby name 
baby address (inc postcode) 
 
 
ii) These data obtained by research midwife from infant medical records 
 after discharge: 
  
If live birth ? live on leaving hospital 
ventilation > 24 hrs 
necrotising enterocolitis 
neonatal convulsions 
admitted to special care 
intraventricular haemorrhage (4 categories) 
congenital abnormality present (y/n).  If y then free text to describe this. 
 
 
See Appendix A for diagram explaining follow up procedure after birth. 
 
d)  Six months after delivery:  The following data will be requested:  
 
Smoking status 
Length of maternal inpatient stay for delivery of > 24 hours duration (if any) 
Any infant neonatal admission to special care 
Length of any infant inpatient stay on special care 
Maternal use of NRT / NHS stop smoking services since childbirth, 
Infant feeding method  
EQ5D questionnaire20 
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e)  At 1 year after delivery:  The following data will be requested:  
smoking status, respiratory symptoms, infant hospital admissions for respiratory 
illness and other causes, and infant feeding method  
 
e)  At 2 years after delivery:  The following data will be requested: 
 
Parent questionnaire - Smoking status, infant behaviour, development, 
respiratory symptoms and hospital admissions.  
Health professional questionnaire - Child’s disability   
 
10.   Interventions 
 
Details of NRT patches are given in section 3.  Details of behavioural support 
follow.  The first behavioural support session will be provided at recruitment by a 
research midwife who has been trained in smoking cessation methods in 
accordance with national standards30 and who has dedicated time for this task.   
Models of behavioural support that are effective in pregnancy vary greatly7 and in 
non-pregnant subjects, behavioural support following very different psychological 
models are all equally effective31.  We will, therefore, standardise the first support 
session to include information on: 
 
i)   the harmful effects of smoking in pregnancy 
ii)   the role of nicotine addiction in sustaining smoking 
iii)  how to use NRT  (including safety concerns) 
iv)  coping with withdrawal symptoms.   
 
Support will be specific to the needs of pregnant women and may involve: 
i)   enlisting partner support 
ii)  a partner quit attempt 
iii) ensuring that the partner has information about smoking cessation services 
 
Study midwives will use brief cognitive - behavioural counselling, combining 
components from effective counselling strategies that are effective31, such as: 
i)  providing structure to quit attempts 
ii) agreeing a "contract" for any attempt 
 
A quit date which is within 2 weeks will be agreed and participants will be 
instructed to start using patches on this date.  
 
Local NHS stop smoking services will provide subsequent behavioural support 
sessions.  These follow up sessions will reinforce women’s reasons for quitting 
and strategies for success.  A standardised approach to follow up support 
sessions is important and NHS stop smoking service staff will be orientated 
towards this. If no local support is available or if the woman declines it, then the 
research midwife will provide further support as required.  
 
11. Statistical analysis plan 
 
General 
a) Primary outcome measure: The proportion of women who report prolonged 
and total abstinence from smoking immediately before child birth will be 
compared between treatment groups by Chi-squared test, on an intention to treat 
basis (all those randomised) with smokers lost to follow up considered to have 
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continued smoking. For this analysis, we will assume that women in each group 
use their allocated treatments as directed and no randomised participants will be 
excluded from analyses.  Baseline data on smoking behaviour and demographic 
information will be compared between groups, and adjustment made for any 
differences, using logistic regression.  
 
b) Child behaviour and development scores at 2 years: We will compare in 
children born to women in the control and intervention groups, using t-test (via 
log transformation) or the Mann-Whitney U statistic.  Again this will be done on 
an intention to treat basis. A small number of children will be born as multiple 
births (e.g. twins) and data for these cases will be clustered rather than 
independent.  Robust standard errors, or a similar appropriate statistical method 
will be used in analysis of child data to allow for this.  
 
There will be two analyses.  The first will be conducted upon data obtained 
around delivery.  The second will be conducted at 2 years after delivery, using 
data obtained between delivery and this time point.  Data collected for secondary 
outcomes will not be analysed until the trial has ended with respect to the 
primary outcome measure. 
 
c) Other outcomes 
 
i) Fetal birth outcomes (section 5b) and ii) Maternal birth outcomes (section 5c) 
will also be compared on an intention to treat basis between the 2 groups in the 
first analysis at delivery (as a & b above)  
 
As these outcomes relate to the safety of NRT in pregnancy we will also conduct 
an analysis of these outcomes comparing participants in each group who report 
using any patches with those in each group who report using none.  
 
d) Sub group analyses 
 
These will be conducted to investigate the relationship between i) baseline 
cotinine levels and cessation and ii) maternal educational level (proxy for socio-
economic status) and cessation.  We will model the relationship between smoking 
cessation, pre-treatment plasma cotinine levels and treatment group in a logistic 
regression, to establish whether there is effect modification by pre-treatment 
plasma cotinine and whether efficacy at given levels of plasma cotinine varies. 
The model will also establish whether or not smoking cessation is constant across 
all levels of pre-treatment plasma cotinine in the NRT group, or reduces with 
increasing pre-treatment plasma cotinine, which could be indicative of inadequate 
replacement of nicotine. We will use similar methods to investigate ii) above. 
 
Health economics 
Economic analysis will be undertaken to investigate short term and longer term 
potential cost-effectiveness of NRT in pregnancy.  The cost-effectiveness of NRT 
use by the general population has been established32 and a small number of 
studies have investigated the potential cost saving of smoking cessation 
interventions in pregnancy33, but few have used empirical data on costs of 
interventions.  Analyses for this study will be primarily undertaken from an NHS 
perspective.  Uptake of behavioural support and NRT will be monitored and costs 
of both estimated with both locally-specific and national average values.  The 
differential consequences in terms of length of maternal stay and post natal 
delivery to special care between the two arms of the trial will be used with the 
estimated costs of delivering interventions with and without NRT patches and 
differential smoking cessation rates to estimate the incremental cost-
effectiveness ratio.  Sensitivity analyses exploring assumptions made in 
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estimating the control state (no NRT) will be undertaken.  The primary health 
outcome will be maternal smoking cessation immediately before delivery and 
differences in health status at 6 months (from EQ5D data) will be converted into 
QALYs to allow cost-utility modelling.  Additionally, a range of modelling 
techniques will be used to estimate longer-term cost-utility from two year follow-
up data.  Epidemiological and economic models will be used to estimate lifetime 
gains in QALYs from smoking cessation and savings in health care 
expenditures32;34.   A full literature review will be undertaken to explore the 
potential for providing monetary estimates of the long term impacts on the child 
of their differential birth outcomes. 
 
Safety 
To minimise the likelihood of women or infants being harmed by unexpected 
effect(s) of nicotine that could not predicted from previous research, the Data 
Monitoring & Ethics Committee will have access to birth outcome data.  These 
data will be available for the DMEC to analyse as is considered appropriate to 
investigate whether or not significant or clinically-important differences arise 
between study groups (e.g. in birth weight).        
 
12. Safety reporting 
 
Nicotine has very low toxicity when used in NRT outside of pregnancy, but the 
impact of nicotine in pregnancy is not clearly defined.  Safety reporting, 
therefore, necessarily involves monitoring a range of adverse pregnancy 
outcomes, such that any previously-unknown adverse effect of NRT in pregnancy 
can be detected. 
 
a) The following will be considered adverse events (AEs): 
 
i) Withdrawal from patch treatment due to skin reaction or other symptom(s) 
which are potentially caused by NRT (listed in section 4.10 BNF)  
 
ii) Events requiring hospital admission which are related to the underlying 
pregnancy (see footnote)  
 
AEs will be reported in an annual safety report to the MHRA, REC and Sponsor. 
 
DMEC meetings will consider unblinded AE data and, if data indicates it 
appropriate, will recommend that individual AEs should be re-classified as SAEs, 
so that in-trial monitoring of such events is more rigorous. 
 
b) The following will be considered Serious Adverse Events (SAEs): 
 
Baby:  miscarriage, stillbirth, neonatal and post-neonatal death  
Maternal:  maternal death   
Other events requiring hospital admission apart from those 
related to the underlying pregnancy or a pregnancy related 
condition (see footnote for excluded hospital admissions)a   
                                           
a The following pregnancy-related hospital admissions are not SAEs but will be treated as AEs: 
delivery (not AE or SAE), recognised pregnancy or postnatal complications, including pre-term 
delivery before 32 weeks, low birth weight (< 2,500g), birth injury, infection, thrombosis, 
haemorrhage, hypertensive disease, instrumental delivery (not AE or SAE), caesarean section (not AE 
or SAE), and antenatal admissions for pregnancy related diseases such as false labour, infection, 
thrombosis, haemorrhage, hypertensive disease, suspected or confirmed fetal compromise, vaginal 
bleeding  fetal congenital abnormalities, and infant hospital admissions.   Incidental hospital 
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Any other serious unexpected event. 
 
All SAEs will be reported on a standard form and assessed by Professor Jim 
Thornton or a named deputy to determine whether or not they should be 
considered as being Suspected Unexpected Serious Adverse Reactions 
(SUSARs) which are potentially-related to trial treatments. 
 
Life threatening or fatal SUSARs will be reported to the MHRA and REC within 7 
days (follow up report within 15 days) and also to relevant NHS trust R&D office 
according to local policies. 
 
Non life threatening SUSARs will be reported to the MHRA and REC within 15 days 
and also to R&D offices, as appropriate.   
 
SUSARs will also be reported to the DMEC chair along with the treatment 
allocation group of the trial subject and a cumulative count of SAE and SUSAR 
frequency in each trial arm. 
 
SAEs which are not considered SUSARs will be reported in an unblinded manner 
to each DMEC meeting and in the annual report to MHRA, REC and Sponsor with 
AEs. 
 
 
13. Publication policy 
 
The success of SNAP is dependant upon participating doctors, midwives and NHS 
stop smoking service staff who successfully recruit and treat patients within the 
trial.  For this reason, credit will be assigned to them in reports from the study 
and they will be named in the trial report.  The principal trial report will be 
authored by “The SNAP Trial Team”. 
 
14. Trial steering committee 
 
Mr Peter Brocklehurst (Chair) Director, National Perinatal Epidemiology Unit, 
University of Oxford 
 
Professor Peter Hajek 
 
Professor of Clinical Psychology, Tobacco 
Dependence Research Centre, Barts and The 
London, Queen Mary's School of Medicine and 
Dentistry 
 
Dr Carol Coupland Senior Lecturer in Medical Statistics, Division of 
Primary Care, University of Nottingham 
 
Mrs Sue Maguire Lay member 
 
Dr Michael Murphy Director, Childhood Cancer Research Group, 
University of Oxford 
 
 
15. Data monitoring and ethics committee 
 
                                                                                                                          
admissions for minor, gastrointestinal diseases, respiratory, cardiac, renal skin, psychiatric and 
neurological problems. 
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Professor Janet Peacock (Chair) Professor of Health Statistics, Brunel University 
 
Professor Khalid Khan (till Oct 2008) Professor of Obstetrics, Gynaecology and Clinical 
Epidemiology, University of Birmingham 
 
Professor David Field Professor of Neonatal Medicine, University of 
Leicester 
Professor Christopher Butler (from Jan 
2009) 
Professor of Primary Care, Cardiff University 
 
16. Centres 
 
In each hospital recruiting centre there is a PI and a midwife lead (hospital 
based) and a NHS stop smoking service lead. 
 
 
 
Hospital recruiting centre 
 
 
NHS stop smoking service 
Derby City General Hospital Fresh Start  
 
Jonathon Allsop (PI), Julia Savage 
 
 
 
Mary Styles 
 
Kings Mill Centre, Mansfield New Leaf, Notts County tPCT 
 
Karen Glass (PI), Alison Witham 
 
 
Barbara Brady 
North Staffordshire University 
Hospitals 
North Staffordshire Quit Smoking 
Service 
 
Khaled Ismail (PI), Christine Kettle 
 
 
Deborah Richardson 
 
Nottingham City Hospital New Leaf, Nottingham 
 
Jim Thornton (PI), Amanda Lindley 
 
 
Indu Hari 
Queens University Medical Centre, 
Nottingham 
New Leaf, Nottingham 
 
Margaret Ramsey (PI), Amanda Lindley 
 
 
Indu Hari 
Leighton Hospital, Crewe Central Cheshire Stop Smoking 
Service 
 
Simon Cunningham (PI), Sandra Smith 
 
 
Paul Jackson 
Macclesfield District General 
Hospital 
Central Cheshire Stop Smoking 
Service 
 
Vince Hall (PI), Grace Hopps 
 
 
Paul Jackson 
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17. Funding 
The research costs of SNAP are funded by the NHS Health Technology 
Assessment Programme and the NHS Support Costs have been met from NHS 
R&D funds. 
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19. Data Collection Forms 
   
 
3 data collection forms will be designed for RMs to use as a paper record of data 
collected at i) baseline ii) one month after quit date and iii) delivery and 
immediately afterwards.  These will be finalised once the online database is 
completed (and if possible generated from this).  NB: These forms will record 
data obtained by RMs and will not be completed by trial participants.
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 Appendix A: Trial Process 
  1 Trial flow from recruitment to delivery      
  (primary outcome ascertainment) 
 
 
 
 
 
 
 
 
 
 
Research midwives in each centre are responsible for accurate data entry to internet hosted database, for sending blood samples to 
appropriate university departments and accurate paper copies of data collection sheets from i) baseline (pre-randomisation) ii) one 
month follow up and iii) delivery to the Nottingham Trial Co-ordinating Team. 
 
Prior to delivery, during hospital admission for delivery – data 
collected directly from trial participant to ascertain trial primary outcome.
RM collects data as in section 9c, including biochemical verification of 
smoking cessation status.  If RM not available, delivery suite staff collect 
data.  If women missed prior to delivery, RM collects data within 4 weeks of 
One month follow up: Women return to RM for further treatment between 
3 and 6 weeks after randomisation. Women who are not smoking, confirmed 
by exhaled CO given one month’s further patch supply (double blind).  Data 
outlined in section 9b collected.  Non-returners sent postal questionnaire 
by NTCT to obtain data.  RM conducts CO validation for women who report 
During initial visit, after consenting - women receive first session of 
behavioural support. Baseline pre-randomisation data and samples 
collected, as sections 9a i-iii. Women set a quit date within 2 weeks of this 
Women who do not 
consent leave at any point 
Further sessions of 
behavioural support 
 
delivered by staff from 
NHS stop smoking 
services 
Randomisation: (after initial visit and 1st behavioural support session).  
Mandatory, enrolment data (section 9a) entered into internet 
randomisation system.  RM is now allowed to randomise woman to 
intervention or control group.  4 weeks treatment (active or placebo 
transdermal patches) dispensed by pharmacy or RM with double blinding.  
Before attendance for U/S dating scan - all women due to attend sent 
trial patient information sheet or trial advert
During attendance for U/S dating scan - RM identifies eligible women 
– as section 7  Women given PIS if not previously received. Initial trial 
Exclusions – as section 7 
Further data collection, after delivery.  RM collects data as in section 
9c from maternal or infant medical records.  
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2 Trial follow- up: delivery to infants’ 2nd birthdays 
 
 
All questionnaires & cards sent by Nottingham Trial Coordinating Team (NCTC) 
 
 
 
 
 
1 year : All infants sent 1st birthday card 
 
Non-respondents to questionnaire above: One 
postal reminder sent, followed by one 
telephone reminder. 
6 months (infant age): Postal questionnaire 
measuring self reported smoking status and 
health economic data. One postal / one 
2 weeks before 1st birthday: postal 
questionnaire to mother  
2 weeks before 2nd birthday: (infant age): 
Postal questionnaire to parents.  
Two years: (infant age): Postal questionnaire 
to GP / health visitor.  
Two years: All infants sent 2nd birthday card 
 
Non-respondents to questionnaire above: One 
postal reminder sent, followed by one 
Non-respondents at two years: One postal 
followed by one telephone reminder. 
 
 
Congratulations card 
sent, as appropriate, to 
mother after baby is born 
 
 
Christmas cards sent, 
Mailings to infants / parents 
Mailings to health professionals 
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Appendix 4 Protocol breaches
O f 2410 women who expressed an interest in the trial and were assessed for eligibility, 1051(43.6%) were randomised: 521 were assigned to receive NRT and 530 to receive placebo patches
(see Figure 2). One woman was mistakenly enrolled for a second time in a subsequent pregnancy; thus,
her second enrolment in the placebo group was removed from all analyses, giving a final sample size of
1050 (529 in the placebo group).
Protocol breaches were discovered for 13 other participants, but after consideration of violation details it
was decided that these were not serious and would have no significant impact on trial participants or the
scientific integrity of the trial. Therefore, these participants remained in the trial and their data were used
in analyses. Two participants had minor chemical dependence problems and three participants were
enrolled 4–5 days before they reached 12 weeks’ gestation; however, they were not randomised until
12 weeks. Seven participants did not receive their investigational medicinal product by their quit date
owing to pharmacy problems, meaning that they needed to set a new quit date that was then > 2 weeks
after their baseline visit. One participant received and used a second supply of patches after the first set
appeared to have been lost in the post, however, as she was still smoking at 1 month she would not have
been eligible to receive a second set.
Two additional problems affecting 27 participants occurred within one site pharmacy, but again these
were judged to have no significant impact on participants or trial integrity. The temperature recorded in
the pharmacy fridge at one site was in excess of 8 °C (this was the maximum temperature specified for
patch storage before dispensing) for 12 days in a 1-month period and, during this time, 25 subjects had
been assigned patches from the pharmacy. On discovery of the problem, unallocated packs were
withdrawn, but as patches could be stored for 3 months at ambient temperature without the potency
being reduced, and there were no safety issues, it was felt that other than informing participants that
patches should not be used for longer than 1 month after issue, no further action needed to be taken with
those packs that had been issued. In another incident, due to a mix-up by the site pharmacy, two
participants were posted each others treatment pack for the first treatment period and had started to use
the patches before the mistake was discovered. The treatment code was not broken, but the trial manager
was informed that the participants had received the same treatment allocation and no further action
was taken.
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Appendix 5 Supplementary data on
adverse events
See Table 7 for information on AEs by treatment group.
Adverse events resulting in women permanently
discontinuing treatment
Nicotine replacement therapy: 50 adverse events in 46 women
Application site reactions (n= 33), nausea (n= 7), headache (n= 3), dizziness (n= 2), palpitations (n= 2),
dyspnoea, oropharyngeal pain, sensory disturbance (all n= 1)
Placebo: 38 adverse events in 32 women
Application site reactions (n= 15), nausea (n= 7), dizziness (n= 5), headache (n= 3), irritability (n= 3),
dyspepsia (n= 2), fetal hypokinesia, influenza like illness, palpitations (all n= 1)
Overnight hospital admissions for other pregnancy complications
In total there were 143 events with hospital admissions in 95 women (NRT group) and 146 events with
hospital admissions in 94 women (placebo group) (admission for any reason, not only pregnancy related).
Hospital admission for less frequent pregnancy-related events
Nicotine replacement therapy: 44 events
Miscellaneous hospitalisation for pregnancy-related events for which the outcome was no abnormality
detected (n= 7), urinary tract infection (n= 7), maternal condition affecting fetus (n= 3), postpartum
haemorrhage (n= 3), proteinuria (n= 3), antepartum haemorrhage (n= 2), dizziness (n= 2),
polyhydramnios (n= 2), premature separation of placenta (n= 2), chest pain, constipation, disseminated
intravascular coagulation, hepatic failure, pruritus generalised, pyelonephritis, renal failure, syncope,
tachycardia, ultrasound Doppler abnormal, vision blurred, visual impairment, vulvovaginal candidiasis
(all n= 1).
Placebo: 41 events
Miscellaneous hospitalisation for pregnancy-related events for which the outcome was no abnormality
detected (n= 5), urinary tract infection (n= 4), maternal condition affecting fetus (n= 4), premature labour
(n= 2), premature separation of placenta (n= 2), anaemia, anaphylactic reaction after iron infusion,
antepartum haemorrhage, back pain, body temperature increased, cervix cerclage procedure, chest pain,
cholestasis of pregnancy, deep-vein thrombosis, diarrhoea, dizziness, dyspnoea, haemoglobin decreased,
migraine, musculoskeletal pain, oedema, placenta praevia, proteinuria, pyelonephritis, scar pain,
threatened labour, abnormal ultrasound Doppler, urinary retention, visual impairment (all n= 1).
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Other, less frequent, adverse events that occurred in < 3% of women or
infants and are not logically grouped together
Nicotine replacement therapy
Maternal adverse events (63 events)
Dizziness (n= 6), fall (n= 4), abnormal dreams (n= 3), back pain (n= 3), dyspnoea (n= 3), urinary tract
infection (n= 3), diarrhoea (n= 2), hypoaesthesia (n= 2), oedema (n= 2), oropharyngeal pain (n= 1),
pruritus (n= 2), chest pain, antepartum haemorrhage, blindness transient, blood pressure decreased,
cholelithiasis, hypothyroidism, influenza like illness, intervertebral disc protrusion, kidney infection, malaise,
migraine, oligohydramnios, overdose, pain in extremity, palpitations, parvovirus infection, photopsia,
pleural effusion, pollakiuria, polyhydramnios, premature separation of placenta, proteinuria, road traffic
accident, sensory disturbance, skin disorder, symphysiolysis, type 1 diabetes mellitus, vaginal discharge,
vaginal infection, vasodilatation, vision blurred, visual impairment (all n= 1).
Fetal adverse events (total 5 events)
Growth restriction (n= 2), heart rate deceleration, large for dates baby, hospital admission for fetal growth
restriction (all n= 1).
Neonatal adverse events (total 32 events)
Jaundice (n= 4), feeding disorder (n= 3), hypoglycaemia (n= 3), hypothermia (n= 2), maternal condition
affecting fetus (n= 2), tachypnoea (n= 2), sepsis (n= 2), shoulder dystocia (n= 2), arrhythmia, C-reactive
protein increased, clavicle fracture, dehydration, Erb's palsy, infantile apnoeic attack, lower respiratory tract
infection, aspiration, respiratory distress syndrome, pyelocaliectasis, temperature regulation disorder,
unresponsive to stimuli (all n= 1).
Placebo
Maternal adverse events (total 73 events)
Fall (n= 8), dizziness (n= 7), abnormal dreams (n= 4), lower respiratory tract infection (n= 3), palpitations
(n= 3), proteinuria (n= 3), visual impairment (n= 3), back pain (n= 2), malaise (n= 2), musculoskeletal
pain (n= 2), oedema (n= 2), physical assault (n= 2), pruritus (n= 2), syncope (n= 2), vaginal discharge
(n= 2), cholestasis of pregnancy, diarrhoea, influenza like illness, maternal condition affecting fetus,
Bartholin’s cyst, chlamydia test positive, cholestasis, dysgeusia, dysuria, emotional disorder, feeling
abnormal, generalised oedema, ocular hyperaemia, pain in extremity, restless legs syndrome, road traffic
accident, hyperhidrosis, injury, intentional self-injury, lethargy, meningitis, thrombophlebitis, toothache,
umbilical hernia, unstable fetal lie, vulvovaginal discomfort (all n= 1).
Fetal adverse events (total 5 events)
Tachycardia (n= 2), heart rate decreased, small for dates baby, admission for fetal growth restriction
(all n= 1).
Neonatal adverse events (total 29 events)
Jaundice (n= 5), hypoglycaemia (n= 5), feeding disorder (n= 3), grunting (n= 3), anaemia (n= 1),
convulsion neonatal (n= 2), infantile apnoeic attack (n= 2), respiratory disorder (n= 2), Erb’s palsy, fever,
hypoxia, aspiration, respiratory distress syndrome, shoulder dystocia (all n= 1).
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